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“Ever since receiving the invitation to write this prefatory chapter, I have been wondering "Why 
me?" After reviewing the list of previous authors of this chapter, I was even more puzzled until I 
realized that this may have been a move to show that it is not necessary to be a genius to contribute 
to science.” 
“This was quite a gamble on the part of the university. I had never had a real course in pharmacology, 
nor had I done any research that was even marginally pharmacological. Moreover, my two 
predecessors, Carl Cori and Herbert Gasser, were both Nobel Laureates, and there was no sign that I 
would get to Sweden except as a tourist”. 
Oliver Howe Lowry 
(1910-1996) 
I chose these citations as it is my uttermost belief that the most fulfilling and exciting way to do 
science is with the mind of a humble person.  
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Summary 
Glycans are structurally the most complex type of biological macromolecule. The diversity of 
structures by far exceeds what has been observed for other molecules such as proteins. They are also 
functionally extremely diverse and contribute to biological processes such as protein folding, 
intracellular trafficking, immune cell polarization and much more. The synthesis of most mammalian 
glycans takes place in the endoplasmic reticulum and in the Golgi apparatus. The latter is responsible 
for synthesizing the diversity that is observed in glycans. It contains a plethora of glycosyltransferases 
which synthesize the glycans that are secreted as free oligosaccharides such as human milk 
oligosaccharides or occur on proteins and lipids. The process is therefore not a template-driven 
process and instead compares more to a melting-pot where various reactions take place 
simultaneously and where enzymes compete for substrates. As a consequence, the created epitopes 
are diverse and it is challenging to associate functions to the specific glycan epitopes due to the 
absence of a linear synthesizing process such as for proteins. Therefore I used chemically synthesized 
oligosaccharides to discover unknown functions of glycans. 
Previously the unconjugated human milk oligosaccharide 3-sialyllactose was shown to stimulate the 
maturation of mesenteric lymph node derived dendritic cells. Additionally, the human milk 
oligosaccharides lacto-N-fucopentaose III and lacto-N-neotetraose induce the proliferation of 
peritoneal macrophage populations. Therefore I speculated that other human milk oligosaccharides 
should also be able to influence antigen presenting cells like dendritic cells, monocytes or 
macrophages. Monocytic THP-1 cells and mesenteric lymph node derived dendritic cells were used as 
a model system to determine the stimulatory influence of human milk oligosaccharides on the 
activation of antigen presenting cells. 3-fucosyl-3-sialyllactose and sialyllacto-N-tetraose c induced a 
cell-density dependent, increased production of lactate by both cell-types which caused acidification 
of the surrounding media. Interestingly, lactate is known to stimulate M2 polarization of 
macrophages which is associated with the increased production of the immune dampening cytokines 
IL-10 and TGF-β.  The results of this study are presented in manuscript 1 of this doctoral thesis. 
I next decided to focus my efforts on identifying novel roles of multivalently presented 
oligosaccharides as they are known to induce more enhanced cellular responses than monovalent 
oligosaccharides. For this a method was developed, which is suitable to modify whole animal and 
bacterial cells as well as proteins, with specific oligosaccharides. Briefly, the oligosaccharides 2-
fucosyllactose, 3-fucosyllactose, 3-sialyllactose, 6-sialyllactose and 3-fucosyl-3-sialyllactose were 
modified at their reducing end to contain a cyclic-carbamate group that reacts with primary amine 
groups. These oligosaccharide derivatives can be used to modify many biological entities including 
whole cells and proteins. I used this method to coat cells with ligands of the E-selectin receptor that 
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are known to mediate leukocyte extravasation, and demonstrated that this influences the behavior 
of the cells in an in vitro model for leukocyte extravasation. Furthermore, I coated Escherichia coli K-
12 cells with sialic acid containing oligosaccharides and demonstrated that these surface glycans 
emulate immune regulatory roles mediated by certain pathogenic bacteria that present the same 
glycans. More specifically, these glycans inactivate the complement cascade by recruiting the 
inhibiting Factor H. Finally, I created custom-made glycoproteins and showed that they enhance the 
production of inflammatory cytokines by lipopolysaccharide-stimulated dendritic cells in a PI3K 
dependent manner. These results are presented in the second manuscript of this thesis. 
While working on the oligosaccharide-cyclic-carbamate technology, I discovered that coating cells 
with sialyllactose leads to rapid cell death that was characterized by extensive blebbing and 
cytoskeleton depolymerization. Cell death could be blocked by using various caspase inhibitors which 
indicates a form of programmed cell death. Furthermore, the toxicity of the sialyllactose-containing 
oligosaccharides was dependent on the linkage of the sialic acid, as α2-3 linked sialic acid coating by 
3-sialyllactose-cyclic-carbamate ligation, was more potent than α2-6 linked sialic acid coating by 6-
sialyllactose-cyclic-carbamate ligation. Intriguingly, incorporating sialyllactose modified 3-sn-
phosphatidylethanolamine into the cell membrane did not induce cell death which indicates that the 
cell death effect depends on the sialyllactose modification of distinct sites that occur in the cell 
membrane. I identified 23 protein components involved in this novel pathway with a CRISPR-Cas9 
based screen and was able to demonstrate that G-protein coupled receptor signaling plays a key role 
during sialyllactose-coating mediated cell death. 
The key contributions of this this work to the scientific community are the establishment of a method 
that enables the modification of whole cells, proteins and lipids with specific oligosaccharides, and 
the identification of a new form of cell death that is initiated by sialylated glycans at the cell surface. 
The oligosaccharide-cyclic-carbamate technique described here can be used to answer many basic 
biological questions concerning the physiological and pathophysiological functions of specific glycan 
epitopes. 
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Zusammenfassung 
Glykane sind komplexe biologische Makromoleküle. Ihre Diversität ist viel grösser als jene von 
anderen biologischen Molekülen wie Proteine. Dazu besitzen sie auch eine grosse funktionelle 
Diversität und sind in Prozessen wie der Faltung von Proteinen, dem intrazellulärem Transport, der 
Polarisierung von Immunantworten und vieles mehr involviert. Die Synthese der meisten Glykane 
findet im endoplasmatischen Retikulum und im Golgi Apparatus statt. Insbesondere der Golgi 
Apparatus ist für die Diversität der Glykane zuständig. Es beinhaltet eine Vielfalt an 
Glykosyltransferasen, welche unkonjugierte Glykane, wie humane Milcholigosaccharide, oder 
Glykokonjugate, wie Glykoproteine oder Glykolipide, aufbauen. Bei der Synthese von Glykanen 
handelt es sich daher nicht um einen linearen Prozess mit Sequenzvorgabe wie bei der Synthese von 
Proteinen, sondern eher um einen komplexen Vorgang bei der verschiedenste Reaktionen 
gleichzeitig stattfinden und sogar miteinander kompetitieren. Die Diversität der generierten Epitope 
ist daher enorm und es ist schwierig den unterschiedlichen Strukturen Funktionen zuzuordnen. Daher 
habe ich chemisch hergestellte Oligosaccharide verwendet, um unbekannte Rollen von Glykanen zu 
entdecken. 
In einer vorherigen Studie wurde demonstriert, wie dass in der menschlichen Milch vorkommende 
Oligosaccharid 3-Sialyllaktose, die Reifung von dendritischen Zellen aus den mesenterischen 
Lymphknoten vorantreibt. Weiterhin ist bekannt, dass die humanen Milcholigosaccharide Lakto-N-
Fukopentaose III und Lakto-N-Neotetraose die Proliferation von peritonealen Makrophagen fördern. 
Ich habe daher spekuliert, dass auch andere Oligosaccharide, die in menschlicher Milch vorkommen, 
Antigen-präsentierende Zellen stimulieren können. Monozytäre THP-1 Zellen und dendritische Zellen, 
die aus mesenterischen Lymphknoten isoliert wurden, habe ich mit chemisch synthetisierten 
humanen Milch-Oligosacchariden stimuliert. 3-Fucosyl-3-Sialyllaktose und Sialyllakto-N-tetraose c 
haben eine Zunahme der Laktatproduktion in den Zellen bewirkt, welches zu einem Ansäuern des 
Mediums geführt hat. Es ist allgemein bekannt, dass Laktat eine M2 Polarisierung von Makrophagen 
bewirkt, welches zur Produktion von Immun-hemmenden Zytokinen wie IL-10 und TGF-β führt. Die 
Resultate hierzu sind in Manuskript 1 dieser Arbeit zu finden. 
Danach habe ich mich entschieden meine Bestrebungen auf die Entdeckung neuer Funktionen von 
multivalenten Oligosacchariden zu fokussieren, da diese bekannterweise zu stärkeren Reaktionen 
führen wie monovalente Oligosaccharide. Dazu wurde eine Methode entwickelt, welches sich dazu 
eignet tierische und bakterielle Zellen, als auch Proteine mit spezifischen Oligosacchariden zu 
modifizieren. Dazu wurden die Oligosaccharide 2-Fukosyllaktose, 3-Fukosyllaktose, 3-Sialyllaktose, 6-
Sialyllaktose und 3-Fukosyl-3-Sialyllaktose an ihrem reduzierendem Ende so modifiziert, dass sie eine 
zyklische Carbamat-Gruppe aufweisen, welches in der Lage ist mit primären Aminen eine kovalente 
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Bindung einzugehen. Diese Methode kann dazu verwendet werden, um viele biologische Entitäten, 
wie ganze Zellen und Proteine zu modifizieren. Anhand dieser Methode habe ich Zellen mit 
Oligosacchariden modifiziert, die als Konsequenz an den Rezeptor E-Selektin binden konnten, 
welches für die Auswanderung von Leukozyten aus den Blutgefässen in das Gewebe verantwortlich 
ist. Mittels einem in vitro Ansatz konnte ich demonstrieren, dass solche Zellen neue 
Bindungseigenschaften für E-Selektin bekommen. Weiterhin, konnte ich auch Escherichia coli K-12 
mit sialinsäurehaltigen Oligosacchariden modifizieren, welche daraufhin immunmodulatorische 
Eigenschaften erhalten haben, die sonst nur bei pathogenen Bakterien beobachtet werden. Die 
Ursache dafür war, dass die Zellen den Komplement-Kaskade inhibierenden Protein Faktor H an ihre 
Oberfläche rekrutieren konnten. Zuletzt, habe ich auch künstliche Glykoproteine hergestellt, welche 
eine PI3K-abhängige Zunahme der Produktion von inflammatorischen Zytokinen, durch 
Lipopolysaccharid-stimulierte dendritische Zellen, vermittelt haben. Diese Resultate sind im zweiten 
Manuskript dieser Arbeit beschrieben. 
Während meiner Arbeit an der oben beschriebenen Technologie, habe ich entdeckt, dass Zellen, die 
mit Sialyllaktose modifiziert wurden schnell sterben. Dabei bilden sich an der Membran Bläschen und 
es kommt zu einem Abbau des Zytoskeletts. Der Zelltod konnte mittels verschiedener Inhibitoren der 
Caspasen verhindert werden, welches dafür spricht, dass es sich um eine programmierte Form von 
Zelltod handelt. Weiterhin war die Toxizität von der Bindung der Sialinsäure abhängig, da 3-
Sialyllaktose, welches eine α2-3 gebundene Sialinsäure aufweist, bei tieferen Konzentrationen Zelltod 
hervorgerufen hat als 6-Sialyllaktose, welches eine α2-6 gebundene Sialinsäure aufweist. 
Interessanterweise, hatte die Inkorporation von Sialyllaktose modifiziertem 3-sn-
Phosphatidylethanolamine in die Plasmamembran keinen Einfluss auf das Überleben der Zellen, 
weshalb ich darauf geschlossen habe, dass die Modifizierung spezifischer Epitope auf der 
Zelloberfläche mit Sialyllaktose, den Zelltod induzieren. Ich habe dann mittels einem genetischen 
CRISPR-Cas9-Screen 23 Proteine identifiziert die eine Rolle bei dieser Form des Zelltodes spielen. Auf 
diesem Screen aufbauend, konnte ich zeigen, dass G-Protein gekoppelte Rezeptoren und ihre 
Signalwege, eine besonders wichtige Rolle spielen. Diese Resultate sind im dritten Manuskript dieser 
Doktorarbeit beschrieben. 
Die wichtigsten Beiträge dieser Arbeit an die wissenschaftliche Gemeinschaft sind die Etablierung 
einer Methode, welches die Modifizierung ganzer Zellen, Proteine und Lipide mit spezifischen 
Oligosacchariden ermöglicht, und die Entdeckung einer neuartigen Art von Zelltod, das durch 
sialinsäurehaltigen Glykanen initiiert wird. Die hier beschriebene Methode kann benutzt werden, um 
viele grundlegende biologische Fragestellungen bezüglich den physiologischen und 
pathophysiologischen Rollen spezifischer Glykane zu beantworten.  
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Abbreviations 
 
2FL 2-fucosyllactose 
3FL 3-fucosyllactose 
3SL 3-sialyllactose 
6SL 6-sialyllactose 
AAL Aleuria aurantia lectin 
Appbp2 amyloid beta precursor binding protein 2 
BSA bovine serum albumin 
Cul5 cullin 5 
DISC Death-inducing signaling complex 
EPO erythropoietin 
ER endoplasmic reticulum 
FCS fetal calf serum 
Ffar4 free fatty acid receptor 4 
FSL 3-sialyl-3-fucosyllactose [Sia(α2-3)Gal(β1-4)[Fuc(α1-3)]Glc] 
Fuc Fucose 
FUT2 2-α-L-fucosyltransferase 2 
Gal galactose 
GalNAc N-acetylgalactosamine 
Glc glucose 
GlcNAc N-acetylglucosamine 
HBSS Hank’s Balanced Salt Solution 
HMO human milk oligosaccharide 
IAP protein that inhibits apoptosis 
IL interleukin 
ITIM immunoreceptor tyrosine-based inhibition motifs 
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LNFP lacto-N-fucopentaose 
LOS Lipid bound oligosaccharide 
LPS lipopolysaccharides 
LST sialyllacto-N-tetraose a 
MAL Maackia amurensis lectin I 
Man mannose 
MLKL mixed lineage kinase domain-like protein 
MurNAc N-acetlymuramic acid 
Olfr olfactory receptor 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
PE phycoerythrin 
RIPK kinase receptor interacting protein 
Rnf133 ring finger protein 133 
RPMI Roswell Park Memorial Institute Medium 
Sia sialic acid 
Siah2 seven in absentia 2 
SMAC secondary mitochondria-derived activator of caspases 
Spn sialophorin 
Surf4 surfeit gene 4 
TGF-β transforming growth factor-β 
TLC thin-layer chromatography 
TLR Toll-like receptor 
TNF-α tumor necrosis factor-α 
TRAIL TNF-related apoptosis-inducing ligand 
UEA Ulex europaeus agglutinin I 
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Introduction 
Glycans are structurally diverse [1] and their synthesis is not template-driven [2] such as for proteins. 
This often impedes the functional characterization of specific glycans because of the deficiency of 
genetic approaches. Mucins for example are proteins that occur at epithelial surfaces and are 
heterogenously glycosylated [3]. The glycans on these proteins are immune suppressing but the 
responsible structures remain unknown [4]. The goal of this project was to tackle this problem and to 
develop new approaches to functionally characterize glycan structures. I used chemically synthesized 
oligosaccharides to define the structural-functional relationship of specific oligosaccharides that are 
secreted as free glycans, such as human milk oligosaccharides, and of glycans coupled to proteins, 
such as mucins. To study the role of glycans that are conjugated to proteins, I used oligosaccharides 
derivatized with a cyclic-carbamate group at their reducing end that can bind covalently to primary 
amines which occur on proteins. During the course of this work I discovered that sialic acid (Sia) 
containing glycans on the cell surface initiate a previously uncharacterized form of programmed cell 
death. This introduction offers a brief overview of the diversity that occurs in glycans and the 
diversity of functions that glycans are involved in. The roles of glycans in cell death are emphasized 
and the various forms of cell death elaborated. 
Glycans and their diversity in structure and function 
Glycans can either occur as soluble molecules that are secreted by cells [5, 6] or attached to other 
biomolecules. When glycans are enzymatically attached to other biomolecules such as proteins, lipids 
or other non-glycans we speak of glycosylation. The products of such reactions are called 
glycoconjugates. Modified proteins are known as glycoproteins or proteoglycans [7] while 
glycosylated lipids are generally classified as glycolipids [8]. Glycosylation is the most common 
posttranslational modification of proteins and a bioinformatics study demonstrated that 50% of all 
proteins registered in the SWISS-PROT database are glycosylated [9]. There are three general types of 
protein-glycosylation which are N-, O- and C-linked glycosylation [10]. Some would also claim that 
glycosylphosphatidylinositol anchors are a form of protein glycosylation as a phosphoinositide lipid is 
attached via a glycan linker to the C-terminus of a protein [10]. 
The structural diversity of glycans 
The chemical basis of glycan diversity 
Glycan diversity is vast due to the great variabilities in the glycosidic bonds, monosaccharide 
composition, branching and length of the glycans [11]. A factor contributing to the heterogeneity of 
glycans is that glycosidic bonds can be made from the reducing end of one monosaccharide to almost 
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any hydroxyl-group of another monosaccharide or even an aglycone. Maltose for example consists of 
α1-4 linked glucose (Glc) while trehalose contains an α1-1 linkage between the two Glc residues. On 
top of this comes the anomerism of the exocyclic oxygen towards the configuration determining C-
atom of the sugar, where the prefix α stands for a cis orientation while β means there is a trans 
configuration. Starch for instance contains α1-4 linked Glc while cellulose contains β1-4 linked Glc.  
Another point of variability, are the monosaccharides that occur in the glycan. The monosaccharides 
vary in the amount of C atoms and the axial orientation of the hydroxyl groups. Figure 1 
demonstrates common monosaccharides that occur in mammalian glycans and introduces the 
abbreviations for the monosaccharides that shall be used throughout this thesis. Note that in all 
mammals except humans N-acetyl-D-neuraminic acid is hydroxylated at the acetyl group and is 
termed N-glycolyl-D-neuraminic acid. Both are classified as Sia residues. 
 
Figure 1: Some common monosaccharides that occur in mammalian glycans. These monosaccharides are 
attached as oligosaccharides to other biomolecules such as lipids or proteins. Each monosaccharide is labelled 
with the corresponding symbol that serves as a simplification for further images (modified from [12]). 
Branching is also a source of diversity in glycans. An example for this is the branching of N-linked 
glycans. N-linked glycans are defined by their attachment to asparagines and in mammals they can 
be biantennary, triantennary or tetraantennary [13]. This is actually of great functional relevance too. 
Tetraantennary N-linked glycans interact more extensively with galectins, a secreted class of lectins, 
which is important for membrane stability of proteins [14] and also inhibits spontaneous crosslinking 
of signaling receptors in T cells [15]. Short and long-chain glycans can also be differentiated. 
Glycosaminoglycans are large unbranched polysaccharides consisting of repeating disaccharide units 
and are good examples of large glycans and consist of repeats of possibly thousands of disaccharide 
repeats [16]. On the other hand glycan-moieties of glycosphingolipids are relatively short and mostly 
have less than ten monosaccharides in the glycan [17]. 
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N-linked Glycosylation 
N-linked oligosaccharides are attached to the asparagine of the tripeptide sequence Asn-X-Thr/Ser 
whereas X can be any amino acid but proline [18]. There are three major classes of N-linked 
saccharides: high-mannose (Man), complex and hybrid oligosaccharides (Fig. 2). High-Man is, in 
essence, just two β1-4-linked N-acetylglucosamine (GlcNACs) with up to nine Man residues in 
mammals, which is the maximal amount of Man that occur on the precursor oligosaccharide before it 
is attached to the protein. Complex N-glycans are generated by cleaving away all Man residues but 
the three closest to the reducing end [13] and they are then extended with other types of 
monosaccharides which will be discussed briefly further below in this section. 
 
Figure 2: Comparative overview of the major types of vertebrate N-glycan subtypes. Complex-type N-glycans 
are trimmed high-Man-type N-linked glycans that are extended with GlcNAc, Gal and Sia. Hybrid-type N-linked 
oligosaccharides have a mixture of high-Man-type and complex-type branches (modified from [19]). 
Proteins destined for N-linked glycosylation possess an N-terminal signal sequence consisting of 
about 5 to 10 hydrophobic amino acids for their transport to the ER lumen [20]. This signal sequence 
is recognized and bound by a signal recognition particle that mediates the transport of the protein 
into the endoplasmic reticulum (ER) [20]. The next step in the ER is the addition of the N-linked 
oligosaccharide (Fig. 3). This process is catalyzed by a membrane protein complex termed 
oligosaccharyltransferase which transfers the N-glycan precursor, which is linked to dolichol, onto the 
nascent protein. This enzyme is positioned next to the translocator in the ER membrane [21]. 
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Figure 3: Dolichol-pyrophosphate (PP)-linked precursor for N-linked glycosylation. The precursor is attached to 
asparagine, which is the first step of N-linked glycosylation. The oligosaccharide can then be processed to 
create the diversity of N-linked glycans (modified from [22]). 
The newly synthesized glycoproteins are transported to the cis-Golgi stack by vesicular transport [23]. 
The high Man oligosaccharides can be further trimmed by the Golgi α-1,2-mannosidase to yield a 
Man5GlcNAc2 structure. In the medial cisternae, further N-glycan heterogeneity is created by the 
branching of complex-type N-glycans. This is accomplished by the GlcNAc-transferases 1-5 that add 
the various branches to the three core Man residues (Fig. 4) [24]. 
 
Figure 4: The branching of complex-type N-glycans is accomplished by the GlcNAc-transferases 1-5. The 
GlcNACs placed by the GlcNAc-transferases are the first monosaccharide of a branch on the N-linked glycan. 
Commonly, N-linked glycans have about two to four branches. Only the GlcNAc positioned by GlcNAc-
transferase 3 is not elongated with further monosaccharides (provided by Thierry Hennet). 
The GlcNAc-initiated branches on N-linked glycans, but also GlcNAc residues that occur in O-glycans 
or glycolipids, can be elongated in different ways. The addition of β1-4 linked galactose (Gal) 
generates a so called type-2 unit that is also known as N-acetyllactosamine [25]. Alternatively, a β1-4 
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N-acetylgalactosamine (GalNAc)-transferase may form so called LacdiNAc units [26]. The latter 
structure is rare in mammals, has however been indicated to play a key role in the capability of 
mouse embryonic stems cells to divide [27]. Instead of the β1-4 linkage, the Gal may also be attached 
in a β1-3 linkage. The respective glycans are termed type-1 glycan units or neo-N-acetyllactosamine 
[28]. The alternating activity of β1-4 Gal-transferases and β1-3 GlcNAc-transferases leads to the 
synthesis of poly-N-acetyllactosamine [29]. This epitope mainly occurs on multiantennary N-glycans 
on the β1-6 branch and is a strong ligand for a class of lectins known as galectins [30]. Poly-N-
acetyllactosamine can also be branched by the addition of β1-6 linked GlcNAc. Branched and 
unbranched poly-N-acetyllactosamine are termed as the “I” and “i” antigens respectively as they are 
also blood groups [31]. Some individuals lack the β1-6 GlcNAc-transferase that is responsible for the 
formation of the antigen and therefore only have unbranched poly-N-acetyllactosamine [32]. 
The final steps of complex oligosaccharide synthesis occur in the trans Golgi cisternae and consist of 
the addition of outer chain Gal and Sia residues [33]. The newly synthesized glycoproteins then exit 
the Golgi and are transported to their final destination [34]. These final steps of N-linked 
glycosylation result in a multitude of different epitopes that are terminally presented by the N-glycan 
chains (Fig. 5). 
 
Figure 5: Some typical epitopes found on complex-type N-linked glycans. Sialylated glycan epitopes often play a 
role in immunological responses as they interact with immune-dampening Siglec receptors or selectins which 
mediate immune cell extravasation from blood vessels. Poly-N-acetyllactosamine is a potent ligand for galectins 
that can regulate cell death or stabilize glycosylated proteins at the cell surface. The blood groups A and B 
occur as epitopes on cells and are the reason for incompatibility between certain blood donors and recipients. 
The Galili epitope is not presented on human cells and therefore the human body forms antibodies against it 
(provided by Thierry Hennet). 
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O-linked Glycosylation 
O-linked glycans can be attached to serine, threonine and hydroxylysine [35]. One exception to this is 
the O-glycosylation of glycogenin, which occurs on tyrosine [36]. Seven different monosaccharides 
can occur at the reducing end of O-linked glycans which are GalNAc, fucose (Fuc), Glc, Man, Gal, 
xylose and GlcNAc [35]. 
O-GalNAcylation is performed in the Golgi apparatus on proteins known as mucins but can occur on 
other proteins too [37]. O-linked GalNAc can be extended in at least eight different ways, resulting in 
eight different core structures (Fig. 6) [38]. The cores are then extended with various 
monosaccharides. The terminal epitopes of O-GalNAc type glycans resemble the ones found on N-
linked glycans and their synthesis is actually catalyzed by the same enzymes (Fig. 5) [37]. The 
placement of an α2-6 linked Sia onto the core GalNAc stops further elongation and results in the so 
called sialyl-Tn-antigen [39]. 
 
Figure 6: Core structures that occur on O-GalNAc type glycans. The cores 1 to 4 are the most common core 
structures to be placed on O-GalNAc type glycans. In some cells, especially in cells with tumorigenic properties 
the core GalNAc is not extended which is known as the Tn-antigen. The core GalNAc can also be elongated by 
an α2-6 Sia-transferase to the so called sialyl-Tn-antigen (provided by Thierry Hennet). 
Another form of O-linked glycosylation is O-linked xylose. This modification is made in the Golgi 
apparatus on serine residues of so called proteoglycans [40]. Proteoglycans are secreted or 
membrane bound proteins that are modified with long carbohydrate polymers that consist of 
disaccharide repeats that belong to the class of the glycosaminoglycans. Due to their modification 
with sulfate, they are highly polar. The glycosaminoglycans that occur on proteoglycans are heparan-, 
chondroitin-, and dermatan-sulfate (Fig. 7) [41]. 
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Figure 7: Proteoglycans and the glycosaminoglycans that occur on them. Chondroitin sulfate is the most 
common glycosaminoglycan. Dermatan sulfate can be distinguished from chondroitin sulfate by the presence 
of iduronic acid. Heparan sulfate is highly similar to heparin and consists of highly sulfated regions that are 
interrupted by non-sulfated regions (modified from [42]). 
Other O-glycans have Fuc, Gal, Glc or Man as their core at the reducing end. Depending on the core, 
the synthesis of these glycans is initiated in the ER or the Golgi apparatus. They can all be extended 
with other monosaccharides and all but O-Gal-type glycans can present terminal Sia [35]. 
Next to proteins also lipids are modified with glycans. As the glycans are attached to the hydroxyl 
group of ceramide, this is actually also a form of O-linked glycosylation. Ceramide is synthesized in 
the ER [17] and can be galactosylated in the ER [43] or glucosylated in the Golgi apparatus [44]. The 
galactosylated form is hardly extended and can maximally be modified with one more Gal while the 
glucosylated form can be elongated to form prominent glycosphingolipid classes such as the Globo-, 
Ganglio- or Lactoseries (Fig. 8). Many of the glycans epitopes can be found on N-linked glycans, on O-
GalNAc-linked glycans and on glycosphingolipids too (Fig. 5) [44]. 
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Figure 8: The various classes of glycosphingolipids with Glc at the reducing end of the oligosaccharide 
component. Globosides are especially common at the cell surface of erythrocytes and present no terminal Sia 
while gangliosides occur on nerve cells and can be modified with terminal Sia (provided by Thierry Hennet). 
Bacterial Glycosylation 
Glycosylation in bacteria is even more diverse than in mammals [45]. The outer-membrane of Gram-
positive bacteria mainly consists of peptidoglycan, which is a polymer consisting of GlcNAc that is β1-
4 linked to N- acetylmuramic acid (MurNAc). MurNAc contains a tri- to pentapeptide at the 2’-
acetamido group that is responsible for crosslinking the layers of the carbohydrate polymer (Fig. 9). 
About every tenth MurNAc also has a teichoic acid attached to it [46]. Teichoic acids protrude from 
the peptidoglycan layer and consist of ribitol-phosphate or glycerol-phosphate polymers [47]. 
Alternatively the teichoic acids of certain bacteria are attached to lipids in the plasma membrane 
[48].  
 
Figure 9: Peptidoglycan consists of repetitive disaccharide repeats of GlcNAc and MurNAc. The 
monosaccharides are linked by β1-4 linkages and each MurNAc is modified with 4 to 5 amino acids. One 
disaccharide repeat with the respective amino acid modification on MurNAc is highlighted in yellow (copied 
from [49]). 
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The peptidoglycan layer and the teichoic acids associated with it are relatively conserved between 
bacteria. Therefore, these molecules are also exploited by the immune system as pathogen 
associated molecular patterns, such as lipoteichoic acid which is recognized by the Toll-like receptor 
2 (TLR2) [50] or the GlcNAcβ1-4MurNAc disaccharide derived from peptidoglycan turnover which is 
also recognized by TLR2 [51]. The intracellular receptors NOD1 and NOD2 that initiate defense 
reactions against intracellular pathogens via the inflammasome also recognize peptidoglycan 
fragments that are in the cytoplasm [52, 53]. 
However many bacteria, including Gram-positive bacteria, also display capsular polysaccharides at 
their surface and these are highly diverse between bacteria. Such glycans are often produced by 
pathogenic bacteria and form thick layers that surround the individual bacterium and enable immune 
evasion. The carbohydrate component of the capsule is commonly acidic and consists of repeating 
units of 1 to 6 monosaccharides [54]. The structural diversity of the capsule is huge, as for example E. 
coli on its own can synthesize more than 80 different capsular polysaccharides [55]. The most 
important functions of capsular polysaccharides are to evade phagocytosis [56], protect the bacteria 
from desiccation by attracting water and also to avoid being infected by bacteriophages [57]. 
In comparison to Gram-positive bacteria, Gram-negative bacteria only have a thin layer of 
peptidoglycan that is covered by an outer membrane. This outer membrane has lipopolysaccharides 
(LPS) incorporated into it. LPS consists of a lipid A moiety that is incorporated into the outer 
membrane and has a carbohydrate moiety as a head group that protrudes out of the outer 
membrane (Fig. 10). The carbohydrate component consists of the oligosaccharide-core and the O-
antigen. Common monosaccharides in the core-oligosaccharide are 2-keto-3-desoxy-octonat, 
heptose, Glc, Gal and GlcNAc. During the synthesis of LPS the core oligosaccharide is attached to lipid 
A inside the cytoplasm before being flipped to face the periplasm where the O-antigen is attached. 
The O-antigen consists of tandem repeats of tetra- or pentasaccharides, depending on the bacterial 
species and strain. While the core oligosaccharide is always present, the O-antigen can also be absent 
in certain strains and species [58]. When the O-antigen is missing, the lipid-A core-oligosaccharide 
structure is defined as a lipooligosaccharide (LOS) [59]. 
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Figure 10: Schematic representation of LPS structure. Lipid A is modified with a disaccharide diphosphate that is 
elongated with a core saccharide. A polymerase then attaches a defined number of O-antigens that are 
premade on bactoprenol to the core polysaccharide (copied from [60]). 
Bacteria are also capable of performing O- and N-glycosylation of proteins. O-linked glycosylation 
most commonly occurs on pili and flagella [61, 62]. As in mammals, serine and threonine can be O-
glycosylated but also tyrosine is a possible acceptor [62]. The oligosaccharides attached via O-
glycosylation are far more diverse in bacteria than in mammals and contain more than the 9 
monosaccharides depicted in figure 1 [63-66]. Some bacteria can also O-glycosylate other proteins 
than pili and flagella such as Neisseria spp. and Bacteroides spp. 
Neisseria gonorrhoeae for instance has Ngo glycoproteins that are O-glycosylated. These proteins are 
likely involved in processes such as the electron transport system and are important redox 
components [67]. Ng1276 for instance is a copper-containing nitrite reductase that is important for 
growth during oxygen-limitation and has been proposed to receive electrons from Ng0994 [68]. 
Ng1371 on the other hand is a multiheme containing c-type cytochrome belonging to the cbb3 
oxidase complex which is the predicted terminal oxidase of the Ngo proteins [69]. 
Bacteroides fragilis, serves as another example of a bacterial species that can O-glycosylate other 
proteins than pili and flagella. B. fragilis is a component of the humans gut microbiota [70]. It can O-
glycosylate many extracytoplasmic proteins that are of importance for the bacteria’s capability to 
colonize the intestine [71]. B. fragilis and also other members of the Bacteroides genera are able to 
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glycosylate proteins that have the three amino acid sequence motif D(S,T)(A,L,V,I,M,T) at the middle 
serine or threonine [72]. 
N-glycosylation in bacteria has been best described in the pathogen Campylobacter jejuni. The glycan 
is synthesized on bactoprenol before being flipped to the periplasm where it is attached to an 
asparagine residue of a carrier protein by the oligosaccharyltransferase PglB [73]. Other bacteria with 
N-glycosylation are Desulfovibrio spp., Helicobacter spp., Haemophilus influenza and Actinobacillus 
pleuropneumoniae [74].  
The functional Diversity of common Glycan Epitopes 
Here, a few examples, of the functions that glycans are involved in, are provided. This by no means 
covers the vast diversity of roles that glycans play. 
ER quality control 
Calnexin and calreticulin are chaperones in the ER that are responsible for the correct folding of 
glycoproteins. They bind to the conserved oligosaccharide that is attached to N-linked glycans and 
regulate the folding of the protein [75]. Once the oligosaccharide precursor (Glc3Man9GlcNAc2) has 
been transferred onto asparagine of the target protein, the two outermost Glc residues are removed 
by the glucosidases I and II [76, 77]. The monoglucosylated oligosaccharide is recognized by the 
folding assistants’ calnexin and calreticulin that both interact with ERp57. ERp57 then forms 
intermolecular disulfide bonds with the glycoprotein to assist with the formation of disulfide bonds 
[78]. Once glucosidase II cleaves off the last Glc, calnexin and calreticulin dissociate from the target 
protein [13]. Correctly folded glycoproteins then enter the secretory pathway. On the other hand, 
glycoproteins that are not correctly glycosylated can be re-glucosylated by UDP-Glc:glycoprotein Glc-
transferase which enables the renewed assembly with calreticulin or calnexin [79]. If however folding 
cannot be achieved at all, at some time the completely de-glucosylated oligosaccharide will be 
processed by the ER degradation-enhancing α1,2-mannosidase-like protein which, once it has 
cleaved its target, will initiate ER-associated degradation [79]. 
IgG glycosylation 
The effector functions of IgG-type antibodies also depend on the N-linked glycan that is attached to 
the Fc-domain at asparagine-297. Core fucosylation of antibodies for instance has been shown to 
dampen antibody-dependent, cell-mediated cytotoxicity, a mechanism of cell-mediated immunity 
whereby natural killer cells actively lyse an antibody covered target cell via the Fcγ-receptor III. This is 
also the reason why therapeutic antibodies against certain forms of cancer are produced in cells that 
lack the core fucosylating enzyme Fuc-transferase 8 [80]. 
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Lysosomal trafficking 
Another key role that can be mediated by glycans is the trafficking of lysosomal resident proteins to 
the early endosomes. In vertebrates and some invertebrates this specificity is made possible by a 
Man-6-phosphate tag that is added to N-linked oligosaccharides of lysosomal resident proteins in the 
Golgi apparatus [81-83]. In the trans-Golgi network, specific luminal Man-6-phosphate receptors 
recognize this tag and bind the respective proteins that are packed into clathrin-coated vesicles 
determined for transport to early endosomes [84, 85]. 
In total, two enzymes are responsible for the addition of Man-6-phosphate. UDP-GlcNAc 1-
phosphotransferase (GlcNAc-1-phosphotransferase) binds to peptides with the recognition sequence 
in the cis Golgi and adds a GlcNAc-phosphate group to one or two of the Man residues on the N-
linked oligosaccharide [86]. A second enzyme, α-GlcNAc-1-phosphodiester α-GlcNAc-aminidase 
(uncovering enzyme), in the trans-Golgi network removes the GlcNAc residue and uncovers the Man-
6-phosphate tag [87, 88]. 
The A, B and H antigens 
In humans, the poly-N-acetyllactosamine chains of N-glycans, O-GalNAc glycans and glycolipids are 
also modified to form the ABO blood group antigens (Fig. 11). 
 
Figure 11: ABO blood group antigens that are attached to the type 1 and type 2 N-acetyllactosamine chains that 
occur on N- and O-glycans. The A antigen is characterized by a terminal α1-3 linked GalNAc while the B antigen 
has an α1-3 linked Gal. The H antigen has neither and is found in individuals that have the O blood group 
(copied from [89]). 
All three antigens are modified by the H α1-2 Fuc-transferase in erythrocyte precursors [90]. This 
modification is also performed on glycans of epithelial cells but by another enzyme called Se α1-2 
Fuc-transferase [91]. The A glycan epitope is made by an α1-3 GalNAc transferase that is encoded by 
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the so called A allele. Another variant of the same gene termed the B allele encodes an α1-3 Gal-
transferase [92]. A third dysfunctional H allele has lost its enzymatic activity completely. An individual 
who is homozygous for one of the A or B genes will have the blood group A or B respectively, as is 
also the case for individuals that are heterozygous for the A and H or B and H alleles. A heterozygous 
individual for the A and B allele will have the blood group AB and present both α1-3-linked GalNAc 
and α1-3-linked Gal on the ABO antigens. The blood group glycan epitopes must be considered when 
performing blood group transfusions. People of blood group A cannot receive blood from a donor 
with blood group B and vice versa. Everybody can however receive blood with the group H antigen as 
anti-H antibodies are not made because the A and B antigens are actually synthesized upon the H 
antigen. The ABO compatibility is also of great importance for heart, kidney, liver and bone marrow 
transplantations [93]. There is also one very rare blood type known as the Bombay phenotype. 
Individuals with this blood type have antigens against the A, B and H antigens because they actually 
lack the α1-2 Fuc-transferase that is needed to synthesize all three blood group determining antigens 
[94]. 
Lewis antigens 
The Lewis blood groups are another class of blood group antigens that contain α1-3 and α1-4 Fuc 
residues. The enzymes Le α1-3/α1-4 Fuc-transferase, that are encoded at the Lewis blood group 
locus, and Se α1-2 Fuc-transferase are central for the synthesis of the Lea and Leb glycan epitopes 
[95]. Some individuals have an inactive Le locus and are therefore negative for these glycan epitopes 
[96]. The Le α1-3/α1-4 Fuc-transferases are expressed by the same epithelial cells that express the Se 
α1-2 Fuc-transferase. As a consequence, the soluble glycans produced by epithelial cells commonly 
present these Lewis glycan epitopes [97]. Erythrocytes also present the Lea and Leb glycan epitopes 
on their cell surface however this is not because erythrocyte precursor can produce them but rather 
because erythrocytes acquire them via passive absorption of glycolipids that are in the plasma as 
components of lipoprotein complexes [98]. The Lex and Ley determinants and their sialylated versions 
are synthesized by α1-3 Fuc-transferases that are distinct from the Le α1-3/α1-4 Fuc-transferase [99]. 
Sialyl-Lewis X 
This glycan epitope mediates cell-cell recognition processes and it’s best known role is the regulation 
of leukocyte extravasation by enabling the tethering of leukocytes to the endothelial layer of blood 
vessels [100]. Sialyl-Lewis X is recognized by L-, P- and E-selectin [101]. L-selectin is present on 
lymphocytes and acts as a homing receptor for lymphocytes that enables them to be recruited to the 
lymph nodes [102]. E-selectin is mainly present on endothelial cells while P-selectin is present on 
platelets and endothelial cells. E- and P-selectin are both present in Weibel-Palade bodies that can be 
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found inside endothelial cells. If endothelial cells receive an appropriate signal, such as by recognizing 
bacterial pathogen-associated molecular patterns like peptidoglycan, the contents of the Weibel-
Palade bodies is released and E-and P-selectin are placed on the luminal membrane of the affected 
endothelial cell. Now the sialyl-Lewis X presenting leukocytes can bind to the endothelial cells, which 
initiates rolling and extravasation and therefore enables immune responses [103-105]. Some cancer 
cells that also present sialyl-Lewis X are able to hijack this system and use it to migrate into the 
underlying tissue therefore making sialyl-Lewis X an important player during metastasis [106, 107]. 
The Galili epitope 
The Galα1-3Gal terminus is synthesized by a specific α1-3 Gal-transferase that is expressed by many 
mammals but not by Old World primates such as humans. Therefore this epitope is immunogenic in 
humans. About 1% of human IgG is specific for the terminal Galα1-3Gal epitope [108]. Studies have 
proposed that this specific antibody may play a role in the removal of normal senescent and 
pathological human erythrocytes from the circulation [109]. Only 1% of normal human red blood 
cells were found to bind anti-Galα1-3. These cells had the highest density, and are thought to be the 
senescent red blood cells. Moreover, much greater proportions of thalassemic and sickle cells 
interact with anti-Galα1-3. Other studies have also shown that the bacterial lipopolysaccharide from 
Salmonella sp. and E. coli contain terminal α-1,3-Gal [110, 111]. 
α2-3-sialylated glycans 
At least six different α2-3 Sia-transferases are responsible for synthesizing α2-3-sialylated glycans in 
deuterostomes [112]. A good example for an α2-3 sialylated glycan epitope is sialyl-Lewis X, the 
selectin ligand that was described above. Terminal α2-3-linked sialylation has been suggested to 
serve as a mask, to cover terminal Gal, that are recognized by the asialoglycoprotein receptor which 
mediates the removal of glycoproteins from the serum [113]. In CD8+ T cells α2-3 sialylated glycans 
have been shown to enhance cell survival and act protectively against apoptosis, which serves as a 
means in lymphocytes to eliminate self-reactive immune responses [114]. 
As α2-3 sialylated glycans are terminal epitopes that are at the outermost layer on the cell surface, 
they also play an important role during infections. Hemagglutinin of the avian influenza virus for 
instance binds to α2-3 sialylated glycans in the avian respiratory tract [115]. For an influenza virus to 
infect humans however, the specificity of hemagglutinin must be altered to bind α2-6 sialylated 
glycans as these are more common in the upper human respiratory tract [116]. Helicobacter pylori is 
another pathogen that exploits sialylation for its disease progression by binding to α2-3 sialylated 
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glycans in the gastrointestinal tract mucosa where it can cause gastritis, gastric ulcers, and 
lymphomas in the gastrointestinal tract mucosa [117]. 
α2-6-sialylated glycans 
There are also at least six enzymes that are able of catalyzing the transfer of α2-6-linked Sia in 
vertebrates [118]. St6gal1 is expressed by hepatocytes and lymphocytes [119]. Because mainly 
St6gal1 is responsible for α2-6 sialylation in lymphocytes, it is not surprising that mice that have a 
debilitating mutation in St6gal1, have an immune pathology that is characterized by a reduced 
antibody response to T-cell dependent and independent antigens [120]. B cell proliferation is also 
strongly reduced in response to CD40 and IgM crosslinking on the cell surface and the IgM serum 
levels are decreased by 65% [120]. Another very critical role of α2-6 surface sialylation is its 
dampening role in B cell responses. On the cell surface of B lymphocytes there is a receptor named 
Siglec-2 which dampens B cell responses when it binds to α2-6 Sia that is presented on the cells own 
cell surface [121]. 
α2-8-sialylated glycans 
The α2-8 Sia epitope occurs mainly in the nervous system of vertebrates [122]. There are at least five 
different α2-8-Sia-transferases in deuterostomes [123] and two of them, St8sia2 and St8sia4 are able 
to synthesize polymers of 200 or more α2-8 linked Sia residues, which are termed poly-Sia [124]. N-
glycans with α2-3 linked Sia serve as an acceptor for Sia-transferases capable of synthesizing 
polysialic acid [123]. An example of such a protein is the embryonic form of NCAM which due to the 
modification has less homotypic interactions than the adult form of the protein [125-127]. This 
interferes with cell-adhesion processes in the nerve system and may create a more plastic 
environment that favors the formation of the nervous system in the early stages [128]. Mice that are 
deficient for St8sia2 for instance, have misguided migration of a subset of hippocampal neurons 
[129]. A deficiency for both St8sia2 and St8sia4 leads to a severe impediment of the nervous system 
and leads to premature death. Interestingly, this phenotype can be rescued by knocking out NCAM 
which shows that the phenotypes are due to the loss of polysialic acid on NCAM [130]. 
Glycolipids can also present α2-8 linked terminal Sia. Unlike the large polysialic acid molecules that 
are observed on NCAM for instance, only oligomeric α2-8 Sia is attached to glycolipids [131]. This is 
catalyzed by the three enzymes St8sia1, St8sia3 and St8sia5 [123].  
Mucins 
A prominent class of O-glycoproteins is the mucin-family. Mucins are high-molecular weight proteins 
and are produced by epithelial cells in animals. The interesting thing about these proteins is that they 
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are heavily glycosylated (Fig. 12). They are often secreted as a gel-like substance and therefore can 
serve as lubricants or barriers. They can however also influence cells by binding to receptors on their 
surface and have attained a reputation as inhibitors of cell signaling. The extensive glycosylation of 
these proteins has given them a large water-holding capacity and also makes the protein backbone 
resistant to protease digestion. Especially the latter is of importance in maintaining mucosal barriers 
that are constantly exposed to proteases such as in the digestive tract [132].  
 
Figure 12: Generic structure of a mucin monomer. Mucins contain repeat structures that have many serine and 
threonine residues that are O-glycosylated, resulting in dense glycosylation (modified from [133]). 
Mucins can either be membrane bound or secreted. Up to now 20 different mucins have been 
characterized in humans. Secreted mucins consist of a heavily glycosylated central region and 
flanking cysteine rich regions that can form intermolecular disulfide bonds with other mucin 
monomers. Due to these intermolecular disulfide bonds, secreted mucins can form massive 
aggregates with molecular weights that can reach 1 to 10 million Daltons. The oligosaccharides are 
attached via an O-GalNAc core to either serine or threonine [132]. 
O-linked GalNAc can be extended in at least eight different ways that result in eight different core 
structures (Fig.6). The cores 1 and 2 are the most common and are established by the attachment of 
β1-3 linked galactose to the reducing end GalNAc to make core 1 and an additional β1-6 linked 
GlcNAc to the reducing end GalNAc to make the second core (Fig. 6). The cores can then be extended 
with various monosaccharides and often present terminal Sia [134]. 
Secreted mucins mostly occur at mucosal surfaces such as the lungs or the intestine for example. 
MUC2 is present at the mucosal surface of the intestine and is produced by secretory goblet cells 
[135]. The O-linked glycans make up about 80% of MUC2’s molecular mass [3, 136]. A monomer of 
MUC2 is about 2.5 MDa and after polymerization it can be more than 100 MDa in size [136]. MUC2 
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polymerization most likely occurs as a result of trimers that are formed between MUC2 dimers [136, 
137]. 
Mucin glycosylation has been shown to play a pivotal role in maintaining the intestinal barrier. Mice 
that are engineered to lack the core 1 Gal-transferase for instance, develop intestinal bowels disease 
within 2 weeks after birth [138]. Another study has confirmed that the inner layer of the mucous can 
be penetrated by bacteria more easily in core 1 Gal-transferase lacking mice [139]. Therefore, it is not 
surprising that if the mice are treated with antibiotics, disease development is ameliorated [138]. 
Similarly, eliminating the core 3 Gal-transferase in mice leads to disturbed intestinal barrier function 
although not as extreme as is observed in core 1 Gal-transferase lacking mice [140]. The core 3 Gal-
transferase deficient mice have increased permeability and colonization of their colon mucosa. The 
application of dextran sodium sulfate also leads to an exacerbated onset of colitis in comparison to 
wild type mice [140]. 
The glycans presented by mucins also seem to influence the microbial composition. Mice that lack 
β1-4-GalNAc-transferase 2 for instance have an altered microbiota that is especially noticeable in the 
ileum [141]. These mutant mice are not able to add GalNAc to Gal residues that are substituted with 
an α2,3-linked Sia and therefore lack the so called Sd[a]/Cad antigen [141]. Interestingly, these 
mutant mice have extremely low numbers of Helicobacter sp. which indicates that the Sd[a]/Cad 
glycan epitope is especially important for this particular species to be able to establish itself in the 
digestive tract [141]. 
The O-glycans on mucins can also promote the cultivation of beneficial bacteria in the gut. The 
symbiont Bacteroides thetaiotaomicron for instance, stimulates angiogenesis to increase the 
absorptive capacities of the gut [142], produces short chain fatty acids that can be used for energy 
when absorbed in the colon, inhibits inflammatory responses in the intestine [143] and induces the 
production of antimicrobial molecules at the mucosal surface [144]. B. thetaiotaomicron has more 
than 80 polysaccharide utilization loci whereas mucin-type O-glycans induces the expression of 16 of 
them. Furthermore, if L-Fuc becomes scarce, B. thetaiotaomicron can induce the expression of 2-α-L-
Fuc-transferase 2 (Fut2) in intraepithelial epithelial cells of the gut which leads to more α1-2 linked 
fucosylation on mucin-type O-glycans in the gut [145, 146]. 
The Bifidobacteria genus is another example for symbiotic bacteria in the intestinal tract. There is 
evidence that they can counteract pathogen colonization [147] and inhibit the development of 
cancer due to colitis [148]. A well-known member of this bacterial genus is Bifidobacterium bifidum 
which is often found in the guts of infants. It possesses many glycosidases that are able to digest the 
oligosaccharides that occur on mucin-type O-glycans [149, 150]. An example of such a glycosidase is 
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endo-α-GalNAc-aminidase which can hydrolyze the bond between GalNAc and serine or threonine in 
O-glycosidic linkages [151]. Also 1,2 α-L-fucosidase, which can cleave off terminally α1-2 linked Fuc, 
occurs in B. bifidum [152]. Interestingly when Bifidobacteria bind to mucins, glycosidases such as the 
ones mentioned above are expressed [153]. 
Escherichia coli is one of the most common facultative anaerobes in the mammalian gut [154]. 
Defects in its carbohydrate utilisation locus impact the capability of E. coli to colonise and persist in 
the gut of mice [154]. Interestingly, the dependence of E. coli on different mucin-type O-glycans 
changes during the course of colonisation. During the log phase of colonisation for instance E. coli 
upregulates genes that are necessary for the catabolism of GlcNAc while Sia and Fuc catabolism is 
required during the stationary phase of gut colonisation [154]. 
Certain bacteria that colonise the gut don’t have the machinery to feed on mucin-type O-glycans. 
They profit from the hydrolytic activity of other intestine colonising bacteria. Akkermansia 
muciniphila for instance can degrade the glycans on MUC2 but Bacteroides vulgatus cannot [155]. 
Therefore, B. vulgatus cannot grow on MUC2 as its sole carbon source. However, when A. 
muciniphila and B. vulgatus are co-cultured, the growth of the latter does take place [155]. 
Another example demonstrating how mucin glycosylation can alter the microbiota in the gut is the 
influence of the secretor status on the microbial composition. The secretor status depends on the 
functionality of the galactoside FUT2. FUT2 is responsible for linking L-Fuc to Gal via an α1-2 linkage 
on mucin-type O-glycans which leads to the formation of the so called H-antigen [156]. The H-antigen 
itself can be further processed to the blood group A and B antigens or can be modified by the Lewis 
transferase, resulting in the production of the Lewis determinants Leb and Ley [156]. About 20% of the 
Caucasian population is homozygous for a null allele within the FUT2 gene, resulting in the total 
absence of the H-antigen on all mucin-type O-glycans [156]. Such individuals are known as non-
secretors while people with at least one functional FUT2 allele are known as secretors. The gut 
microbiota of “non-secretors” is distinctly different from that of secretors. Species of the genus 
Prevotella for instance are enriched within the gut of non-secretors [157]. This genus of bacteria is 
able to hydrolyze terminal 6-SO3-GlcNAc on mucin-type O-glycans [158]. The desulfation of mucins 
by Prevotella species is a critical observation especially as desulfated mucin O-glycans have been 
associated with exacerbated inflammation after dextran sodium sulfate treatment [158]. Mice that 
lack the GlcNAc 6-sulfotransferase for instance have an increased infiltration of CD45+ inflammatory 
cells, including neutrophils and macrophages, into the colon [159]. Also the absence of the sulfate 
transporter NaS1, which maintains the levels of circulating sulfate, in knockout mice leads to an 
exacerbation of colitis in the DSS model [160]. 
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O-glycans on mucins can also influence the immune system directly. Recently, the group of Andrea 
Cerutti demonstrated that MUC2 can be ingested by antigen-sampling dendritic cells. The glycans 
presented by MUC2 had an anti-inflammatory effect that is mediated via a galectin-3-Dectin-1-
FcγRIIB receptor complex that activates the transcription factor β-catenin. They then showed that β-
catenin can block the expression of inflammatory cytokines by inhibiting the nuclear factor κB. 
Tolerogenic cytokines on the other hand aren’t influenced by β-catenin [4]. 
Some mucins are not secreted but instead are incorporated into the plasma membrane of the 
expressing cell. Examples for membrane incorporated mucins are MUC1, MUC3A, MUC3B, MUC4, 
MUC12, MUC13, MUC15, MUC16, MUC17, MUC20 and MUC21. They have a single transmembrane 
domain, a short intracellular domain (22-80 amino acids) and a large extracellular domain. The major 
components of the extracellular domain are the tandem-repeat domains which is also the key 
feature of all proteins that are classified as mucins. As with the secreted mucins these repeats are 
highly glycosylated. Membrane-bound mucins are highly diverse and involved in many different 
processes such as modulating immune responses or facilitating adhesion between cells [161]. 
Soluble Glycans 
Not all glycans are attached to another biomolecule. Human milk oligosaccharides (HMOs) and 
hyaluronan are examples for glycans that are secreted by cells and also have important modulatory 
functions. HMOs are a structurally highly diverse collection of sugars that occur in human milk. They 
contain the five monosaccharides Glc, Gal, GlcNAc, Fuc and Sia. The reducing end is always lactose 
that is elongated with β1-3- or β1-6-linked lacto-N-biose (Galβ1-3GlcNAc) or N-acetyllactosamine 
(Galβ1-4GlcNAc). Lacto-N-biose chains cannot be further modified with Gal, Fuc or Sia while N-
acetyllactosamine can be modified with one or two further monosaccharides. β1-6-linkages between 
monosaccharides introduce branching points in the lacto-N-biose and N-acetyllactosamine chains 
(Fig. 13). 
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Figure 13: The structural diversity of HMOs. (A) The structure of all HMOs follows the same blueprint with 
lactose at the core. The elongation of lactose occurs by attaching N-acetyllactosamine or lacto-N-biose repeats. 
(C) Simple trisaccharides can be established by sialylating or fucosylating lactose. Elongated HMOs can also be 
(D) fucosylated or (E) sialylated (copied from [5]). 
HMOs play an important role for the breastfed infant. Originally, HMOs were discovered as factors 
that promote the growth of Bifidobacteria, which are desirable bacteria that grow in the gut of 
neonates. Furthermore, HMOs can serve as soluble decoys for pathogens that bind to them, which 
ultimately displace them from the epithelium. The best example for this role of HMOs was observed 
in studies with Campylobacter jejuni that bind to α1-2-fucosylated surface glycans and can be 
displaced by soluble α1-2-fucosylated HMOs. Feeding mice with α1-2-fucosylated HMOs lead to 
reduced colonization by C. jejuni [162]. HMOs can also directly interact with epithelial cells to alter 
their gene expression, leading to changes in the cell’s surface glycans which directly affects the 
adhesion of bacterial subtypes to the guts epithelium. 3’-sialyllactose binding to epithelial cells for 
instance lowers the expression of the Sia-transferases St3gal1, St3gal2 and St3gal4 which leads to 
decreased α2-3- and α2-6-sialylation on the cell surface [163]. HMOs are also able to directly affect 
leukocytes. They can influence the production of cytokines by lymphocytes leading to a more 
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balanced Th1/Th2 response [164]. This was shown with cord blood T-cells that have been exposed to 
sialylated HMOs which increases the amount of interferon-γ-producing CD3+CD4+ and interlukin-13 
(IL-13) producing CD3+CD8+ lymphocytes [164]. Another study was able to show that human milk 
oligosaccharides interfere with the interaction of selectins with their ligands, ultimately leading to 
less leukocyte rolling on activated endothelial cells which is required for leukocyte extravasation and 
the recruitment of cells to inflamed tissues [165]. 
Recent results indicate that HMOs may directly regulate antigen presenting cells like dendritic cells. 
The onset of colitis was delayed in IL10-/- mice that were deficient for the α2-3 Sia-transferase 4 that, 
among other functions, is responsible for the synthesis of 3-sialyllactose. When these mice were 
supplemented with 3-sialyllactose the severity of colitis was restored. The authors then 
demonstrated that 3-sialyllactose was able to directly stimulate lymph node CD11c+ dendritic cells via 
TLR4 signaling [166]. 
Hyaluronan is another soluble glycan that has many regulatory functions. It consists of the 
monosaccharides glucuronic acid and GlcNAc that are linked alternately by β1-4- and β1-3-linkages. 
The polymers can range from 5’000 to 20’000 kDa in size [6]. Hyaluronan binds to membrane 
proteins such as CD44 and leads to their clustering on the cell surface. This mediates the activation of 
downstream kinases like c-Src and the focal adhesion kinase. In tumor cells this results in 
proliferation and invasion while in embryonic cells an epithelial to mesenchymal transition is induced 
[167]. Surprisingly in light of these results however, high-molecular weight hyaluronan has been 
shown to be protective against cancer metastasis in naked mole rats which is the reason why these 
animals don’t suffer from cancer although cancer often affects aged rodents [168]. Hyaluronan is also 
an important component in joints where it acts as a lubricant but also dampens impacts during 
movement which counteracts degradative processes [169]. Another important role of hyaluronan is 
the protective layer it forms around the egg cells. To successfully fertilize the egg cell, sperm cells 
therefore must produce hyaluronidases, so that they can access the plasma membrane [170]. 
Hyaluronan is also crucial in other processes such as wound repair, inflammation and cell migration 
[6]. 
Immune regulatory roles of bacterial glycans 
As with mammalian cells the outermost layer of bacterial cells is composed of glycans which form the 
interface of bacterial cells with their environment and with other bacteria or host cells. The capsules 
and O-antigens are the outermost glycans of many bacterial cells and they are highly immunogenic 
and result in strong antibody responses. Bacterial species are often classified into serological groups 
according to their specific O-antigen. In E. coli alone 173 different O-antigens and 103 different 
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capsular polysaccharides have been identified. The consequence is that contact to one specific 
serotype does not mean that the immune system can mount a challenge against the pathogen in 
general but to the specific serotype. Therefore it is possible that the same species can infect a host if 
it has a serotype that the immune system has not encountered yet [171]. 
The N- and O-glycosylation machineries also exist in bacterial cells. S layer glycoproteins that occur in 
the peptidoglycan layer of Gram-positive bacteria were one of the first bacterial protein classes 
where glycosylation was detected [172, 173]. Later, the pili of Neisseria gonorrhoeae and N. 
meningitides, as well as the flagella of Pseudomonas aeruginosa and Helicobacter pylori were proven 
to be glycosylated [171]. These glycoproteins are frequently of great relevance for interactions of the 
host with bacteria. The mannosylated Apa glycoproteins of Mycobacterium spp. is able to inflict 
delayed-type-hypersensitivity reactions in vivo and activate the amplification of T lymphocytes in 
vitro but these effects are lost when the Apa glycoprotein is chemically or enzymatically 
deglycosylated [174]. 
Some bacteria are able to ingest the glycans of their host and present them on their own surface. 
One example is the pathogen Haemophilus influenzae which can scavenge Sia from its environment 
and activate it to CMP-Sia to attach the monosaccharide to its lipopolysaccharides [175]. Not only 
pathogens can present host derived glycans on their surface but also commensals such as B. 
thetaiotaomicron for instance can enhance the expression of α1-2 fucosyltransferase by intestinal 
epithelial cells [176]. This leads to the upregulation of fucosylated glycans on the host’s epithelium. 
These Fuc residues are released and absorbed by B. thetaiotaomicron with a Fuc specific permease. 
Inside the cell the Fuc is metabolized to GDP-Fuc and subsequently incorporated into the capsular 
polysaccharides and lipopolysaccharides [177]. The surface Fuc is very important for B. 
thetaiotaomicron to colonize the gut of their host as was shown with mutant strains that are not able 
to incorporate Fuc [178]. 
The oligosaccharides on the cell surface are also a useful tool for bacteria to evade immune 
surveillance. Neisseria meningitidis for example presents Sia on its surface to evade the complement 
cascade [179]. Sia is a common terminal monosaccharide on many host glycans in mammals. It has 
many functions of which one is to hinder the hosts own cells being attacked by the complement 
system, by recruiting the complement factor H. The central component of the complement cascade is 
the factor C3 which binds to cell surfaces and via different mechanisms is cleaved to the factors C3a 
and C3b. The latter of the two acts as an opsonization signal and also initiates cytolysis by initiating 
the formation of a membrane attack complex [180]. If factor H is recruited to the cell surface 
however, it mediates the cleavage and deactivation of factor C3b, thereby stopping the complement 
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system in its track [181]. The production of a hyaluronic acid capsule by group A streptococci is 
another good example of molecular mimicry by a pathogen to avoid the host’s immune system [182].  
Another class of polysaccharides that have very interesting immunological properties are so called 
zwitterionic polysaccharides. These sugars have both a positive and a negative charge. Normally, 
polysaccharides are T-cell-independent antigens and can therefore not stimulate IgG class switching 
in B cells or elicit immunologic memory. However, zwitterionic polysaccharides have been shown to 
be presented on MHC class II. The pathway of presentation remains the same as for protein antigens 
[183]. 
Bacterial glycans are also a key class of molecules to establish long-term interactions between 
commensal bacteria and the host. Bacteroides fragilis can produce at least eight capsular 
polysaccharides [184]. Phase variation between the different capsular polysaccharides is controlled 
by a DNA inversion based mechanism and enables this commensal species to react to the immune 
system and phage infections, making it extremely competitive in cultivating the mammalian gut 
[184]. Some of the capsular polysaccharides of B. fragilis are also important in maintaining the health 
of the host. Polysaccharide A is the most commonly produced capsular polysaccharide produced by 
B. fragilis and it plays an essential role in the maturation of the immune system [185]. It is a well-
known fact that mice kept in a germ-free environment have an underdeveloped intestinal immune 
system [186]. If the mice are mono-associated with B. fragilis, immune system maturation is rescued. 
However, if the bacteria lack the genetic locus that is responsible for the synthesis of polysaccharide 
A, the maturation of the immune system is not restored. Mice that are cultured with polysaccharide 
A lacking B. fragilis had less CD4+ splenic lymphocytes and these cells produced markedly less 
interferon-γ. However they produced more IL-4 which lead the authors to speculate that 
polysaccharide A plays a key role in regulating the homeostasis of the Th1/Th2 response and that this 
is central for the correct maturation of the guts immune system [187]. 
The glycans on Helicobacter pylori also seem to regulate the host’s immunity. Many O-antigens are 
fucosylated and resemble the Lewis blood group antigens of the host [188]. Similar to the capsular 
polysaccharides of B. fragilis, the antigens presented by H. pylori are phase variable which is steered 
by slip-strand mispairing in the coding regions of the Fuc-transferase genes [189]. This results in a 
heterogeneous population of H. pylori. The Lewis antigen-positive bacteria can bind to the C type 
lectin DC-SIGN that is expressed by dendritic cells and thereby inhibit the differentiation of T cells 
into Th1 cells and block immune responses [190]. The Lewis antigen-negative population on the 
other hand fails to bind to DC-SIGN and promotes the development of Th1 cells and a 
proinflammatory environment instead. Phase variation therefore enables H. pylori to modulate its 
environment to create an ideal niche to colonize the host [191]. 
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The glycobiology of cell death 
In the 1980s researchers were able to show that lectins expressed on the cell surface of macrophages 
can specifically recognise dead cells. Therefore, dying cells must have their own specific cell surface 
glycome [192]. This opened up an interface between the fields of cell death biology and glycobiology. 
Not only is altered glycosylation a consequence of cell death but it also plays a modulating role on 
programmed cell death. Glycosylation of cell-death receptors for instance can fine tune the 
sensitivity of cells to death [193]. Certain glycans can also recruit a class of lectins termed galectins 
that can initiate apoptosis after being recruited to the cell surface [194]. 
Galectins 
Galectins are a family of β-galactoside binding lectins that are atypically secreted into the 
extracellular space. They are also present in the cytoplasm or in the nucleus. Up to now 15 galectins 
have been discovered in mammals of which only 13 occur in humans. Galectins are either dimers or 
have a tandem conformation, except for galectin-3 which has a chimeric shape (Fig. 14). The 
structure of galectins enables them to crosslink different glycan epitopes [195]. 
 
Figure 14: Some galectins form dimers with two equal carbohydrate binding domains (dimeric) while others 
have two different carbohydrate binding domains (tandem). Galectin-3 is an exception and can form so called 
chimeras with five equal carbohydrate binding domains (copied from [196]). 
The major ligands of the galectins are lactose and N-acetyllactosamine. Tandem repeats of these 
motifs, like for instance poly-N-acetyllactosamine, lead to increased binding affinities of the galectins 
due to more Van der Waals interactions taking place between the carbohydrate and carbohydrate 
binding pocket of the galectin. The binding specificities of the individual galectins to different glycan 
structures do vary however [197]. The galectins-2 and -3 bind more strongly to fucosylated A and B 
blood group antigens than galectin-1 while galectin-2 exhibits reduced binding to sialylated glycans 
compared to the galectins-1 and -3 [198]. 
Galectins are involved in many processes such as mediating cell-cell interactions, cell-matrix adhesion 
and transmembrane signaling [196]. Interestingly they can also regulate cell death either from 
outside or from inside the cell. On the cell surface galectins can initiate cell death by triggering 
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further downstream signaling processes by crosslinking glycosylated receptors on the cell surface 
[194]. One example for galectin-mediated cell death is the negative selection of T cells in the thymus. 
The galectins-1 and -9 are both secreted by epithelial cells in the thymus and can mediate T cell 
apoptosis. The galectins-1 and -9 are also crucial for the elimination of activated and infected T cells 
after immune responses in the periphery [194]. Galectin-1 can interact with several receptors on the 
cell surface but especially its interactions with CD7, CD43 and CD45 are important to induce 
apoptosis. In keratinocytes the expression of galectin-7 is regulated by p53 and is believed to be 
necessary to regulate apoptosis after damage by UV-light [194, 196]. Galectin-12 is also apoptosis 
promoting but in adipocytes [196]. Galectin-3 on the other hand has anti-apoptotic properties. 
Interestingly it is the intracellular form of galectin-3 that has been shown to have an anti-apoptotic 
effect. Although the precise mechanism is unclear, it seems to be due to its ability to bind to Bcl-2, an 
anti-apoptotic, intracellular protein [194]. Extracellular galectin-3 on the other hand can promote cell 
death as has been observed for T cells and neutrophils [196]. 
Siglecs 
Siglecs are type I membrane proteins that have an extracellular N-terminal and intracellular C-
terminal domain. The N-terminus consists of a V-type immunoglobular domain that is responsible for 
ligand binding. The primary ligands of Siglec proteins are Sia containing glycans. As the most Siglecs 
have a relatively short stem, they do not usually bind to the glycans on other cells but to the glycans 
on the own cell surface. The only exception is Siglec-1 which has 16 C2-Ig domains, making it long and 
capable of binding to glycans on other cells [199]. 
In primates 17 Siglecs have been identified to date. Mice on the other hand only have 8 Siglecs. Most 
of them are expressed by immune cells such as Siglec-2 which is expressed by B cells [121, 200]. But 
some Siglecs, such as Siglec-4 that is present on myelin cells [201], are also expressed by other cells. 
The most Siglecs have an intracellular immunoreceptor tyrosine-based inhibition motif (ITIM)-
domain. Once a respective Siglec has bound its ligand, a tyrosine residue in the ITIM-domain is 
phosphorylated which enables the recruitment of SH2 domain-containing proteins such as SHP 
phosphatases. This leads to the dephosphorylation of several proteins and is responsible for immune 
dampening reactions [202]. Activated Siglec-7 for example will mediate the dephosphorylation of the 
activatory nuclear factor ZAP-70 that is downstream of T cell receptor signaling [203]. The Siglecs-14 
and -15 in primates and Siglec-H in mice have a positively charged arginine or lysine residue in the 
cytoplasmic domain that is able to recruit ITAM-containing adapter proteins such as DAP10 or DAP12 
that mediate the up-regulation of several phosphorylation cascades and the activation of cellular 
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signaling cascades [200, 204, 205]. DAP12 for instance is able to phosphorylate Syk in myeloid and NK 
cells as well as ZAP-70 in NK cells which all mediate proinflammatory signaling [206]. 
Recently, Siglecs have also been shown to be able to induce cell death. Siglec-8 for instance is present 
on the surface of eosinophil cells and its ligation leads to apoptosis. In the presence of IL-5 however, 
the cells undergo caspase-independent necrotic-like cell death that is dependent on the formation of 
reactive oxygen species and the phosphorylation of ERK1/2 and MEK1 [207]. 
The clustering of Siglec-7 by specific F(ab’)2 fragments also leads to cell death in the monocytic cell 
line U937. However, the effect is independent of the intracellular ITIM-domain as cells expressing a 
truncated version of Siglec-7 still underwent cell death when Siglec-7 was clustered. Also the oxygen 
radical scavenger N-acetyl cysteine completely inhibits this form of Siglec-7 mediated cell death but a 
pan-caspase inhibitor did not. The authors identified the middle of the membrane-proximal C2-set 
domain as absolutely required for cell death and therefore concluded that the cell death inducing 
signal is transduced extracellularly [208]. Human neutrophils can undergo autophagic-type cell death 
as a consequence to Siglec-9 ligation in the presence of cytokines that are required for neutrophil 
survival such as GM-CSF. For this type of cell death to occur the inhibition of caspases and the 
production of reactive oxygen species is required [209]. 
Death-receptor glycosylation and cell death regulation 
The TNF-related apoptosis-inducing ligand (TRAIL) induces cell death by binding and activating the 
receptors TRAIL-R1 and TRAIL-R2. The ligation of TRAIL to these receptors initiates the formation of 
the Death-inducing signaling complex (DISC) by recruiting the caspases-8 and -10 together with the 
adaptor protein FADD [210]. These initiator caspases then mediate the activation of effector 
caspases such as caspase-3 that cause the dismantling of the cell [211]. 
The sensitivity of a cell to TRAIL is not only dependent on the expression level of the receptors but 
also on their post-translational modifications. TRAIL-R2 for example is O-glycosylated which is 
required for the formation of the DISC and apoptosis as a consequence of TRAIL binding [212]. On the 
other hand, N-glycosylation regulates TRAIL-R1 as was shown in N-glycosylation-deficient TRAIL-R1 
mutants. Cells that express unglycosylated versions of the human TRAIL-R1 or the murine TRAIL-R are 
less sensitive to TRAIL treatment due to lower TRAIL receptor aggregation and less DISC formation, 
however the binding affinity of TRAIL to the receptor is not affected [193]. 
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Programmed cell death 
Cell death can either be the result of necrosis or due to a form of programmed cell death [213]. 
Necrosis is a process that is caused by cell injury or infection and is dependent on cell external 
factors. Programmed cell death however is a regulated process that leads to the death of a cell in a 
defined manner with a specified outcome. There are several forms of programmed cell death such as 
apoptosis, pyroptosis and necroptosis. While apoptosis is not inflammatory, necroptosis and 
pyroptosis are highly inflammatory processes [214]. 
Necrosis 
Necrosis can be viewed as the premature death of a cell caused by cell injury. In contrast to 
programmed forms of cell death, necrosis is almost always a negative event that is detrimental and 
can be fatal for the organism. Necrosis is not initiated by a general signaling pathway as apoptosis is, 
instead it is caused by the loss of membrane integrity and the leakage of cellular components into 
the extracellular space [215]. This leads to an inflammatory response in the vicinity which attracts 
leukocytes to the site of damage that eliminate the debris by phagocytosis. Necrosis is characterized 
by oncosis which is cell swelling. The cell starts to bleb and the nucleus shrinks before dissolving into 
the cytoplasm [216]. 
Apoptosis 
Apoptosis can be initiated in many different ways. It is characterized by morphological and 
intracellular changes. First the cells start to shrink and become round because the cytoskeleton is 
being digested by caspases [217]. The cytoplasm becomes dense and the organelles become tightly 
packed. The chromatin then starts to become denser and compact patches develop beneath the 
nuclear envelope, a process that is known as pyknosis [218, 219]. In later stages the DNA starts to 
fragment [220] and irregular blebs start to occur on the cell membrane. Finally the cell starts to break 
apart. The fragments that are formed are known as apoptotic bodies [221]. Apoptosis can be 
initiated by an intrinsic and an extrinsic pathway (Fig. 15). The intrinsic pathway is initiated by cell 
endogenous stress such as the formation of reactive oxygen species while the extrinsic pathway is 
initiated by signals derived from other cells such as cell death signaling proteins like TRAIL [222]. 
Proteases called caspases play a central role during apoptosis. The caspases 8, 9 and 10 are initiator 
caspases [223] while the caspases 3, 6 and 7 are effector caspases [224]. Initiator caspases require 
activation by either the intrinsic or extrinsic pathway. They then activate the effector caspases by 
cleaving them. The effector caspases then start proteolytically digesting an array of intracellular 
proteins which ultimately leads to cell death [224]. 
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Intrinsic pathway 
The intrinsic pathway is initiated via apoptotic proteins that disrupt the mitochondria. This often 
leads to mitochondrial swelling and increased mitochondrial permeability which causes pro-
apoptotic factors to leak into the cytoplasm [225]. Proteins called secondary mitochondria-derived 
activator of caspases (SMACs) are released into the cytoplasm as a consequence. They can bind to 
proteins that inhibit apoptosis (IAPs) and block their activity. IAPs normally suppress apoptosis by 
binding to caspases and inactivating them [226]. 
Cytochrome c is another component that is released by the mitochondria that plays a central role 
during apoptosis [227]. In the cytoplasm it binds to the apoptotic protease activating factor-1 and 
ATP which then associates with the pro-caspase-9 to form a complex known as the apoptosome (Fig. 
15). In this complex pro-caspase-9 is cleaved to its active form which can then activate the effector 
caspase-3 [223]. 
Extrinsic pathway 
TNFR1 stimulation can lead to the activation of caspases through the TNF receptor-associated death 
domain and the Fas-associated death domain proteins that together with the caspases 8 and 10 
assemble to form the DISC (Fig.15). However, usually tumor necrosis factor-α (TNF-α) stimulation 
does not induce apoptosis due to simultaneous NF-κB signaling that leads to the expression of FLIP, a 
protein that stops the activation of caspase-8 [228]. Furthermore, the proteins cIAP1 and cIAP2 are 
upregulated that are able to ubiquitinate an apoptosis promoting protein called the kinase receptor 
interacting protein 1 (RIPK1). The consequence of RIPK1 ubiquitination is that it associates with the 
pro-survival kinase TAK3 and becomes deactivated [229]. If cIAP 1 and 2 are depleted, RIPK1 will not 
be ubiquitinated and will become an essential part of the DISC that ultimately mediates the 
activation of the caspases 8 and 10 [230]. 
The Fas pathway is another possibility to extrinsically induce apoptosis. It occurs when the 
transmembrane protein “Fas ligand” binds to the Fas receptor on the designated target cell [231]. Fas 
ligand itself is actually a member of the TNF family [231]. The interaction of Fas ligand with the Fas 
receptor leads to the formation of the DISC which contains the Fas-associated death domain protein, 
caspase-8 and caspase-10. Activation of the initiators caspases-8 and -10 leads to the activation of 
the downstream effector caspases [232]. 
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Figure 15: Intrinsic and extrinsic apoptosis inducing pathways. In the intrinsic pathway, cytochrome c is 
released from the mitochondria, which initiates the formation of the apoptosome that cleaves and activates 
caspase-9. In the extrinsic pathway the stimulation of a death receptor leads to the intracellular formation of 
the DISC which mediates the activation of caspase-8 (copied from [233]). 
Pyroptosis 
Pyroptosis is a form of programmed cell death that mainly occurs in immune cells and is initiated 
from within the cell itself by the recognition of cell internal pathogens or danger associated 
molecular patterns. Unlike during apoptosis, the plasma membrane ruptures and damage associated 
patterns such as ATP, DNA or the adapter protein ASC are released into the extracellular space. The 
inflammatory cytokines IL-1β and IL-18 are also released. Pore formation which leads to a disrupted 
cellular ionic gradient, results in disturbed osmotic pressure and the influx of water that ultimately 
causes the cell to swell and burst [234]. 
For the initiation of pyroptosis so called NOD-like receptors are required that recognize pathogen- or 
danger associated molecular patterns inside the cytoplasm. There are more than 20 subsets of NOD-
like receptors [235]. The best characterized are NOD1, NOD2, NLRP3 and NLRC4 [236]. They all 
recognize bacterial, viral and toxic foreign components or danger associated molecular patterns in 
the cytoplasm. The recognition of ligands by NOD-like receptors leads to the formation of a so called 
inflammasome which is a single large protein complex that takes shape in the cytoplasm (Fig. 16) 
[237]. The inflammasome has many protein components but its most important are the respective 
NOD-like receptor protein, caspase-1 and the adaptor protein ASC [235]. 
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The inflammasome is ultimately responsible for cleaving and activating caspase-1 [238]. Caspase-1 
itself initiates pyroptosis and is responsible for cleaving the precursors of IL-1β and IL-18 into their 
active form. Until recently, caspase-1 was believed to be the only caspase that can initiate pyroptosis. 
However in 2013 murine caspase-11 and its human homologs caspases-4 and -5 were also proven to 
cause pyroptosis. For pro-caspase-11 expression, TRIF activation is absolutely necessary which can be 
caused by TLR3 or TLR4 signaling. Unlike caspase-1 that requires a receptor/scaffold mediator to 
recognize intracellular pathogen- or danger- associated molecular patterns to be activated, caspase-
11 can directly bind to LPS via its caspase recruitment domain and become activated [239]. For 
pyroptosis to occur, affected cells often require priming by Toll like receptor signaling that leads to 
NF-κB signaling. The production of pro-IL-1β and pro-IL-18 is actually a consequence of Toll-like 
receptor signaling [240]. 
Not so long ago a protein called Gasdermin-D was identified as a substrate of the caspases-1/4/5 and 
-11. These caspases cleave Gasdermin-D in the middle linker, which releases the N-terminal fragment 
that perforates the plasma membrane during pyroptosis [241-244]. Recently, Gasdermin-E was 
shown to be cleaved by caspase-3 in the linker region, establishing an N-terminal fragment that can 
perforate the cell membrane [245]. Until this discovery, caspase-3 activity had mainly been 
associated with apoptosis. However, Gasdermin-E activation can direct cell death towards pyroptosis. 
The ectopic expression of gasdermin E was furthermore shown to be able to redirect TNF-α induced 
apoptosis to pyroptotic cell death in cultured cancer cells [245]. 
 
 
 
 
 
Sialylated Glycans as Regulators of Cell Activation and Cell Death 
43 
 
 
Figure 16: Pyroptosis is executed by Gasdermin-D. NOD receptors act as sensors for intracellular pathogens and 
danger-associated molecular patterns. The ligation of NOD receptors to a target mediates the formation of the 
inflammasome. ASC filaments acts as the central scaffold of the inflammasome and recruit pro-caspase-1 which 
is then activated. Pro-caspase-11 on the other hand does not need to be recruited to the inflammasome and 
can directly recognize its ligands such as LPS. Caspase-1 mediates the activation of IL-1β and both caspase-1 
and -11 can activate gasdermin-D which then incorporates itself into the plasma membrane and forms pores 
that ultimately kill the cell (copied from [244]). 
Necroptosis 
Necroptosis is actually a programmed form of necrosis. It is a caspase-independent form of cell death 
that occurs in response to viral infections but also if cell homeostasis is lost. DNA damage for instance 
can lead to the downstream phosphorylation of the necroptosis drivers kinase receptor interacting 
proteins (RIPKs) 1 and 3 [246, 247]. Necroptosis can also be induced by TNF-α via the TNFR1. As with 
extrinsically induced apoptosis, the TNF-receptor associated death domain is responsible for 
initiating TNF-α inflicted necroptosis by signaling to RIPK1 which then recruits RIPK3 (Fig. 17) to the 
so called necrosome. The necrosome is only formed when caspase-8 remains inactive, otherwise 
DISC assembly and apoptosis will occur [248]. The necrosome is a microfilament-like protein complex 
that also accommodates the RIPKs 1 and 3 and is responsible for phosphorylating and activating a 
protein called mixed lineage kinase domain like pseudokinase (MLKL) [249]. Phosphorylation leads to 
MLKL oligomerization and its incorporation into the plasma membrane (Fig. 17) and the membranes 
of organelles inside the cell which leads to their permeabilization [250, 251]. This leads to the leakage 
of damage-associated patterns into the extracellular space which can elicit immune responses [249]. 
Incorporation of MLKL into the mitochondrial membrane may block the electron transport chain in 
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the mitochondria which inflicts mitochondrial damage and permeability [252]. The lysosomes are 
also damaged by MLKL which in response start to leak lysosomal hydrolases into the cytoplasm [253]. 
 
Figure 17: The necroptosis pathway. When caspase-8 is inactive, death receptor signaling leads to the assembly 
of the necrosome that consists of the RIPKs 1 and 3. The necrosome then phosphorylates MLKL which 
oligomerizes and is inserted into the plasma membrane. This leads to membrane damage and therefore cell 
lysis and death. Necroptosis can be inhibited with the small molecules necrostatin-1 (Nec-1) and 
necrosulfonamide (NSA) (copied from [248]). 
The pathways that are involved during necroptosis and apoptosis are highly intervened and share 
many components. RIPK1 for example has been implicated during apoptosis [254] and necroptosis 
[255, 256]. RIPK1 interacts with both FADD and caspase-8 and is absolutely required for the induction 
of apoptosis in the presence of the IAP inhibiting SMAC mimetics [257]. This is evident in mice that 
lack RIPK1 as they have an increased amount of apoptosis and die at 1 to 3 days of age [258]. 
RIPK1 has a death domain which enables it to interact with death receptors such as the TNF receptor 
1 or the Fas receptor that are required for caspase-8 mediated apoptosis [259, 260]. Furthermore, 
RIPK1 contains a RIP homotypic domain that is required for its interaction with RIPK3 [261]. The 
influence of RIPK1 on cell death is also dependent on its posttranslational modifications. RIPK1 can 
be ubiquitinated at lysine 63 which leads to the downstream activation of mitogen-activated protein 
kinases as well as NF-κB and the induction of downstream pro-survival genes. The ubiquitination of 
RIPK1 at lysine 63 is depleted in cells that lack cIAP 1 and 2. Depletion of cIAP 1 and 2 can be 
achieved by genetic means or by treating cells with so called SMAC mimetics that cause the 
degradation of IAPs [262, 263]. Deubiquitinated RIPK1 can then mediate apoptosis or necroptosis 
and is responsible for the formation of the apoptosis or necroptosis promoting signaling complexes 
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[264]. Caspase activity during apoptosis can inhibit necroptosis by cleaving RIPK1 and 3. If apoptosis 
is inhibited by applying pan-caspase inhibitors such as benzyloxycarbonyl-Val-Ala-Asp(OMe)-
fluoromethylketone, cell death becomes skewed from apoptosis to necroptosis. In the necroptotic 
pathway, RIPK3 is further downstream of RIPK1 [265]. A-type NIH 3T3 and L929 cells that do not 
express RIPK3 and have been treated with zVAD, are protected from necroptosis [266].  
Surprisingly, the Bcl-2 protein family member Bcl-2 modifying factor is required for necroptosis to 
take place. Bcl-2 is a protein that is located in the outer membrane of the mitochondria where it 
plays an important role as an inhibitor of pro-apoptotic proteins. There are however related proteins 
that fulfil a pro-apoptotic function such as Bax and Bak that are also in the outer mitochondrial 
membrane and mediate its permeabilization when activated during apoptosis. This results in pro-
apoptotic mitochondrial residents, such as cytochrome c or reactive oxygen species, being released 
into the cytoplasm. Both Bax and Bak are activated by BH3-only proteins and are inhibited by BCL-2 
and BCL-XI [267]. 
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Abstract 
Human milk oligosaccharides are responsible for maintaining homeostasis in the infants gut such as 
by promoting the growth of beneficial bacteria like Bifidobacteria or by acting as antiadhesives for 
pathogens. Human milk oligosaccharides can also influence the behavior of leukocytes but relatively 
little is known about the direct regulatory effects that human milk oligosaccharides have on 
immunity. This especially applies for antigen presenting cells that play an important role in initiating 
immune response as the first line of defense. We used a panel of 15 synthesized human milk 
oligosaccharides to investigate if human milk oligosaccharides are capable of stimulating THP-1 and 
murine mesenteric lymph node derived dendritic cells. None of the human milk oligosaccharides led 
to the upregulation of the activation markers CD54 on THP-1 cells or CD80 on mesenteric lymph node 
derived dendritic cells. However, we were able to show that 3-sialyl-3-fucosyllactose and sialyllacto-
N-neotetraose c were able to increase the amount of lactate produced and secreted by these cells. 
High lactate levels are known to be a mechanism deployed by tumor cells to influence tumor-
associated macrophages to gain M2-like characteristics which leads to the greater production of 
immunosupressive cytokines like IL-10 or the transforming growth factor-β (TGF-β). We therefore 
suggest that the sialylated human milk oligosaccharides 3-sialyl-3-fucosyllactose and sialyllacto-N-
neotetraose c increase the production of lactate by antigen presenting cells which is known to 
initiate M2-like polarization in macrophages and also inhibit the activation of cytotoxic T-cells as is 
analogously done by cancer cells. 
Introduction 
Human milk contains a vast diversity and great abundance of oligosaccharides which makes it almost 
unique compared to the milk of many other mammalian species such as cows that only have trace 
amounts of complex milk oligosaccharides [1]. Up to now about 200 different oligosaccharides have 
been identified in human milk [1]. These oligosaccharides however cannot be metabolized in the 
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human gut and therefore the question arises what these sugars actually do [2]. Before the human 
milk oligosaccharides (HMOs) were identified, a fraction of milk was discovered that promotes the 
growth of bacteria of the genus Bifidobacteria. This genus has been shown to be highly beneficial in 
the human gut and its presence can be correlated with increased rates of remission in patients 
affected with ulcerative colitis [3]. Later, it was found that this fraction of human milk was actually 
the HMOs. 
Next to this effect on the proliferation of beneficial bacteria in the gut, HMOs have also been shown 
to support the human infant by other mechanisms too. HMOs act as anti-adhesives for pathogenic 
bacteria such as Campylobacter jejuni. Some studies even claim that HMOs can directly influence the 
epithelial cells that reside in the gut. Gut epithelial immortalized cell lines such as HT-29, HIEC and 
Caco-2 cells, were shown to suppress cell cycle progression in response to HMOs and induce 
apoptosis when treated with 7.5 mg/ml of HMOs [4]. Although it is unlikely that such high 
concentrations of HMOs actually occur at the gut epithelium. Another study showed with 
radioactively labelled HMOs, that the oligosaccharides actually pass the epithelial barrier and gain 
access to the human blood compartment and are then excreted via the urine [5]. That means HMOs 
could also play roles on the basolateral side of the guts lumen. Certain HMOs for instance can block 
the adhesion of monocytes, lymphocytes and neutrophils to endothelial cells by interfering with 
selectin binding [6]. 
Our interest is how HMOs influence the immune cells at the mucosal surface in the gut. Sialylated 
HMOs were shown to increase the amount of interferon-γ producing CD3+CD4+ and CD3+CD8+ 
producing cord blood derived T-cells [7] and sialylated HMOs cause a reduction in IL-4 production in a 
subset of lymphocytes derived from patients that suffered from peanut allergies [8]. Furthermore, 
one study demonstrated that pig peripheral blood mononuclear cells that are stimulated with HMOs, 
secrete more IL-10 [9]. 
Less is known about the regulatory effects of HMOs on antigen presenting cells such as macrophages 
or dendritic cells. Lacto-N-fucopentaose III (LNFPIII; Tab. 1) and Lacto-N-neotetraose (Galβ1-
4GlcNAcβ1-3Galβ1-4Glc) are able to induce the proliferation of peritoneal macrophages and can 
suppress naïve CD4+ T-cell responses [10, 11]. LNFPIII stimulation also leads to an increase of 
prostaglandin E2, IL-10 and TNFα secretion by peritoneal macrophages [12]. 
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Table 1: Human milk oligosaccharides and their levels of contaminating LPS. 
Abbreviation Full name Structure LPS level 
(pg/mg) 
2FL 
 
2‐Fucosyllactose Fuc(α1‐2)Gal(β1‐4)Glc n.d. 
3FL 
 
3‐Fucosyllactose Gal(β1‐4)[Fuc(α1‐3)]Glc n.d. 
3SL 
 
3‐Sialyllactose Sia(α2‐3)Gal(β1‐4)Glc n.d. 
6SL 
 
6‐Sialyllactose Sia(α2‐6)Gal(β1‐4)Glc n.d. 
FSL 
 
3‐Sialyl‐3‐fucosyllactose Sia(α2‐3)Gal(β1‐4)[Fuc(α1‐3)]Glc 3.1 
DFL 
 
Difucosyllactose Fuc(α1‐2)Gal(β1‐4)[Fuc(α1‐3)]Glc n.d. 
LNFPI Lacto‐N‐fucopentaose Fuc(α 1‐2)Gal(β1‐3)GlcNAc 
(β1‐3)Gal(β1‐4)Glc 
n.d. 
LNFPII Lacto‐N‐fucopentaose II Gal(β1‐3)[Fuc(α1‐4)]GlcNAc 
(β1‐3)Gal(β1‐4)Glc 
n.d. 
LNFPIII Lacto‐N‐fucopentaose III Gal(β1‐4)[Fuc(α1‐3)]GlcNAc 
(β1‐3)Gal(β1‐4)Glc 
n.d. 
LST-a Sialyllacto‐N‐tetraose a Sia(α2‐3)Gal(β1‐3)GlcNAc(β1‐3) 
Gal(β1‐4)Glc 
2.4 
LST-c Sialyllacto‐N‐neotetraose c Sia(α2‐6)Gal(β1‐4)GlcNAc(β1‐3) 
Gal(β1‐4)Glc 
2.4 
LST-d Sialyllacto‐N‐neotetraose d Sia(α2‐3)Gal(β1‐4)GlcNAc(β1‐3) 
Gal(β1‐4)Glc 
2.4 
Para-LNnH Para‐lacto‐N‐neohexaose Gal(β1‐4)GlcNAc(β1‐3)Gal(β1‐4) 
GlcNAc(β1‐3)Gal(β1‐4)Glc 
4.4 
LNnH Lacto‐N‐neohexaose Gal(β1‐4)GlcNAc(β1‐3)[Gal(β1‐4) 
GlcNAc(β1‐6)]Gal(β1‐4)Glc 
2.2 
DSLNT Disialyllacto-N-tetraose Sia(α2-3)Gal(α1-3)[Sia(α2-6)] 
GlcNAc(β1‐3)Gal(β1‐4)Glc 
n.d. 
Siglecs are immune-modulating receptors that occur on leukocytes including antigen-presenting cells 
[13]. Interestingly, sialylated HMOs have been shown to be able to bind to these receptors [14] and 
also galectins which bind to β1-3 and β1-4 linked galactose are potential receptors for the HMOs 
[15]. However the precise consequences of HMO binding to these receptors in different cell types 
remains to be elucidated. 
We set out to identify novel roles of HMOs on antigen presenting cells. In the guts lamina propria 
there are macrophages and dendritic cells that act as sentinels and can take up antigens. Antigen 
loaded dendritic cells can then migrate into the mesentery lymph nodes to present their cargo to T-
cells for example [16]. Both macrophages and dendritic cells are key determinants of the type of 
immune reaction that is launched because of the amount and types of cytokines that they produce 
after activation [17, 18]. Previous studies have shown that bacterial glycans and the glycans that 
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occur on mucins can influence the cytokine response of antigen presenting cells [19-21]. So we asked 
ourselves if HMOs could actually also regulate the immune responses that are initiated by antigen 
presenting cells. 
For the stimulation experiments we chose to work with the monocytic immortal cell line THP-1 and 
murine mesenteric lymph node derived dendritic cells from C57BL/6 mice. The prior is a commonly 
used model system for monocytes derived from an acute monocytic leukemia patient. The cells are 
often used as they still have the potential to differentiate into macrophages and fulfill functions that 
are performed by monocytes and macrophages such as phagocytosis, producing inflammatory 
cytokines or removing cellular debris [22]. Mesenteric lymph node derived dendritic cells on the 
other hand are in close proximity to the intestinal barrier and are therefore at the actual site that 
comes into contact with the complex oligosaccharides that occur in milk. Dendritic cells from gut 
associated lymph nodes react differently to stimuli from the gut such as derived from the commensal 
gut microbiota compared to dendritic cells that occur in gut distant tissue such as the spleen [23]. 
While the prior will act immune regulatory the latter will initiate a strong inflammatory response to 
the same stimulus [23]. 
Materials and Methods 
Human milk oligosaccharides 
2-Fucosyllactose (2FL), 3-fucosyllactose (3FL), 3-sialyllactose (3SL), 6-sialyllactose (6SL), 3-sialyl-3-
fucosyllactose (FSL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto-N-fucopentaose II 
(LNFPII), lacto-N-fucopentaose III (LNFPIII), sialyllacto-N-tetraose a (LST-a), sialyllacto-N-neotetraose c 
(LST-c), sialyllacto-N-neotetraose d (LST-d), para-lacto-N-neohexaose (Para-LNnH) and disialyllacto-N-
tetraose (DSLNT) were all synthesized and supplied by the company Glycom (Tab. 1). 
Lipopolysaccharide quantification and removal 
Lipopolysaccharide (LPS) levels were determined with the Endotoxin Plus kit 0.03 EU/ml sensitivity 
(Lonza) according to the provided instructions. If the LPS contamination was above 5 pg per mg 
oligosaccharide, LPS was removed with Endotoxin Removal Beads (Miltenyi Biotec). 
Briefly, the respective oligosaccharide was resuspended in a volume of 500 to 1000 μl of water and 
50 μl of the resuspended beads were added to the oligosaccharide solution. This was incubated for 1 
h rotating end over end at 4°C. The beads were then centrifuged down at 500 x g for 5 min and the 
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oligosaccharide containing supernatant was harvested. The LPS levels were determined again to 
confirm the absence of endotoxins (Tab. 1). 
THP-1 cultivation 
THP-1 cells were cultured in Roswell Park Memorial Institute (RPMI) medium with 10% fetal calf 
serum (FCS). 
Mesenteric lymph node dendritic cell isolation and cultivation 
Mesenteric lymph node derived dendritic cells were harvested and cultured as previously described 
[24]. Briefly, mesenteric lymph nodes were removed from euthanised mice and incubated in 2.5 
mg/ml collagenase D (Roche) in RPMI medium with 10% FCS for 10 min shaking at 150 rounds per 
minute (rpm) at 37°C. The lymph nodes were then gently homogenized by aspirating them through 
an 18G syringe. The homogenate was incubated for a further 20 min at 37°C in a water bath. The 
cells were then pelleted by centrifuging them for 7 min at 300 x g. The pellet was resuspended in 1 
ml of 2 mM EDTA and 0.5% bovine serum albumin (BSA) in phosphate buffered saline (PBS; pH 7.2). 
Clumps were further homogenized by gently aspirating them through an 18G syringe. Next, the cells 
were passed through a 40 μm cell strainer to remove any cell aggregates. The cells were then 
centrifuged again and resuspended in 100 μl of 2 mM EDTA and 0.5% bovine serum albumin (BSA) in 
PBS (pH 7.2). Purified rat anti-mouse CD16/32 (Affymetrix eBioscience) was added at 5 μg/ml and the 
mix was incubated at 4°C for 10 min to block Fc receptors. Then CD11c beads (Miltenyi Biotec) were 
added to isolate the CD11c+ cells according to the provided manual with a magnetic separator. The 
cells were cultivated in RPMI medium with 10% FCS supplemented with penicillin and streptomycin. 
Reverse transcription PCR for Siglecs and galectins in THP-1 cells 
The reverse transcription step was performed with the Omniscript RT kit (Qiagen) with random 
hexamers (Qiagen) according to the procedure described by the supplier. 
PCRs were performed with Taq polymerase (Sigma Aldrich) according to the protocol provided by the 
supplier. The following forward (FP) and reverse (RP) primers were designed for the Siglecs -2 (FP: 5’-
GAGTGCAACCCTGACCTGTG-3’; RP: 5’-GAGCTTGAGCCCACAGATTG-3’), -3 (FP: 5’-
TACTCACTCCTCGGTGCTCA-3’; RP: 5’-TGAGGCAGAGACAAAGAGCG-3’), -14 (FP: 5’-
ATGCTCCACAGAACCTCGC-3’; RP: 5’-CCTATGTTAGGCAGCTCCAGG-3’), -15 (FP: 5’-
ACCTAGTGACCGCCGAACTG-3’; RP: 5’-GTGTCCGGGGTGTCCAGATG-3’) and the galectins -1 (FP: 5’-
ATCTCAAACCTGGAGAGTGCC-3’; RP: 5’-CTGGAAGGGAAAGACAGCCTC-3’), -2 (FP: 5’-
GGGGTCAACCCTGAAGATCA-3’; RP: 5’-ACCCAGCCTGTTGGGAAAAG-3’), -3 (FP: 5’-
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CTTATCCTGGACAGGCACCTC-3’; RP: 5’-CCCAGGCAAAGGCAGGTTAT-3’), -9 (FP: 5’-
GGGCTGTACCCATCCAAGTC-3’; RP: 5’-AGGCAGTGAGCTTCACACAA-3’), -10 (FP: 5’-
CCACCCAGAAGGAGACAACA-3’; RP: 5’GGCCATCCTGAAAGGGCATA-3’). 
Flow cytometry 
In each experiment 40’000 cells were stained with 5 μg/ml of the anti-murine CD11c-allophycocyanin 
(APC) (Biolegend), anti-murine CD80-phycoerythrin (PE) (BD Pharmingen), anti-human CD54-PE 
(Affymetrix eBioscience), anti-human CD107a-PE (Affymetrix eBioscience) and/or anti-human Siglec-
1-PE (Affymetrix eBioscience) antibodies in Hank’s Balanced Saline Solution (HBSS) at 4°C for 30 min, 
then washed twice in HBSS before analysis using a FACScanto II flow cytometer (BD Bioscience). 
Cell stimulation with human milk oligosaccharides 
Generally, THP-1 cells and mesenteric lymph node derived dendritic cells were sawn at 200’000 
cells/ml in 200 μl and cultured in 96-well plates unless specified otherwise. Then the cells were 
stimulated with 1 mM of each HMO. Positive controls were stimulated with 500 ng/ml LPS for 
mesenteric lymph node derived dendritic cells or 10 ng/ml of LPS for THP-1 cells. Mesenteric lymph 
node derived dendritic cells were cultivated for 14 h before the cells were used for flow cytometry 
while THP-1 cells were used 24 h after stimulation. In certain experiments the THP-1 cells were pre-
treated with 1 mM of each oligosaccharide before being treated with 10 ng/ml of LPS. If the cells 
were cultured as drop cultures on Terasaki plates, they were sawn at 800’000 cells/ml and stimulated 
with 1 mM of the respective HMO for 14 h (dendritic cells) or 24 h (THP-1). 
Measuring the pH of cell culture media 
These experiments were conducted blinded. For the measurement pH test strips with a resolution of 
0.3 to 0.4 pH units between the pH values 6.0 and 7.7 were used (Sigma-Aldrich) 
Determination of lactate levels in the culture media 
To measure the amount of lactate in the culture media a commercial L-lactate assay (ScienCell) was 
used according to the provided instructions. The measurement was done with an Infinite® 200 Pro 
plate reader (Tecan Trading AG, Männerdorf, Switzerland). 
3-(4,5-dimethylthiazol-2-yl)-2,5,diphenyltetrazolium bromide assay 
The cells were cultured in 100 μl of media and 10 μl of a 12 mM 3-(4,5-dimethylthiazol-2-yl)-
2,5,diphenyltetrazolium bromide stock was added. The cells were then incubated at 37°C for 4 h. 
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Then, all but 25 μl of the media was removed. 50 μl of DMSO was then added to each well and the 
plates were incubated at 37°C for 10 min. The liquid content of each well was mixed well and the 
absorption was determined at 540 nm with an Infinite® 200 Pro plate reader (Tecan Trading AG, 
Männerdorf, Switzerland). 
Quantification and statistical analysis 
All results are presented as means with their standard deviations unless otherwise indicated. The 
data was analyzed in GraphPad Prism 5 by ANOVA with Bonferroni’s multiple comparison post-
testing to determine statistical differences between different experimental groups. A p-value below 
0.05 was considered as statistically significant. 
Results 
Determination of Lipopolysaccharide levels in human milk oligosaccharide preparations 
To be able to use the synthesized HMOs in immunological in vitro assays, it was important for us to 
determine if any of the oligosaccharides were contaminated with LPS as this could lead to the 
stimulation of immune cells independently of HMOs and enable false conclusions [25, 26]. Therefore 
we used the Limulus Amebocyte lysate assay to determine the amount of LPS contamination in the 
HMOs. The LPS in contaminated oligosaccharide preparations was removed by polymyxin B coated 
agarose beads to achieve an LPS load of maximally 5 pg/mg of oligosaccharide. This threshold was 
chosen as previously it was shown that LPS can induce the activation of immune cells at 
concentrations as low as 10 pg/ml in the media [27] (Table 1). 
HMOs do not influence THP-1 or mesenteric lymph node derived dendritic cell activation 
Dendritic cells express many lectins that may be able to bind human milk oligosaccharides such as C-
type lectins [28], galectins [29, 30] or Siglecs [31, 32]. We demonstrated that THP-1 cells highly 
express the Siglecs -3 and -14 (bands at 260 bp and 229 bp respectively) and the galectins 1, 2 and 3 
(bands at 212 bp, 289 bp and 215 bp) (Fig. 1A). The expression of Siglec-2 was very low (band at 295 
bp) while Siglec-15 (band expected at 238 bp) and the galectins-9 and -10 (bands expected at 251 bp 
and 279 bp) were not expressed (Fig. 1A). On protein level Siglec-1 was shown to be present on the 
surface of THP-1 cells by flow cytometry (Fig. 1B). That means THP-1 cells as well as mesenteric 
lymph node derived dendritic cells express proteins that can bind HMOs which may lead to 
intracellular signaling for instance via the intracellular ITIM-domain that that many Siglecs have [13]. 
Alternatively galectins have also been shown to be able to modulate immune reactions such as when 
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galectin-3 binds to the glycans on the intestinal mucin MUC2 and then forms a complex with dectin-1 
and FcγRIIB which activates β-catenin and influences the production of cytokines [21]. 
 
Figure 1: Expression of Siglec and galectins by THP-1 cells. (A) RT-PCR was performed for the Siglecs -2, -3, -14, -
15 and the galectins -1, -2, -3, -9, -10. The expected band sizes are 295bp, 260 bp, 229 bp, 238 bp, 212 bp, 289 
bp, 215 bp, 251 bp and 279 bp in that order. (B) THP-1 cells were stained with an antibody targeting Siglec-1 to 
show that it is present on the surface of THP-1 cells by flow cytometry. Unstained cells (red lines), isotype 
control (blue lines), anti-Siglec-1-PE stained (orange lines). The presented data is representative for three 
independent experiments. 
The stimulation of mesenteric lymph node derived dendritic cells with LPS lead to a two fold increase 
of the costimulatory activation marker CD86 on the surface of the cells. The HMOs on the other hand 
did not lead to a further increase in CD86 surface levels (Fig. 2A). Similarly, LPS stimulation induced a 
60 fold increase of the integrin CD54 on the surface of THP-1 cells but HMOs did not lead to an 
increase of CD54 (Fig. 2B). CD54 is an integrin that appears on the cell surface of THP-1 cells when 
they have been activated and plays a role during the extravasation of monocytes into inflamed 
tissues in vivo [33]. 
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Next, we examined if pre-stimulating THP-1 monocytes with HMOs could influence the degree of 
CD54 surface presentation of LPS stimulated cells. However none of the HMOs influenced the 
amount of CD54 presented on the cell surface (Fig. 2C). 
 
Figure 2: Stimulation of mesenteric lymph node derived dendritic cells and THP-1 cells with HMOs (A) 
Mesenteric lymph node derived dendritic cells were stimulated with HMOs for 14 h and then the cells were 
stained with anti-CD80-PE to determine the amount of the activation marker CD80 on their surface by flow 
cytometry. (B) THP-1 cells were stimulated with HMOs for 24 h and then the cells were stained with anti-CD54-
PE to determine the amount of the activation marker CD54 on their surface by flow cytometry. (C) THP-1 cells 
were pre-treated with 1 mM of the respective HMO and then stimulated with LPS for a further 24 h. The cells 
were harvested and stained with anti-CD54-PE to determine the amount of the activation marker CD54 on their 
surface. -, no treatment; +, 10 ng/ml LPS (THP-1) or 500 ng/ml LPS (mesenteric lymph node derived dendritic 
Sialylated Glycans as Regulators of Cell Activation and Cell Death 
75 
 
cells); MFI, median fluorescence intensity. The median fluorescence intensity is plotted in a bar graph and the 
error bar is the standard deviation of three independent samples. The statistical significance was calculated by 
ANOVA with Bonferroni post-testing in all three graphs. 
FSL, LST-c and LST-d stimulation of THP-1 cells leads to acidification of the surrounding media 
When THP-1 cells were cultured in drop cultures on Terasaki plates, the addition of FSL, LST-c and 
LST-d lead to a visible acidification of the phenol-red containing media which turns yellow when it 
becomes more acidic. We measured the pH of these drops after 24 h of cultivation and determined 
that there was a pH of 7.15 in the media of cells treated with the oligosaccharides FSL and LST-c and 
a pH of 7.3 in the media of cells treated with LST-d while all other HMOs did not cause this pH shift 
and the pH was at 7.7 as the untreated control was (Fig. 3A). The same effect could also be obtained 
by culturing the cells at high density (1’000’000 cells per ml) in round bottom 96-well plates (data not 
shown) in comparison to the low densities that we typically used (200’000 cells per ml).  
We then tracked the dynamics of the pH change in FSL, LST-c and LST-d treated cells over a period of 
24 h. As a control we treated cells with 3SL, which did not lead to a decrease of the pH after 24 h 
compared to untreated cells. Both the FSL and LST-c treated cells had a clearly lower pH of 7.3 after 6 
h of cultivation compared to 3SL treated cells that remained at pH 7.7. The pH dropped to 7.15 
between 12 and 24 h of cultivation (Figs. 3B, C). The pH of LST-d treated cells also dropped to 7.3 
between 12 and 24 h of cultivation (Fig. 3D). 
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Figure 3: FSL, LST-c and LST-d induced THP-1 cells to acidify the media. (A) THP-1 cells were cultivated in drop 
cultures on Terasaki plates and 1 mM of each human milk oligosaccharide was added. 24 h later the pH of the 
cell culture media was determined by high resolution pH strips. All data points represent triplicates. (B, C, D) 
THP-1 cells were cultured in Terasaki plates and stimulated with 1 mM of 3SL, FSL, LST-c or LST-d for 24 h. The 
pH was measured after 1, 2, 4, 6, 8, 10, 12 and 24 h. Black, 3SL; red, FSL; green, LST-c; blue, LST-d. For each 
measurement a single drop was used and per time point three independent measurements were made. The pH 
determination occurred blinded. 
Increased production of lactate explains the drop in pH of FSL and Lst-c treated THP-1 cells 
The decrease of the pH in the media of FSL, LST-c and LST-d treated cells could be due to several 
mechanisms. One possibility is the release of the acidic lysosomal interior liquid into the extracellular 
space via secretion. This occurs in macrophages for instance that use secretory lysosomes to 
transport MHC-II to the cell surface to present antigens [34]. Another example for cells that secrete 
their lysosomes, are osteoclasts which secrete enzymes for bone resorption enabling the remodeling 
of bones [35, 36]. A marker of lysosomal fusion with the plasma membrane is the presence of the 
lysosomal membrane protein CD207a at the plasma membrane so we tested if the treatment of THP-
1 cells with FSL and LST-c lead to increased staining of CD207a compared to 3SL treated cells, 
however no increase was observed (Fig. 4A). 
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We next asked ourselves if the increased pH may be due to increased metabolic activity of the cells 
as a consequence of the treatment with FSL, LST-c or LST-d. Increased levels of soluble CO2 and lactic 
acid may cause the media to turn acidic [37-39]. Therefore we used the 3-(4,5-dimethylthiazol-2-yl)-
2,5,diphenyltetrazolium bromide assay, which is a colorimetric assay, to assess the metabolic activity 
of cells. In this assay the dye 3-(4,5-dimethylthiazol-2-yl)-2,5,diphenyltetrazolium bromide is reduced 
to it insoluble form formazan by the activity of NAD(P)H-dependent oxidoreductase enzymes [40]. 
The FSL, LST-c and LST-d treated cells had no increased absorption at 540 nm compared to untreated 
and 3SL treated cells (Fig. 4B) and the number of living cells remained equal between all the 
treatments at around 3x105 to 4x105 cells per ml (Fig. 4C, D) which, taken together, indicates that the 
metabolic rate remains the same between the cells. 
A further possibility however, is that there is no change in the overall metabolic rate but rather that 
there is reprogramming of the metabolism such as occurs in cancer cells that are often characterized 
by the Warburg effect where the metabolism is redirected towards more glycolysis at the cost of 
oxidative phosphorylation, leading to the greater production of lactate which causes media 
acidification [41-43]. This effect has also been observed in antigen presenting cells such as dendritic 
cells or macrophages and has been shown to be of great importance for the activation of T cells for 
instance [44, 45]. Indeed, we were able to show that THP-1 cells treated with FSL and LST-c have 
about 3 times more lactate in their surrounding media than untreated or 3SL treated THP-1 cells (Fig. 
4E). However LST-d treated cells don’t have significantly more lactate in their surrounding media (Fig. 
4E). 
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Figure 4: FSL and LST-c treated THP-1 cells secrete lactate. (A) Flow cytometry was performed with THP-1 cells 
that were treated with 3SL, FSL or LST-c and stained with a PE labelled antibody targeting CD207a. 
Measurements were conducted 4, 5, 6, 7 and 8 hours after the addition of the respective HMO and the median 
fluorescence intensity was determined and plotted on the y-axis. Black, 3SL; red, FSL; green, LST-c. (B) THP-1 
cells were either untreated or treated with 3SL, FSL, LST-c or LST-d for 5 h. Then the 3-(4,5-dimethylthiazol-2-
yl)-2,5,diphenyltetrazolium bromide assay was performed over a duration of 4 h prior to dissolving the 
produced formazan with DMSO and measuring the absorption at 540 nm. -, control without cells; unt., 
untreated. The experiment was performed in triplicate and the error bars indicate the standard deviation. The 
absence of statistical significance was determined by ANOVA with Bonferroni post-testing. (C, D) To count the 
amount of cells, a Neubauer improved cytometer was used and the amount of dead cells was determined by 
staining dead cells with trypan blue. Unt., untreated.  The experiments were performed in triplicates and the 
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absence of statistical significance was determined by ANOVA and Bonferroni post-testing. (E) The cells were 
either untreated or stimulated with 3SL, FSL or LST-c for 24 h. Then the media was collected and the amount of 
lactate was determined in the supernatant. Unt., untreated. The experiments were performed in triplicates and 
the statistical significance was determined with ANOVA and Bonferroni post-testing. 
Media acidification occurs in FSL and LST-c treated mesenteric lymph node derived dendritic cells 
The next question that we asked ourselves was if the same effect could also be observed in 
mesenteric lymph node derived dendritic cells. To determine this we also incubated the cells in drop 
cultures on Terasaki plates and stimulated the cells with the two stronger acting HMOs FSL and LST-c 
but also 3SL as a negative control. As with the THP-1 cells, mesenteric lymph node derived dendritic 
cells made the media more acidic when treated with FSL or LST-c, resulting in a pH of 7.3 after 24 h 
(Figs. 5A, B). 3SL on the other hand did not induce this change of pH. Instead, the pH remained at 7.7 
(Figs. 5A, B). We also measured the lactate levels, and although the mean levels were increased from 
the baseline of around 10 mM in untreated cells to around 25 mM in FSL and LST-c treated cells, it 
was not statistically significant. 
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Figure 5: FSL and LST-c stimulation lead to the acidification of the media of mesenteric lymph node derived 
dendritic cells. (A, B) Mesenteric lymph node derived dendritic cells were cultured in Terasaki plates and 
stimulated with 1 mM of 3SL, FSL, LST-c or LST-d for 24 h. The pH was measured after 1, 2, 4, 6, 8, 10, 12 and 24 
h. Black, 3SL; red, FSL; green, LST-c; blue, LST-d. For each measurement a single drop was used and per time 
point three independent measurements were made. The pH determination occurred blinded. (C) The cells were 
either untreated or stimulated with 3SL, FSL or LST-c for 24 h. Then the media was collected and the amount of 
lactate was determined in the supernatant. Unt., untreated. The experiments were performed in triplicates and 
the statistical significance was determined by ANOVA with Bonferroni post-testing. 
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Discussion 
To generate energy, mammalian cells catabolize glucose into pyruvate and the most of it is then 
directed into the tricarboxylic acid (TCA) cycle. Only some of the pyruvate is fermented into lactate. 
However in 1929, Otto Warburg discovered that in tumor cells, pyruvate fermentation predominates 
despite the availability of oxygen [46]. 20 years later, activated macrophages were discovered to 
have increased rates of glycolysis and reduced oxygen consumption [47]. As a consequence, most of 
the glucose is metabolized into lactate at the cost of oxidative phosphorylation [48]. 
Dendritic cells as well as macrophages react by reducing oxidative phosphorylation and increasing 
glycolysis when they are stimulated with activating stimulants such as LPS, interferon-γ or the Toll-
like receptor 3 (TLR3) ligand poly(I:C) [49, 50]. Analogous to the Warburg effect there is also 
increased flux through the pentose phosphate pathway which means increased production of 
purines and pyrimidines that are available for biosynthesis and also an increase in the amount of 
NADPH that can be used by NADPH oxidases to generate reactive oxygen species [51]. This metabolic 
switch is essential for the maturation of macrophages and dendritic cells and inhibition of this 
process, such as by using inhibitors of glycolysis like 2-deoxy-D-glucose, leads to decreased antigen 
presenting cell maturation as is evident by the reduced amounts of the costimulatory proteins CD80 
and CD86 on the cell surface [52]. 
Interestingly, in our experiments, no observable pH decrease occurs in LPS treated THP-1 cells or 
mesenteric lymph node derived dendritic cells, and the lactate amount in the media is not increased 
after 24 h either, although LPS stimulation has been shown to lead to the metabolic switch from the 
TCA cycle to glycolysis. This indicates that the lactate remains intracellular after the treatment with 
LPS. There are two control points that can influence the increase in extracellular lactate 
concentrations, one is the activity of lactate dehydrogenase which is responsible for the regeneration 
of pyruvate from lactate and the other is the transport of lactate through specific monocarboxylate 
transporters [53]. Both checkpoints may be involved as regulators of lactate secretion and the HMOs 
FSL, LST-c and LST-d may serve as switches that initiate lactate production and secretion. The precise 
mechanism leading to this switch still remains to be identified. Both THP-1 cells and mesenteric 
lymph node derived dendritic cells have many lectins on their cell surface such as Siglecs [31, 32], 
galectins [29, 30] or C-type lectins [28] which could initiate the described process (Fig. 1). 
The secretion of lactate is actually something that is done by cancer cells and the increased lactate 
levels in the surrounding media have been shown to have a profound influence on the surrounding 
antigen presenting cells. Another study was able to show that lactate is the component in tumor 
conditioned media that is able to activate HIF1α in macrophages, ultimately leading to an M2-like 
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transcriptional profile [54]. In tumors this is critical, as it leads to the production of 
immunosuppressive cytokines like IL-10 and TGF-β and less inflammatory cytokines like IL-12, IL-1β, 
TNF-α or IL-6 [55]. Furthermore lactate is able to suppress the proliferation and cytokine production 
by human cytotoxic T lymphocytes [56]. We therefore propose that FSL and LST-c can reprogram 
antigen presenting cells to be more immunomodulatory than inflammatory which makes sense when 
considering that the gut lumen, where these oligosaccharides occur in the suckling after 
breastfeeding, is rich in external stimuli from food and the microbiota that should not induce an 
inflammatory immune response in the healthy state. 
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Highlights 
 Custom glycosylation of proteins and bacterial and animal cells 
 
 Presentation of E-selectin ligands on cells by 3-fucosyl-3-sialyllactose coating 
 
 Complement factor H binds α2-3 but not α2-6 linked sialic acid on coated E. coli 
 
 Custom glycoproteins stimulate PI3K regulated inflammatory cytokine production 
In Brief 
The structural heterogeneity impairs the functional characterization of glycan epitopes. Whitehead et 
al. use cyclic-carbamate-derivatized oligosaccharides to glycosylate proteins and bacterial and animal 
cells to examine the biological roles of such oligosaccharide epitopes. 
Summary 
The structural complexity of glycosylation restrains the functional characterization of glycans. We 
present a versatile carbohydrate ligation technique based on the reaction of cyclic-carbamates with 
primary amines. Cyclic-carbamate-derivatized carbohydrates can be added to primary amine-
containing molecules in aqueous solution to yield glycoconjugates. This method enabled the 
presentation of carbohydrate epitopes on live animal cells, as shown by the acquisition of E-selectin 
binding sites on mouse MC-38 cells decorated with 3-fucosyllactose or 3-fucosyl-3-sialyllactose. 
Ligation of 3- and 6-sialyllactose to Escherichia coli demonstrated the importance of sialic acid 
linkages in regulating complement factor H binding. Proteins were modified with oligosaccharides to 
study their role in stimulating cytokine secretion by dendritic cells, thus pointing to interactions 
between glycoproteins and phosphoinositide 3-kinase signaling in controlling IL-12, tumor necrosis 
factor alpha and IL-1β release. Overall, cyclic-carbamate-mediated ligation is useful to study the 
biology of carbohydrate epitopes on proteins and on cell membranes. 
Introduction 
Unlike nucleic acids and polypeptides, complex carbohydrates do not follow a template-driven 
assembly. The lack of blueprints hampers the large-scale production of pure glycoconjugates given 
that enzymatic biosynthesis often yields a large heterogeneity of products. Various strategies have 
been designed over the past years to facilitate the production of uniformly glycosylated proteins and 
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lipids. For example, lectin-resistant Chinese hamster ovary (CHO) cells harbor limited glycosylation 
pathways, which enables the expression of glycoproteins of low glycan complexity [1]. More recently, 
targeted gene inactivation has been applied to generate CHO cell lines that produce glycoproteins 
decorated with specific glycan structures [2]. Chemical approaches have also been developed to 
generate uniformly glycosylated glycoconjugates, such as glycolipids [3], mucin-type glycoproteins 
[4], and glycopolymers [5]. Whereas chemical synthesis enables large-scale production of 
homogeneous glycoconjugates, the synthesis reactions applied are often specifically tailored to each 
glycan produced, thereby restricting the portability of established procedures to multiple structures. 
A simplified approach consists of ligating specific complex carbohydrates to carrier molecules. Such a 
strategy has been described recently, taking advantage of coupling pre-assembled glycans to 
phospholipids [6]. This method applies aminooxy glycans condensed to a polymethyl vinyl ketone 
scaffold via the formation of oximes. The resulting artificial glycolipids were incorporated into cell 
membranes and used successfully to assess the role of the sialic-acid-binding lectin Siglec-7 in cancer-
cell immune evasion [6]. Other conjugation approaches, such as the succinimidyl ester coupling 
method, are broadly used for the preparation of conjugated molecules, but are usually unsuited for 
the glycosylation of viable cells due to their significant cytotoxicity [7-9]. 
Homogeneous glycoconjugates are valuable to investigate the functional significance of specific 
glycan epitopes in the context of natural carrier molecules. The ligand properties of carbohydrate-
binding proteins can be analyzed quantitatively using arrays of immobilized glycans [10]. However, 
arrays do not replicate the natural context and density of glycan chains on glycoconjugates. Also, the 
immobilization of glycans on solid surfaces sometimes shortens the reducing end of glycans, as for 
example achieved after reductive amination reactions [11, 12]. Whereas glycan arrays can be used to 
delineate the carbohydrate-binding specificity of lectins, such as selectins and Siglecs [13-15], 
signaling cascades and cell responses induced by lectin-glycan interactions cannot be addressed using 
such tools. Selectin binding for instance regulates leukocyte adhesion [16] and chemotaxis [17], 
which cannot be studied on glass slides covered with glycans. Similarly, Siglecs are signaling 
molecules that stimulate or repress cell activation through immunoreceptor tyrosine-based 
activation motifs and immunoreceptor tyrosine-based inhibition motifs [18]. Methods mediating the 
attachment of glycans to cellular surface proteins are useful to change the surface glycosylation of 
bacterial and eukaryotic cell membranes.  
The pathogenicity of Neisseria gonorrhoeae has been related to its surface sialylation, which mimics 
host cells [19]. Surface sialylation has been shown to dampen complement activation through the 
recruitment of factor H, which directly interacts with surface-bound sialic acid [20]. The selective 
decoration of bacterial membranes with animal glycans featuring sialylated and fucosylated epitopes 
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would for example allow the importance of molecular mimicry in bacterial pathogenicity to be 
addressed. The selective glycosylation of polypeptides would also be of interest to study the role of 
specific glycan epitopes in activating lectin proteins of unclear ligand specificity, such as the broad 
family of C-type lectins expressed on macrophages and dendritic cells [21]. 
We present here a carbohydrate ligation technique that is suitable to modify primary amines as 
found on proteins. Specific oligosaccharides were synthesized to include a strained cyclic-carbamate 
functional group, which can covalently react with primary amines in aqueous solution [22] and in 
conditions suitable for labeling living cells at physiological pH and temperatures. This technique 
enables the rapid and efficient engineering of cells and glycoproteins to study carbohydrate-lectin 
interactions in natural settings. 
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STAR methods 
Key resources table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti-IgG-Fc-domain antibody labelled with biotin Sigma-Aldrich B3773 
Complement factor H antibody (OX-24) Life Technologies MA1-70057 
Alexa488 labelled anti-mouse-IgG-Fc-domain targeting antibody Sigma-Aldrich M0284 
Bacterial and Virus Strains  
Escherichia coli K-12 Thermo Fisher Scientific 18265017 
Chemicals, Peptides, and Recombinant Proteins 
Ficoll-Paque PLUS GE Healthcare Life Sciences 17-1440-02 
Human GM-CSF, research grade MACS Miltenyi Biotec 130-093-862 
Human IL-4, research grade MACS Miltenyi Biotec 130-093-917 
3-sialyl-3-fucosyllactose Glycom A/S N/A 
6-sialyllactose Glycom A/S N/A 
3-fucosyllactose Glycom A/S N/A 
3-sialyllactose Glycom A/S N/A 
2-fucosyllactose Glycom A/S N/A 
Albumin bovine, fraction V from bovine MP Biomedicals 0216006910 
Staphylococcus aureus protein A Sigma-Aldrich P6031 
Fluorescein isothiocyanate labelled Ulex Europaeus agglutinin Vector Laboratories FL-1061 
Fluorescein isothiocyanate labelled Aleuria aurantia agglutinin Vector Laboratories FL-1391 
E-selectin-human IgG Fc domain probe Borsig et al. 2002 N/A 
P-selectin-human IgG Fc domain probe Borsig et al. 2002 N/A 
L-selectin-human IgG Fc domain probe Borsig et al. 2002 N/A 
Strepatavidin-PE-Cy5 BD Bioscience 554062 
Complement factor H Complement Technology 
Inc. 
A137 
Fluorescein isothiocyanate labelled Sambucus nigra agglutinin Vector Laboratories FL-1301 
Fluorescein isothiocyanate labelled Maackia amurensis agglutinin I Vector Laboratories FL-1311 
Lipopolysaccharide Sigma-Aldrich L2630 
Wortmannin Enzo Life Sciences BML-ST415 
Critical Commercial Assays 
ProcartaPlex Human Th1/Th2/Th9/Th17/Th22/Treg Cytokine Panel 
(18plex) 
Affymetrix eBioscience EPX-180-12165-901 
Experimental Models: Cell Lines 
MC-38 cells (C57BL6 murine colon adenocarcinoma) Kerafast ENH204 
RAW264.7 ATCC TIB-71
TM
 
B16-F0 ATCC CRL-6322
TM
 
THP-1 ATCC TIB-202
TM
 
Jurkat, Clone E6-1 ATCC TIB-152
TM
 
Human: PBMC derived dendritic cells University of Zurich 
according to O’Neil and 
Bhardwaj, 2005 
N/A 
Green fluorescent protein-expressing MC-38 cells Borsig et al., 2002 N/A 
Software and Algorithms 
GraphPad Prism 5 GraphPad Software http://www.graphpad.com 
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Contact for reagent and resource sharing  
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Thierry Hennet (thierry.hennet@uzh.ch). 
Experimental model and subject details 
Cell lines 
Mouse colon carcinoma MC-38 cells [23], mouse macrophage RAW264.7 cells and B16 melanoma 
cells were cultured in Dulbecco’s Modified Eagle medium with 10% fetal calf serum. Human 
monocytic THP-1 cells and human lymphoma Jurkat cells were cultured in RPMI medium with 10% 
fetal calf serum. 
Dendritic Cell Cultivation 
Peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll-Paque PLUS (GE Healthcare) 
according to the procedure described by the manufacturer. Dendritic cells were obtained by culturing 
the PBMCs as described by O’Neill and Bhardwaj [24]. Briefly, PBMCs were cultured in RPMI medium 
with 10% fetal calf serum for 2 h. Non-adherent cells were removed by two washes with RPMI 
medium. Adherent monocytes were further cultured in RPMI medium with 10% FBS supplemented 
with 100 IU/ml GM-CSF and 200 IU/ ml IL-4 for five days to induce the differentiation of monocytes 
to immature dendritic cells. 
Method details 
Oligosaccharide ligation 
Human THP-1 cells, mouse MC-38, RAW264.7 and B16 adherent cells were detached with 2 mM 
EDTA solution in phosphate buffered saline (PBS), pH 7.4 for 10 min then washed twice with PBS. 
Cells were resuspended at 4 x 105 cells/ml in HBSS supplemented with 1 - 20 mM of oligosaccharide-
cyclic-carbamate and incubated at 20 C for 3 h. Escherichia coli K-12 was grown to an OD600 value of 
1.0. Bacteria were fixed in acetone:methanol (1:1, v:v) at -20 C for 15 min, then washed twice with 10 
mM borate buffered saline, pH 10. Fixed bacteria were resuspended in 5-15 mM of oligosaccharide-
cyclic-carbamate in borate buffered saline and incubated at 20° C for 4 h. BSA fraction V (MP 
Biomedicals) and Staphylococcus aureus protein A (Sigma-Aldrich) were solubilized at 1 mg/ml in 
borate buffered saline, pH 10 containing 20 mM of oligosaccharide-cyclic-carbamate and incubated 
at 4 C for 30 h. Unreacted oligosaccharide-cyclic-carbamates were removed by dialysis using a 
molecular weight cut-off of 1’000 Da. 
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Flow cytometry 
Bacterial and animal cells were stained with 5 μg/ml fluorescein isothiocyanate labelled Ulex 
europaeus agglutinin I (UEA) and fluorescein isothiocyanate labelled Aleuria Aurantia lectin (AAL) 
(Vector Laboratories) in HBSS at 4° C for 20 min, then washed twice in HBSS before analysis using a 
FACScanto II flow cytometer (BD Bioscience). To detect E-, P- and L-selectin ligands on human and 
mouse cell lines, 10 mg/ml of each selectin probe, that consist of the carbohydrate binding domain of 
the respective murine selectin fused to an IgG Fc domain [25], were used. These selectin probes were 
pre-complexed with an anti-IgG-Fc-domain antibody labelled with biotin (Sigma-Aldrich) before being 
used to stain the cells for 50 min. Afterwards the cells were incubated for another 20 min with 
streptavidin-PE-Cy5 (BD Bioscience). Before the measurement, the cells were washed one time with 
HBSS. Images of single cells analyzed during flow cytometry were recorded using an ImageStream 
Mark II Imaging Flow Cytometer (Merck). 
E-selectin adhesion assay 
Microtiter plates were coated with 4 μg/ml of Staphylococcus aureus protein A (Sigma Aldrich) in 50 
mM Na2CO3/NaHCO3, pH 9.5 at 4° C for 14 h and washed twice with HBSS. After blocking with 1% BSA 
in HBSS at 25° C for 30 min, the wells were coated with 6 μg/ml of E-selectin-IgG-Fc-domain in 1% 
BSA in HBSS for 1 h. The wells were washed twice with 1% BSA in HBSS and 6 x 104 green fluorescent 
protein-expressing MC-38 cells [25] were added in 1% BSA in HBSS. The plate was incubated at 4° C 
for 1 h while being shaken at 80 rounds per minute. Non-adherent cells were removed by washing 
the wells with HBSS. Fluorescence was measured using a Genios Spectra Fluor Plus fluorescence plate 
reader (Tecan Trading AG, Männerdorf, Switzerland) at 509 nm. 
Selectin Blot 
BSA and its glycosylated variants were dotted at 500, 250, 125 or 60.5 ng onto nitrocellulose 
membranes. Membranes were blocked with 5% BSA in PBS for 1 h at 20° C. E-, P- or L-selectin human 
Fc-domain chimeras were pre-complexed with anti-IgG-Fc-domain antibodies labelled with biotin 
(Sigma-Aldrich) in PBS with 0.1 mM calcium chloride and this mix was added to the membranes for 
14 h at 4° C. Membranes were washed 3-times with PBS, 0.05% Tween20 for 5 min and then 
incubated with streptavidin-HRP (Sigma-Aldrich) for 1 h at 20° C before developing blots with an X-
OMAT 2000 Processor (Kodak) using Hyperfilms for enhanced chemiluminescence (Amersham). 
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Factor H binding assay 
About 109 E. coli K-12 cells were incubated in HBSS with 25% human serum (Sigma-Aldrich) at 37° C 
for 30 min. Bacteria were washed twice with HBSS then incubated for 50 min at 20° C in HBSS, 1 mM 
CaCl2, 1 mM MgCl2 and 20 μg/ml factor H (Complement Technology, Inc.) [26, 27]. Bound Factor H 
was detected using a complement factor H antibody (OX-24, Life Technologies) and an Alexa488 
labelled anti-mouse-IgG-Fc-domain targeting antibody (Sigma-Aldrich). 
Fluorescence and confocal microscopy 
E. coli K-12 cells were stained with 5 μg/ml of fluorescein isothiocyanate labelled UEA or fluorescein 
isothiocyanate labelled AAL at 4 C for 20 min. Alternatively bacteria were stained with 20 μg/ml of 
fluorescein isothiocyanate labelled Sambucus nigra agglutinin (SNA) or 20 μg/ml fluorescein 
isothiocyanate labelled MAL (Vector Laboratories) at 25° C for 1 h. Fluorescence was recorded using 
an Axiovert 200M fluorescence microscope (Zeiss). To visualize 2FL coating on MC-38 cells using 
confocal microscopy, cells were cultured on coverslips for 2 days to a confluency of 50%. Cells were 
incubated with 4 mM 2FL-cyclic-carbamate for 30 min prior to fixation with 3% formalin for 20 min at 
20° C. The cells were washed three times with PBS, permeabilized with 0.1% saponin in PBS, and 
incubated in 20 mM glycine for 15 min at 20° C to quench unreacted formalin. Cells were stained for 
30 min at 20° C with 10 μg/ml UEA-biotin (Vector Laboratories) in PBS with 0.1 mM calcium chloride. 
After 3 washes in PBS, cells were stained with 10 μg/ml streptavidin-Alexa647 (Thermo Fisher 
Scientific), 10 μg/ml wheat germ agglutinin-Alexa488 (Thermo Fisher Scientific) and 500 μg/ml 4’6-
diamidin-2-phenylindol (Biotium) in PBS with 0.1 mM calcium chloride for 1 h at 20 C. The cells were 
then washed 3 times in PBS before being mounted in ProLongTM Gold Antifade Mountant (Thermo 
Fisher Scientific). Confocal microscopy was performed with an SP5 microscope (Leica). 
Dendritic cell stimulation 
Aliquots of 1.5 x 105 human PBMC-derived dendritic cells were incubated with E. coli K-12 cells at a 
1:1 ratio. Alternatively, 1.5 x 105 human PBMC-derived dendritic cells were incubated with 250 μg/ml 
of custom-glycosylated BSA for 3 h at 37 C, followed by stimulation with 500 ng/ml of 
lipopolysaccharide (Sigma-Aldrich). In some experiments 300 nM Wortmannin (Enzo Life Sciences, 
Lausen, Switzerland) was added to the cells 3 h before incubation with custom-glycosylated BSA. Cell 
supernatants were collected 24 h later for cytokine determination. 
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Cytokine determination 
Supernatants of PBMC-derived dendritic cells were used undiluted for the determination of the 
concentrations of IL-10, IL-6, IL-12p70, TNF-α, IL-1β, interferon-γ, IL-18, and IL-23. The ProcartaPlex 
Human Th1/Th2/Th9/Th17/Th22/Treg Cytokine Panel (18plex, Affymetrix eBioscience) was applied 
according to the standard procedure of the manufacturer. 
Compound preparation 
Details of compound preparation and characterization are given in Methods S1. 
NMR and mass spectrometry 
Proton and carbon nuclear magnetic resonance (1H and 13C NMR) spectra were recorded on a Bruker 
Advance-400 (400 MHz and 100 MHz, respectively) at the Department of Chemistry of the Danish 
Technical University (DTU). Chemical shifts are reported in ppm (parts per million) with reference to 
residual solvent signal as indicated. 1H NMR data are reported in the following order: chemical shift, 
multiplicity, coupling constant(s) (J) in Hz, integration, and assignment if available. Multiplicity is 
indicated as s (=singlet), d (=doublet), t (=triplet), q (=quartet), quint (=quinted), dd (=doublet of 
doublets), dt (doublet of triplets), td (triplet of doublets), br (=broadened), m (=multiplet). 13C NMR 
data are extracted from APT (attached proton test) spectra and reported as chemical shifts with key 
assignments. High-resolution mass spectra (HRMS) were recorded on a Bruker microQTof II MS 
coupled to a Dionex Ultimate 3000 UHPLC at Glycom A/S with electrospray ionization method (ESI) 
either in negative or positive mode and calibrated by sodium formate cluster ions; or on a QExactive 
instrument (Thermo Fisher Scientific, Bremen, Germany) equipped with a heated electrospray 
ionization (ESI) source and connected to a Dionex Ultimate 3000 UHPLC system with the same 
method. Reactions were followed by thin-layer chromatography (TLC) on silica gel 60 F254 coated on 
aluminum plates (MERCK 1.05554.0001). Eluted TLC plates were developed by carbonisation at ca. 
300° C after treatment with 10% H2SO4 in ethanol. The starting oligosaccharides 6SL (Na-salt), 2FL, 
and 3FL were previously synthesized at Glycom A/S in multi-kg quantities. 3SL (Na-salt) was 
purchased from GeneChem Inc. (http://genechem.co.kr/index_e.php, catalog No. BCBO0007, Lot No. 
BO 07KI30-2, NMR assay 85.7% (calc. for the free acid), 88.6% (Na-salt)). 2FL cyclic-carbamate and 
lactose cyclic-carbamate were prepared previously at Glycom A/S from 2FL and lactose, respectively, 
as described in WO2009/040363. The general procedures for preparation of novel cyclic-carbamates 
and corresponding intermediates are exemplified for 3SL. Other cyclic-carbamates (3FL, 6SL, FSL) 
were prepared analogously. 
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Quantification and statistical analysis 
All results are presented as means with their standard deviations unless otherwise indicated. The 
data was analyzed in GraphPad Prism 5 by one-way analysis of variance with Bonferroni’s multiple 
comparison post-testing to determine statistical differences between different experimental groups. 
A p-value below 0.05 was considered as statistically significant. 
Results 
Oligosaccharide-cyclic-carbamate synthesis 
The synthesis of oligosaccharide-cyclic-carbamates and their ligation with primary amino groups are 
depicted in Figure 1. The synthesis was performed based on the adapted procedures described in 
WO2009/040363. Most of the starting oligosaccharides were available in kilogram quantities. The 
corresponding unprotected oligosaccharides (2a-e) except 3-sialyl-3-fucosyllactose [Sia(α2-3)Gal(β1-
4)[Fuc(α1-3)]Glc] (FSL) (2f) were peracetylated (3a-e) under standard conditions with acetic 
anhydride in pyridine followed by anomeric bromination with 30% HBr in acetic acid (compounds 4a-
e). The peracetylated α-bromides obtained were inverted into β-azides 5a-e with NaN3 in aqueous 
acetone. Then, unprotected β-azides 6a-e were prepared by Zemplén deacetylation with MeONa in 
methanol. The precipitated β-azides were of sufficient purity and were converted into β-cyclic-
carbamate derivatives 1a-e in anhydrous dimethylformamide with Ph3P saturated with CO2 and 
were isolated from the reaction mixture by precipitation with acetone or an acetone-hexane mixture. 
The initial attempt to convert unprotected 6-sialyllactose [Sia(α2-6)Gal(β1-4)Glc] (6SL)-azide 6e in the 
free acid form into cyclic-carbamate was not successful. Later, all the unprotected sialylated azides 
6d-f as Na salts were smoothly converted into cyclic-carbamates under anhydrous conditions. FSL-
azide (6f) was prepared from 3-fucosyllactose [Gal(β1-4)[Fuc(α1-3)]Glc] (3FL)-azide (6c) and 3-
sialyllactose [Sia(α2-3)Gal(β1-4)Glc] (3SL) by trans-sialylation catalyzed by trans-sialidase isolated 
from Trypanosoma cruzi according to a general method described in patent WO2013/ 190531 A1. 
The FSL-azide (6f) was isolated as a mixture with unreacted 3SL after ion-exchange chromatography 
and converted into a mixture of FSL-cyclic-carbamate and 3SL, which was used in the following 
derivatization without further purification. The structural integrity of oligosaccharide-cyclic-
carbamate products was confirmed by high-resolution electrospray-ionization mass spectrometry 
and routine nuclear magnetic resonance (see Supplemental Information). 
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Figure 1: Synthesis of Oligosaccharide-cyclic-carbamates The oligosaccharides 2-fucosyllactose, 3-
fucosyllactose, 3-sialyllactose, and 6-sialyllactose were peracetylated and then anomerically brominated. The 
resulting peracetylated α-bromides were then inverted into β-azides, which could then be converted into β-
cyclic-carbamate derivatives. 3-Sialyl-3-fucosyllactose-cyclic-carbamate was synthesized by trans-sialylating the 
unprotected 3-fucosyllactose-azide with the trans-sialidase from Trypanosoma cruzi before converting it to the 
β-cyclic-carbamate derivative. 
Custom glycosylation of cell membranes 
The ligation of oligosaccharide-cyclic-carbamates to biological surfaces was first tested on the murine 
MC-38 cell line. The covalent attachment of the oligosaccharide 3FL-cyclic-carbamate to MC-38 cells 
was concentration and time dependent, showing a linear increase of surface α1,3-fucosylation as 
measured by AAL staining (Fig. S1). Reaction times longer than 3 h decreased cell viability, probably 
because of the absence of serum and nutrients in Hank’s balanced salt solution. Similarly, 3FL-cyclic-
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carbamate concentrations above 20 mM decreased cell viability as assessed by Trypan blue exclusion 
(data not shown). We then ligated oligosaccharide-cyclic-carbamates to murine MC-38 and 
RAW264.7 cells, and human THP-1 and Jurkat cells to assess the feasibility of the method to increase 
surface α1,2-fucosylation and α1,3-fucosylation. The incubation of MC-38 cells with 14 mM 2-
fucosyllactose [Fuc(α1-2)Gal(β1-4)Glc] (2FL)-cyclic-carbamate yielded an increase in α1,2-fucosylation 
as measured by Ulex europaeus agglutinin I (UEA) staining, which was 7.5-fold increased (Fig. 2A). 
Under the same conditions, the staining of α1,3-fucosylation increased by 2.5-fold after incubating 
MC-38 cells with 3FL-cyclic-carbamate (Fig. 2B). The increase in α1,3-fucosylation staining was more 
moderate than the increase in α1,2-fucosylation staining because of elevated AAL binding to 
uncoated MC-38 cells, which indicates high levels of surface α1,3-fucosylation for this cell line. 
Treatment of additional mouse and human cell lines with 2FL-and 3FL-cyclic-carbamate (Fig. S2A–
S2F) confirmed the general applicability of the oligosaccharide ligation technique to increase surface 
α1,2-fucosylation and α1,3-fucosylation. Coating RAW264.7 and Jurkat cells with 3FL-cyclic-
carbamate did not lead to increased staining by AAL due to high background levels of already present 
surface α1,3-fucosylation. We furthermore confirmed the localization of oligosaccharide-cyclic-
carbamate to the surface of MC-38 cells by coating adherent MC-38 cells with 2FL-cyclic-carbamate 
and staining with UEA. As shown by confocal microscopy, UEA staining co-localized with the cell 
membrane staining wheat germ agglutinin (Figure S3A). The cell-surface localization of 2FL-cyclic-
carbamate was also confirmed by recording fluorescence images of UEA-stained MC-38 cells 
analyzed by flow cytometry using ImageStream technology (Figure S3B). 
The addition of fucosylated epitopes to MC-38 cells also increased binding of members of the selectin 
family to the cells. The best known ligand of the selectins is the carbohydrate epitope sialyl-Lewis X, 
which includes α1-3 linked fucose [28]. We observed that ligating 3FL-cyclic-carbamate to MC-38 
cells increased E-selectin binding, whereas ligation with 2FL-cyclic-carbamate had no effect (Fig. 2C). 
Coating MC-38 cells with FSL-cyclic-carbamate, which has a Sia(α2-3)Gal(β1-4)[Fuc(α1-3)]Glc epitope 
similar to sialyl-Lewis X, led to even stronger binding of E-selectin (Fig. 2C). This result was replicated 
using B16 melanoma cells, which also showed the strongest E-selectin binding to FSL, followed by 3FL 
and no effect for 2FL (Fig. 2D). The impact of coating MC-38 cells with fucosylated oligosaccharides 
on E-selectin-mediated adhesion under rotational stress was also assessed. Only cells presenting 3FL 
and FSL adhered to E-selectin-coated plates, whereas the presentation of 2FL did not increase 
adhesion (Fig. 2E). The adhesion of 3FL- and FSL-coated cells was eliminated upon incubation with 5 
mM EDTA, thus confirming the Ca2+-dependency of selectin binding. Fluorescence intensities in wells 
of 3FL- or FSL-coated cells were approximately three to four times higher than for uncoated and 2FL-
coated cells, or 3FL- and FSL-coated cells treated with EDTA (Fig. 2E). The addition of 3FL and FSL 
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epitopes to MC-38 cells, however, did not further increase adhesion to L- and P-selectin, which was 
already strong in untreated cells (Fig. 2F and 2G). 
 
Figure 2:  Coating Cells with Oligosaccharide-Cyclic-carbamates. (A and B) MC-38 cells were coated with 2FL- or 
3FL-cyclic-carbamate or left uncoated, then stained with fluorescein-isothiocyanate-labeled UEA (A) or AAL (B) 
before being analyzed by flow cytometry. Unstained cells (red lines), uncoated cells (blue lines), 2FL-coated 
cells (orange lines), 3FL-coated cells (green lines). (C, D, F, and G) MC-38 (C, F, G) and B16 melanoma cells (D) 
were coated with fucosyllactose-cyclic-carbamates or left uncoated. The cells were then labeled with an E-
selectin (C, D), L-selectin (F), or P-selectin (G) probe with a human Fc domain, which was detected with a biotin-
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labeled antibody and streptavidin PE-Cy5 in flow cytometry. Negative control MC-38 cells were not coated or 
stained with the respective selectin probe. Instead they were stained directly with the Fc domain targeting 
biotinylated antibody and PE-Cy5-labeled streptavidin. Uncoated cells (blue lines), biotin anti-IgG + streptavidin 
PE-Cy5 (black lines), 2FL-coated cells (orange lines), 3FL-coated cells (green lines), FSL-coated cells (grey lines). 
E-selectin mediated adhesion of MC-38 cells coated with 2FL, 3FL, or FSL after 2 h agitation at 80 rounds per 
minute. Data are shown as average and SD of three samples analyzed. 
Custom glycosylation of bacterial membranes 
We next tested the possibility to glycosylate bacterial membranes with oligosaccharide-cyclic-
carbamates. We coated Escherichia coli K-12 with the four oligosaccharides 2FL, 3FL, 3SL, and 6SL. 
The presentation of the corresponding oligosaccharides was assessed by staining decorated E. coli 
with the lectins UEA and AAL for α1,2-fucose and α1,3-fucose, respectively. Membrane sialylation 
was detected using the Maackia amurensis lectin I (MALI) [29] for α2,3-sialic acid and the SNA [30] 
for α2,6-sialic acid. Untreated E. coli remained unstained by the four lectins, while ligation with 
oligosaccharide-cyclic-carbamates yielded strong staining for the respective lectins (Fig. 3A). 
The addition of specific oligosaccharide structures to bacterial membranes enabled the investigation 
of these epitopes in the context of immune recognition. Some pathogenic bacteria, such as N. 
gonorrhoeae [20], evade recognition  from host immunity by exposing sialylated glycans on their 
membranes. Sialylated membranes, for example, recruit factor H, which prevents C3 activation and 
subsequent C3b opsonization [31]. Whereas N. gonorrhoeae mainly presents α2,3-sialic acid on 
lipooligosaccharides [32], it is unclear whether factor H binding solely depends on the negative 
charge of sialic acid or whether the glycosidic linkage influences binding as well. To address this 
point, we labeled E. coli with increasing concentrations of 3SL- or 6SL-cyclic-carbamate. We found 
that only the presentation of α2,3-linked sialic acid increased factor H recruitment as assessed by 
flow cytometry (Fig. 3B). Coating E. coli with 20 mM 3SL-cyclic-carbamate yielded a 3-fold increase of 
factor H staining, whereas 6SL-cyclic-carbamate had no effect up to a concentration of 25 mM (Fig 
3C). 
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Figure 3: Oligosaccharide Coating of E. coli K-12 and Complement Factor H Recruitment by 3SL. (A) Fixed E. coli 
K-12 coated with 3FL, 2FL, 3SL, and 6SL or left uncoated were stained with fluorescein-isothiocyanate-labeled 
AAL, UEA, MALI, and SNA and examined by fluorescence microscopy. Scale bar, 10 μm. (B) Binding of 
complement factor H to fixed E. coli K-12 coated with 2FL, 3FL, 3SL, or 6SL detected by anti-factor H IgG and 
anti-heavy chain binding antibody coupled to Alexa 488. Uncoated (red lines), 2FL-coated cells (orange lines), 
3FL-coated cells (green lines), 3SL-coated cells (black lines), 6SL-coated cells (grey lines). (C) Titration of E. coli 
K-12 cells coated with increasing amounts of 3SL (open circles) or 6SL (closed circles) and detection of 
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complement factor H binding. MFI, median fluorescence intensity. Data are shown as averages and SD of three 
values. 
Previous studies have shown that bacterial glycans influence the pattern of cytokines released by 
dendritic cells upon stimulation [33, 34]. To determine if the coating of bacteria with different 
oligosaccharides leads to changes in the cytokine response of dendritic cells, we incubated human 
PBMC-derived dendritic cells with E. coli K-12 cells labeled with lactose [Gal(β1-4)Glc] (Lac), 2FL, 3FL, 
3SL, and 6SL derivatized to cyclic-carbamates. The stimulation of dendritic cells by oligosaccharide-
coated bacteria differentially affected the production of several cytokines investigated. Whereas the 
release of IL-6 and IL-10 remained insensitive to oligosaccharide coating, the levels of interferon 
(IFN)-γ, IL-1β, IL-12p70, IL-18, TNF-α, and IL-23 by dendritic cells increased after coating of E. coli with 
3FL, 3SL, and 6SL but not after coating with 2FL and Lac (Fig. 4). These results demonstrate that 
bacterial glycosylation is a critical factor that influences the pattern of cytokines produced by 
dendritic cells. Dendritic cells express many C-type lectins [35], such as dectins and DC-SIGN, which 
coordinate the recognition of carbohydrate epitopes and trigger different signaling pathways 
resulting in various cytokine responses. By enabling the display of unique carbohydrate structures on 
bacterial membranes, oligosaccharide-cyclic-carbamates represent valuable tools to dissect the 
pathways involved in the recognition of bacterial glycans by immune cells. 
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Figure 4: Cytokine Response of Human Dendritic Cells to Oligosaccharide-Coated E. coli. Cytokine response of 
human PBMC-derived dendritic cells to oligosaccharide-cyclic-carbamate-coated E. coli K-12 at a ratio of 1:1. 
(A) interferon-γ; (B) IL-1β; (C) IL-12p70; (D) IL-18; (E) IL-6; (F) TNF-α; (G) IL-10; (H) IL-23. Cytokines were 
measured after 24 h. Unc, uncoated. Data represent averages and SD of three experiments. *p < 0.05. 
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Custom glycosylation of proteins 
Beside animal and bacterial cells, oligosaccharide-cyclic-carbamates can also be ligated directly to 
primary amines on proteins. Such modified proteins can then be used as customized glycoproteins to 
study the roles of multivalent glycans on protein backbones. For example, we modified BSA and 
Staphylococcus aureus protein A with 2FL, 3FL, 3SL, and 6SL. BSA has 59 lysine residues, and their 
complete modification with each trisaccharide tested would result in a mass in-crease from 69 kDa to 
about 100 kDa. The molecular mass shift observed ranged between 10 kDa for 6SL and 20 kDa for 3SL 
(Fig. 5A), which was expected considering that BSA includes 17 disulfide bridges [36], which decrease 
the accessibility of some lysine residues for oligosaccharide-cyclic-carbamates. Denaturing BSA by 
adding thiol reducing agents was not an option, given that cyclic-carbamates can react with thiols 
[22]. Staphylococcus aureus protein A, on the other hand, has no disulfide bridges and can therefore 
be completely denatured by heat treatment. After incubation with oligosaccharide-cyclic-
carbamates, the molecular mass of Staphylococcus aureus protein A increased from 42 kDa to up to 
80 kDa, which indicated a nearly complete glycosylation of its 58 lysine residues (Fig. 5B). As 
expected, heat-denatured protein A, with and without oligosaccharide modification, did not retain its 
IgG-binding activity, as demonstrated by ELISA (data not shown). Given that the ligation of MC-38 
cells with fucosylated oligosaccharides increased E-selectin binding, we also tested the affinity of 
glycosylated BSA for E-, P-, and L-selectin. 
BSA decorated with 3SL, 6SL, and 2FL remained unbound by the three selectin proteins, whereas 
decoration with 3FL and FSL increased selectin binding as assessed by dot blotting (Fig. 5C–5E). In this 
setting, 3FL-BSA and FSL-BSA were equally recognized by E-selectin (Fig. 5C) and P-selectin (Fig. 5D). 
Recognition by L-selectin was weaker for 3FL-BSA but equally strong for FSL-BSA (Fig. 5E). These 
findings are compatible with data obtained from glycan arrays showing that selectins mainly bind to 
glycans carrying sialyl-Lewis A and sialyl-Lewis X epitopes [15, 37-39]. 
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Figure 5: Gel Electrophoresis of Oligosaccharide-Coated Proteins and Selectin Binding (A and B) The 
oligosaccharides 2FL, 3FL, 3SL, 6SL were coupled to (A) BSA and (B) Staphylococcus aureus protein A. Custom-
glycosylated proteins were stained using Coomassie blue. Molecular weight markers are indicated in kDa at the 
left of each panel. (C–E) BSA coated with 2FL, 3FL, 3SL, 6SL, FSL was dotted onto nitrocellulose membranes at 
the indicated amounts (ng). (C) E-selectin binding, (D) P-selectin binding, and (E) L-selectin binding was 
assessed using selectin probes fused to a human Fc domain, detected by a biotinylated anti-Fc antibody and 
streptavidin-linked horseradish peroxidase. 
Previous studies have shown that the glycan moiety of mucins regulate the production of the 
cytokines IL-10 and IL-12 by dendritic cells [40]. We therefore applied glycosylated BSA to determine 
the impact of different glycans on cytokine secretion by human PBMC-derived dendritic cells. We 
tested the tetrasaccharide FSL and its related trisaccharides 3FL and 3SL at 10, 50, and 250 μg/ml. Pre-
incubating dendritic cells with 3FL- and FSL-BSA decreased IL-10 production after lipopolysaccharide 
(LPS) stimulation. By contrast, pre-incubation with 3SL-BSA had no effect on IL-10 production (Fig. 
S4A). The pre-treatment of dendritic cells with glycosylated BSA had no impact on IL-6 and IL-12p70 
production (Fig. S4B and S4C). To identify the mechanisms causing the effect of FSL-BSA on cytokine 
release, we pre-treated dendritic cells with the dectin-1 inhibitor laminarin [41, 42], a DC-SIGN 
inhibiting antibody [43, 44], the SHP1/2 PTPase inhibitor NSC-87877 [45], and the phosphatidylinositol 
3-kinase (PI3K) inhibitor wortmannin [46]. Whereas pre-treatments with laminarin, the DC-SIGN 
inhibiting antibody, and NSC-87877 had no impact on the regulatory effect of FSL-BSA toward the 
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release of IL-10 (data not shown), we found that blocking PI3K with wortmannin strongly increased 
the levels of the pro-inflammatory cytokines TNF-α, IL-12p70, and IL-1β produced by dendritic cells 
after FSL-BSA pre-incubation and LPS stimulation (Fig. 6A–6C). By contrast, the inhibition of PI3K had 
no effect on the production of IL-6 (Fig. 6D) and IL-10 (Fig. 6E), indicating that FSL-BSA pre-treatment 
enhanced TNF-α, IL-12p70, and IL-1β secretion through a mechanism that is normally suppressed by 
PI3K. PI3K is known to negatively regulate TLR signaling [47], suggesting that lectins involved in the 
recognition of FSL-BSA are also suppressed in a PI3K-dependent manner. We next addressed whether 
the stimulatory effect of glycosylated BSA was restricted to the FSL epitope by also testing Lac-BSA, 
3FL-BSA, and 3SL-BSA. 
 
Figure 6: Effect of PI3K Inhibition on Cytokine Production in LPS Stimulated Dendritic Cells Pre-treated with 
Glycosylated BSA. FSL-modified BSA was added to PBMC-derived human dendritic cells at the indicated 
concentrations (μg/mL). Some cells were treated with wortmannin (labeled with W) before the addition of FSL-
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modified BSA. Finally the cells were stimulated with LPS. The medium was collected and (A) TNF-α, (B) IL-
12p70, (C) IL-1β, (D) IL-6, and (E) IL-10 levels were determined. W, wortmannin; -, untreated; +, stimulated with 
500 ng/mL LPS. Data represent averages and SD of three experiments. *p < 0.05. 
We compared IL-12p70 and IL-6 as these two cytokines were either sensitive or insensitive to 
wortmannin-mediated PI3K inhibition. The same stimulatory effect was observed for all forms of 
glycosylated BSA, whereas non-glycosylated BSA was inactive (Fig. 7A). As noticed for FSL-BSA before, 
any type of glycosylated BSA failed to influence IL-6 in dendritic cells stimulated with LPS (Fig. 7B). 
These experiments showed that custom-glycosylated proteins such as BSA can be applied to 
investigate the regulatory effects of endogenous lectins on immune cell activation. 
 
Figure 7: Effect of PI3K Inhibition on Cytokine Production Depends on Glycan Chains. Native and glycosylated 
BSA was added to PBMC-derived human dendritic cells at 250 μg/mL with or without pre-treatment with 
wortmannin. (A) IL-12p70, (B) IL-6 levels in cell supernatants after 24 h incubation. -, untreated; +, stimulated 
with 500 ng/mL LPS. Data represent averages and SD of three experiments. *p < 0.05. 
Discussion 
We present a method with which whole cells and any molecule containing primary amines can be 
modified to expose specific oligosaccharide structures. The simplicity and the lack of toxicity of the 
cyclic-carbamate-mediated ligation technique enable its application under physiological conditions at 
neutral pH and over a broad range of temperatures. The versatility of the technique was illustrated 
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by investigating selectin binding to glycan-decorated murine MC-38 cells, factor H binding to 
decorated E. coli, and dendritic cell activation by custom-glycosylated proteins. 
As shown through the ligation of fucosylated oligosaccharides to MC-38 cells, the technique enables 
the study of carbohydrate-binding proteins in the context of cellular membranes. The sialyl-Lewis X 
epitope is the generally accepted ligand for selectins, implying that α2-3 linked sialic acid linked to 
galactose increases the binding affinity to selectins [48-50]. Sulfated Lewis X has also been reported to 
be a selectin ligand, which implies that the negative charge facilitates selectin binding [51, 52]. Our 
comparative study of selectin binding demonstrated that α1-3 fucosylation without sialylation 
mediates strong E-selectin binding to mouse cells. These results confirm the previous observation 
that α1-3-fucosyltransferase overexpression is sufficient to enable cells to roll on E-selectin [53]. 
However, increasing α1-3 fucosylation of MC-38 cells by decorating them with 3FL did not increase 
the binding to P- and L-selectin, although significant binding to P- and L-selectin was observed when 
α1-3 fucosylated epitopes were exposed on glycosylated BSA spotted on nitrocellulose membranes. 
This illustrates that the context of epitope presentation, either on a cell membrane or on a solid 
surface, affects the binding specificity of selectin isoforms. Such differences in carbohydrate-binding 
behavior indicate that results obtained with glycans spotted on glass arrays may diverge from the 
binding properties to the same epitopes presented on glycoconjugates inserted in cell membranes. 
The application of the cyclic-carbamate ligation technology to coat E. coli demonstrated its value as a 
tool to study the role of specific bacterial glycan structures and their interaction with host proteins. 
Whereas membrane sialylation was previously shown to interfere with complement activation [20, 
54], the importance of the glycosidic linkage of sialic acid remained unclear. The decoration of 
bacterial membranes with α2-3 and α2-6 linked sialic acid using cyclic-carbamate ligation clearly 
demonstrated the preferential binding of complement factor H to α2-3 linked sialic acid. In 
pathogenic bacteria, sialic acid either occurs in the context of lipooligosaccharides that are 
incorporated into the outer membrane of Gram-negative bacteria or in capsular polysaccharides [55, 
56]. N. gonorrhoeae and N. meningitidis sialylate their lipooligosaccharides with an outer-membrane  
α2-3 sialyltransferase. Gonococcal sialylated lipooligosaccharides have been shown to recruit factor 
H to the bacterial cell surface and protect the cell from C3 attack as observed for mammalian cell 
membranes [20]. Haemophilus influenzae expresses the α2-3 sialyltransferase Lic3A that is absolutely 
required for its survival in the middle ear of a mouse model for otitis media [57]. Up to now, 
Streptococcus agalactiae is the only Gram-positive bacterium that has been shown to have sialic acid 
in its capsule, and the responsible sialyltransferase has been shown to catalyze an α2-3 linkage [58]. 
Interestingly, capsule sialylation of S. agalactiae has been associated with the prevention of 
complement activation [59]. Accordingly, the experimental evidence gained from E. coli coating 
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confirmed the critical importance of α2-3 sialylation on bacterial surfaces to mediate factor-H-
dependent complement inhibition. 
The heterogeneous glycosylation of mucins renders the assignment of functions to specific glycan 
structures on these proteins difficult. The dense glycosylation of mucins occurs on serine and 
threonine residues, which offer poor reactivity for chemical ligations. Lysine-rich polypeptides can 
therefore be used as backbones for modification using the oligosaccharide-cyclic-carbamate ligation 
technique to mimic heavily glycosylated mucins. Recently, a method enabling the production of 
multivalent glycoproteins presenting carbohydrates on serine has been developed [4]. Although this 
method generates polypeptides including α-GalNAc-modified serines, the procedure has not been 
advanced to yield proteins carrying complex oligosaccharide epitopes yet. In our work, we used BSA 
as a backbone to investigate the role of specific glycan epitopes during dendritic cell activation. Our 
results clearly showed that glycan moieties have an impact on the activation of dendritic cells as 
exemplified by differential regulation of cytokine expression. Interestingly, glycosylated BSA affected 
cytokine production in a PI3K-regulated manner. The PI3K is known to downregulate Toll-like 
receptor signaling [46, 60, 61]. The release of the cytokines IL-1, IL-12, and TNF-α was strongly induced 
in LPS stimulated dendritic cells that were pre-treated with glycosylated BSA once PI3K was blocked 
by wortmannin. The carbohydrate-binding receptors involved in sensing of glycosylated BSA are 
currently unknown, but dendritic cells express a multitude of C-type lectins [35], which contribute to 
the regulation of immune reactions by recognizing glycoconjugates. C-type lectins, such as the 
macrophage mannose receptor and DC-SIGN, influence cytokine production in dendritic cells [62, 63]. 
The availability of uniformly glycosylated proteins will be helpful in delineating ligand specificity and 
the signaling properties of C-type lectin family members in the context of living cells. 
In addition to the direct glycosylation of cell membranes and the production of custom glycoproteins 
as outlined in the present study, other carrier molecules, such as the phospholipid 
phosphatidylethanolamine, are suitable supports to produce specific glycolipids. In conclusion, the 
cyclic-carbamate ligation technique introduces a simple and versatile method to generate specific 
glycoconjugates by modifying primary amines. 
Significance 
We have developed a glycan conjugation method based on the derivatization of oligosaccharides 
with cyclic-carbamates. The resulting compounds enabled the targeted glycosylation of live cells with 
specific oligosaccharide epitopes. This approach opens the way to engineering rapid and specific 
changes in cell-surface glycosylation, which for example enables the characterization of carbohydrate 
ligands presented in the context of cell membranes rather than solid surfaces such as oligosaccharide 
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arrays on glass slides. We illustrated this concept here by coating multiple mouse and human cell 
lines with fucosylated oligosaccharides, thereby increasing E-selectin binding. The same approach 
could be applied to prokaryotic cells to, for example, to study their interactions with proteins from 
the innate immune system. 
The decoration of E. coli with sialylated oligosaccharides demonstrated the specific requirement for 
α2,3-linked sialic acid for the binding of complement factor H to the bacterial membrane. The 
technology also allows the study of signaling cascades activated by the recognition of specific 
oligosaccharide epitopes presented on glycoproteins. Here, we showed that proteins such as BSA can 
be glycosylated uniformly to address the carbohydrate ligand specificity of cytokine production in 
stimulated dendritic cells, which express a large number of C-type lectins. Altogether, cyclic-
carbamate-derivatized oligosaccharides represent a fast and efficient resource enabling the selective 
glycosylation of cell surfaces and proteins. 
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Figure S1: Optimization of cell surface coating with oligosaccharide-cyclic-carbamate, related to Figure 2. (A) 
MC-38 cells were incubated with 14 mM 3FL-cyclic-carbamate from 0.5 to 3 h before determining the extent of 
surface coating with FITC labelled AAL by flow cytometry. (B) MC-38 cells were incubated with 0 - 20 mM of 
3FL-cyclic-carbamate and surface fucosylation was measured by flow cytometry using FITC labelled AAL. MFI, 
median fluorescence intensity; 3FL, 3-fucosyllactose. 
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Figure S2: Coating cells with oligosaccharide-cyclic-carbamates, related to Figure 2. (A, B) THP-1, (C, D) 
RAW264.7 and (E, F) Jurkat cells were coated with 2FL- or 3FL-cyclic-carbamate or left uncoated, then stained 
with FITC labelled UEA or AAL before being analyzed by flow cytometry. Unstained cells (red lines), uncoated 
cells (blue lines), 2FL-coated cells (orange lines), 3FL-coated cells (green lines). 
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Figure S3: Surface coating of MC-38 cells with 2FL, related to Figure 2. (A) MC-38 cells were coated with 2FL, 
fixed with formaldehyde (3%), permeabilized with 0.1 % saponin and stained with UEA. Cell membranes and 
Golgi apparatus were stained using wheat germ agglutinin, and nuclei were stained using 4’,6-diamidino-2-
phenylindole. (B) Cells coated with 2FL or left uncoated were stained with FITC-labeled UEA and analyzed by 
flow cytometry. Single cell images were captured using ImageStream® technology. UEA, Ulex Europaeus 
Agglutinin; WGA, wheat germ agglutinin; BF, brightfield. Scale bars: 5 μm. 
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Figure S4: Cytokine response of lipopolysaccharide stimulated dendritic cells pre-treated with glycosylated 
bovine serum albumin, related to Figure 6. Bovine serum albumin decorated with the oligosaccharides 3FL, FSL, 
3SL were added to PBMC-derived human dendritic cells at the indicated concentrations (μg/ml) for 3 h, and 
then stimulated with lipopolysaccharide at 500 ng/ml. The cytokines (A) IL-10, (B) IL-12p70 and (C) IL-6 were 
determined in the cell supernatants after 24 h incubation. -, untreated; +, stimulated with 500 ng/ml LPS. Data 
represent average and standard deviation of three experiments. *, p-value < 0.05. 
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Methods S1, related to STAR Methods 
β-D-Galactopyranosyl-(1‒4)-β-D-glucopyranosyl azide (Lactosyl azide, 6a) 
 
 
 
 
It was prepared previously at Glycom as described in WO2009/040363. 
1
H NMR (400 MHz, DMSO-d6, δ DMSO-d5=2.50) δ 5.65 (d, J = 5.5 Hz, 1H), 5.09 (d, J = 4.0 Hz, 1H), 4.79 (d, J = 
4.7 Hz, 1H), 4.77 (d, J = 1.6 Hz, 1H), 4.66 (dt, J = 8.2, 5.6 Hz, 2H), 4.57 (d, J = 8.7 Hz, 1H), 4.52 (d, J = 4.6 Hz, 
 
1H), 4.19 (d, J = 7.3 Hz, 1H), 3.76 (ddd, J = 12.0, 5.5, 2.3 Hz, 1H), 3.66 – 3.57 (m, 2H), 3.56 – 3.40 (m, 4H), 3.39 
– 3.24 (m, 4H, overlapping with H2O), 3.04 (td, J = 8.5, 5.4 Hz, 1H). 
13
C APT NMR (101 MHz, DMSO, δ DMSO-d5=39.52) δ 103.80 (CH-1’), 89.72 (CH-1), 79.92, 77.02, 75.58, 74.84, 
73.25, 73.14, 70.55, 68.18, 60.45 (CH2OH), 60.12 (CH2OH). 
β-D-Galactopyranosyl-(1‒6)-β-D-glucopyrano[2,3-d]oxazolidin-2-one (cyclic-carbamate of Lactose, 1a) 
 
 
 
 
 
It was prepared previously at Glycom as described in WO2009/040363. 
1
H NMR (400 MHz, DMSO-d6, δ DMSO-d5=2.50) δ 8.49 (br d, J = 2.2 Hz, 1H, NHCO), 5.10 (d, J = 1.8 Hz, 1H, OH), 5.06 (d, J = 
4.6 Hz, 1H), 4.86 (dd, J = 8.8, 2.1 Hz, 1H, H-1), 4.77-4.82 (m, 2H), 4.75 (t, J = 5.0 Hz, 1H), 4.53 (d, J = 4.6 Hz, 1H), 4.25 – 4.07 
(m, 1H), 3.91 (ddd, J = 10.7, 7.1, 1.9 Hz, 1H), 3.74 (ddd, J = 12.0, 5.4, 2.2 Hz, 1H), 3.65 (ddd, J = 11.8, 6.7, 4.7 Hz, 1H), 3.61 – 
3.38 (m, 7H), 3.34 – 3.27 (m, 2H). 
13
C APT NMR (101 MHz, DMSO-d6, δ DMSO-d5=39.52) δ 157.70 (-OCONH-), 104.20 (CH-1’), 84.27 (CH-1), 
82.35, 81.22, 79.37, 75.66, 73.24, 71.70, 70.55, 68.22, 60.60 (CH2OH), 59.93 (CH2OH). 
HRMS (ESI(-)): m/z calc. for [C13H20NO11]
-
 366.1042 ([M-H]
-
), found 366.1053. 
α-L-Fucopyranosyl-(1‒2)-β-D-Galactopyranosyl-(1‒6)-β-D-glucopyrano[2,3-d]oxazolidin-2-one (cyclic-carbamate of 2FL, 
1b) 
 
 
 
 
 
 
It was prepared previously at Glycom as described in WO2009/040363. 
HRMS (ESI(-)): m/z calc. for [C19H30NO15]
-
 ([M-H]
-
) 512.1620, found 512.1582. 
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4,7,8,9-tetra-O-acetyl-N-acetyl-α-neuraminosyl-(2‒3)-2,4,6-tri-O-acetyl-β-D-galactopyranosyl-(1‒4)-1,2,3,6-tetra-O-
acetyl-α,β-D-glucopyranose (Peracetylated 3SL, 3d) 
 
 
 
 
 
3SL-Na salt 2d (10.00 g, 15.3 mmol, GeneChem) was suspended in a mixture of pyridine (80 mL) and acetic anhydride (40 
mL) and stirred overnight at r.t. followed by stirring at 40°C for 3 days until all dissolved. The obtained reaction mixture was 
evaporated in vacuo and co-evaporated with toluene (4x50 mL) at 50°C/<1 mbar to give 18.73 g of a pale brown foam 
which was used in the next step directly without further purification. 
1
H NMR (400 MHz, CDCl3): ca 60:40 mixture of β- and 
α- anomers. 
4,7,8,9-tetra-O-acetyl-N-acetyl-α-neuraminosyl-(2‒3)-2,4,6-tri-O-acetyl-β-D-galactopyranosyl-(1‒4)-2,3,6-tri-O-acetyl-α-
D-glucopyranosyl bromide (peracetylated 3SL-bromide, 4d) 
 
 
 
 
 
The crude peracetylated 3SL 3d (ca. 15 mmol) was dissolved in anhydrous CH2Cl2 (80 mL) followed by addition of acetic 
anhydride (6 mL, 63.5 mmol). The obtained mixture was allowed to cool by stirring on an ice bath and followed by addition 
of 33% (w/w) HBr in acetic acid (30 mL). The ice bath was removed and stirring continued for 2 h at r.t. The obtained 
solution was cooled again on an ice bath, then it was extracted with ice-cold water (4x100 mL). The combined aqueous 
phase was re-extracted with CH2Cl2 and the obtained organic phase was washed with water (3x50 mL) and brine (50 mL). 
The combined organic phase was dried (Na2SO4) and evaporated in vacuo at <20°C to give pale yellow-brown foam (17.37 g, 
at <1 mbar), which was used in the next step directly. 
 
1
H NMR (400 MHz, CDCl3, δ (CHCl3)=7.26 ppm) δ 6.53 (d, J = 3.9 Hz, 1H, CH-1 of Glc-Br), 5.66 (t, J = 9.7 Hz, 1H), 5.58 (d, J = 
9.8 Hz, 1H, NH), 5.47 – 5.35 (m, 2H), 5.30 (dd, J = 7.2, 2.0 Hz, 1H), 5.08 (ddd, J = 7.1, 5.9, 2.9 Hz, 1H), 4.78 (dd, J = 9.8, 3.9 Hz, 
1H), 4.71 (dd, J = 10.6, 7.7 Hz, 1H), 4.64 (d, J = 7.7 Hz, 1H), 4.56 – 4.45 (m, 2H), 4.32 (m, 2H), 4.21 – 3.93 (m, 6H), 3.66 (dd, J = 
10.5, 2.0 Hz, 1H), 2.43 (dd, J = 13.5, 5.5 Hz, 1H), 2.21 (s, 
3H), 2.13 – 2.04 (m, 21H), 2.00 (s, 3H), 1.88 (s, 3H), 1.85 (dd, J = 13.4, 11.1 Hz, 1H). 
13
C APT NMR (101 MHz, CDCl3, δ (CDCl3)=77.16 ppm) δ 171.03, 170.74, 170.63, 170.56, 170.54, 170.03, 
169.74, 169.54, 163.25 (impurity), 98.99 (CH-1 of Gal), 97.11 (C-2 of αDNeuAc 2-3), 86.98 (CH-1 of Glc-N3), 
75.22, 73.72, 73.36, 73.10, 72.91, 71.44, 71.16, 69.82, 69.52, 68.97, 67.29, 66.05, 62.14 (CH2O), 61.66 (CH2O), 
61.40 (CH2O), 49.17 (CH-5 of NeuAc), 43.58 (impurity), 37.70 (CH2-3 of NeuAc), 23.26, 21.00, 20.84, 20.83, 
20.80, 20.77, 20.71, 20.57. 
4,7,8,9-tetra-O-acetyl-N-acetyl-α-neuraminosyl-(2‒3)-2,4,6-tri-O-acetyl-β-D-galactopyranosyl-(1‒4)-2,3,6-tri-O-acetyl-β-
D-glucopyranosyl azide, Na-salt (peracetylated 3SL-azide, 5d) 
 
 
 
 
The crude peracetylated bromide 4d (17.3 g, ca 15.7 mmol) from previous step was dissolved in acetone (100 mL) and 
allowed to stir on an ice bath. To the obtained cold solution NaN3 (3.06 g, 47 mmol) in water (20 mL) was added. The cold 
bath was removed and the stirring continued for 1 h. It was quenched with 80 mL H2O and most of acetone was removed 
under reduced pressure at ambient temperature, extracted with EtOAc (100 mL) and washed with brine (3x50 mL). The 
residual amount of product was re-covered by additional extraction with EtOAc and washing with brine. The combined 
organic solution was dried (Na2SO4) and evaporated in vacuo to give 15.75 g of nearly colorless foam, which was used in the 
next step directly. 
1
H NMR (400 MHz, CDCl3, δ (CHCl3)=7.26 ppm) δ 5.65 (d, J = 10.2 Hz, 1H, NH), 5.42 (dd, J = 3.2, 1.3 Hz, 1H), 
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5.38 (dt, J = 10.9, 5.5 Hz, 1H), 5.26 (dd, J = 6.8, 1.9 Hz, 1H), 5.23 (t, J = 9.3 Hz, 1H), 5.11 (td, J = 6.4, 3.0 Hz, 
 
1H), 4.84 (t, J = 9.1 Hz, 1H), 4.73 (dd, J = 10.8, 7.7 Hz, 1H), 4.67 (d, J = 8.8 Hz, 1H, H-1 of Glc-N3), 4.56 (d, J = 
7.9 Hz, 1H, H-1 of Gal), 4.53 (dd, J = 12.7, 2.0 Hz, 1H), 4.44 (dd, J = 12.4, 4.3 Hz, 1H), 4.24 (dd, J = 12.4, 3.0 Hz, 
1H), 4.20 – 4.01 (m, 3H, overlapping with EtOAc), 3.97 (dd, J = 7.9, 2.9 Hz, 1H), 3.95 – 3.89 (m, 2H), 3.81 (ddd, J 
 
10.0, 4.3, 2.2 Hz, 1H), 3.64 (dd, J = 10.5, 1.9 Hz, 1H), 2.42 (dd, J = 13.5, 5.4 Hz, 1H), 2.11 (s, 3H), 2.09 – 2.00 (m, 27H), 2.00 (s, 
3H), 1.87 (s, 3H), 1.84 (dd, J = 13.4, 11.1 Hz, 1H), contains ca 1 eq. of EtOAc. 
 
13
C NMR (101 MHz, CDCl3, δ (CDCl3)=77.16 ppm) δ 171.01, 170.73, 170.70, 170.54, 170.48, 169.84, 169.79, 
169.77, 169.73, 169.59, 163.25 (impurity), 99.93 (CH-1 of Gal), 97.13 (C-2 of αDNeuAc 2-3), 87.75 (CH-1 of Glc-N3), 76.17, 
74.79, 73.71, 73.49, 72.95, 72.35, 71.41, 71.22, 69.72, 69.50, 67.38, 65.94, 62.29 (CH2O), 62.07 (CH2O), 61.17 (CH2O), 60.51 
(CH2O of EtOAc), 49.19 (CH-5 of NeuAc), 37.66 (CH2-3 of NeuAc), 23.23, 21.16, 21.02, 21.00, 20.85, 20.77, 20.76, 20.74, 
20.70, 20.55. 
N-Acetyl-α-neuraminosyl-(2‒3)-β-D-galactopyranosyl-(1‒4)-β-D-glucopyranosyl azide, Na-salt (3SL-azide, 6d) 
 
 
 
 
Peracetylated azide 5d from previous step (15.5 g, ca 15.7 mmol) was dissolved in MeOH (250 mL) followed by addition of 
MeONa (25% in MeOH, 5.5 mL, 24 mmol) while stirred on an ice bath. After stirring for 22 h at +3°C, extra 2 mL of MeONa 
solution was added and stirred for extra 19 hrs. TLC indicated the presence of intermediates. It was concentrated under 
reduced pressure at 0°C with the removal of ca. 150 mL MeOH and MeOAc followed by addition of water (100 mL, pH=13). 
TLC after 30 min at 0°C indicated a full conversion. It was neutralized with Amberlite IR-120 (H
+
 form, 20 g, pH=3), filtered, 
concentrated under reduced pressure at 0°C to a small volume, then pH was adjusted to 7.0 with 1 M NaOH (12 mL). The 
obtained solution was freeze-dried to give 9.57 g of very pale yellow solid. TLC Rf=0.46 (SiO2, eluent 5:4:1:0.1 EtOAc-MeOH-
H2O-AcOH) indicated ca 90% purity with ca 5% 3SL (Rf=0.25) and unidentified impurity (Rf=0.31). The solid was dissolved in 
MeOH (40 mL) and precipitated with 200 mL iPrOH, stirred for 1 h, filtered, washed with iPrOH, acetone, hexane, dried in 
vacuo (<1 mbar, r.t.) to give 9.86 g of white solid. NMR indicated ca 95% purity containing ca. 2% 3SL and residual solvents. 
 
1
H NMR (400 MHz, D2O, δ DHO=4.79) δ 4.78 (d, overlapping with DHO, 1H, H-1 of Glc-N3), 4.54 (d, J = 7.9 Hz, 1H, H-1 of 
Gal), 4.12 (dd, J = 9.9, 3.2 Hz, 1H), 4.06 – 3.53 (m, 17H), 3.32 (t, J = 8.9 Hz, 1H, H-2 of Gal), 2.77 (dd, J = 12.5, 4.6 Hz, 1H), 
2.04 (s, 3H), 1.81 (t, J = 12.1 Hz, 1H). 
 
13
C APT NMR (101 MHz, D2O) δ 175.00, 173.87, 102.60 (CH-1 of Gal), 99.79 (C-2 of αDNeuAc 2-3), 89.95 (CH-1 of Glc-N3), 
77.56, 76.70, 75.47, 75.18, 74.31, 72.88, 72.52, 71.77, 69.35, 68.34, 68.09, 67.46, 62.58 (CH2OH of NeuAc), 61.04 (CH2OH), 
59.82 (CH2OH), 51.68 (CH-5 of NeuAc), 39.64 (CH2-3 of NeuAc), 22.05 (Ac of NeuAc). 
N-Acetyl-α-neuraminosyl-(2‒3)-β-D-galactopyranosyl-(1‒6)-β-D-glucopyrano[2,3-d]oxazolidin-2-one, Na-salt (cyclic-
carbamate of 3SL, 1d) 
 
 
 
 
 
3SL-azide 6d, Na-salt (9.86g, 14.5 mmol) was dissolved in 600 mL DMF (anhydrous) and dehydrated by co-evaporation with 
toluene (100 mL, gelly suspension after addition) at 25°C to 3 mbar. The obtained solution was saturated with CO2 by 
passing the gas through the solution via cannula connected to a round bottom flask filled with excess of dry ice. Solution of 
Ph3P (7.63 g, 29.0 mmol, 2.0 eq.) in anhydrous DMF (20 mL) was dehydrated by co-evaporation with toluene (10 mL) as 
above and added dropwise with stirring under constant flow of CO2 in 30 min. After addition was completed, the mixture 
was allowed to stir under flow of CO2 for 2.5 hrs. TLC (5:4:1:0.1 EtOAc-MeOH-H2O-AcOH) indicated no difference after 40 
min and 2 h, since the product had the same Rf as starting azide. It was poured slowly into vigorously stirred 1:1 acetone-
hexane mixture (1 L). After 30 min it was filtered, washed with acetone, hexane (3x), dried in vacuo (<1 mbar, r.t., o.n.) to 
give 9.62 g of white solid. NMR indicated >95% purity with ca 30 mol% residual DMF and traces of Ph3P/Ph3PO (ca 1 mol% 
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only), traces of hexane and acetone. 
1
H and 
13
C NMR of the same sample in D2O was re-measured after 3 days and 11 days 
indicating ca 30% and 80% hydrolysis, respectively. NMR sample in CD3OD was decomposing much faster: by 80% after ca 5 
hrs. 
 
1
H NMR (400 MHz, D2O, δ DHO=4.79) δ 5.06 (d, J = 9.0 Hz, 1H, H-1 of Glc-CC), 4.54 (d, J = 7.8 Hz, 1H, H-1 of Gal), 4.22 (dd, J 
= 11.0, 7.1 Hz, 1H), 4.14 (dd, J = 9.8, 3.2 Hz, 1H), 4.05 – 3.52 (m, 17H), 2.77 (dd, J = 12.4, 4.7 Hz, 1H, H-3’’eq.), 2.04 (s, 3H), 
1.81 (t, J = 12.1 Hz, 1H, H-3’’ax). 
13
C NMR (101 MHz, D2O) δ 175.00 (Ac of NeuAc), 173.86 (CO2
-
), 159.99 (OCONH), 103.10 (CH-1 of Gal), 99.81 (C-2 of 
αDNeuAc 2-3), 84.82 (CH-1 of Glc-CC), 80.98, 80.50, 79.26, 75.38, 75.22, 72.87, 71.80, 71.76, 69.24, 68.35, 68.08, 67.32, 
62.57 (CH2OH of NeuAc), 60.87 (CH2OH), 59.89 (CH2OH), 51.68 (CH-5 of NeuAc), 39.62 (CH2-3 of NeuAc), 22.05 (Ac of 
NeuAc). 
 
HRMS (ESI(-), done at U. of Zurich): m/z calc. for [C24H37O19N2]
-
 ([M-H]
-
) 657.19960, found 657.20024. 
4,7,8,9-tetra-O-acetyl-N-acetyl-α-neuraminosyl-(2‒6)-2,3,4-tri-O-acetyl-β-D-galactopyranosyl-(1‒4)-2,3,6-tri-O-acetyl-α-
D-glucopyranosyl bromide (peracetylated 6SL-bromide, 4e) 
 
 
 
 
 
 
15 g and then 30 g of 6SL-Na salt was converted into 20.8 g and 50.32g, respectively, of bromide 4e as nearly colorless solid. 
 
1
H NMR (400 MHz, CDCl3, δ (CHCl3)=7.26 ppm) δ 6.55 (d, J = 4.0 Hz, 1H, H-1 of Glc-Br), 5.98 (d, J = 9.8 Hz, 1H, NH), 5.52 (t, J 
= 9.7 Hz, 1H, H-3 of Glc), 5.38 (d, J = 3.4 Hz, 1H), 5.33 – 5.25 (m, 2H), 5.11 (dd, J = 10.3, 7.9 Hz, 1H), 5.05 – 4.94 (m, 2H), 4.77 
(dd, J = 10.0, 4.1 Hz, 1H, H-2 of Glc), 4.54 (d, J = 7.9 Hz, 1H, H-1 of Gal), 4.52 – 4.45 (m, 1H, CH2O), 4.29 (dd, J = 11.8, 1.7 Hz, 
1H, CH2O), 4.25 – 4.17 (m, 2H), 4.14 (dd, J = 10.8, 1.6 Hz, 1H), 
 
4.09 – 3.97 (m, 2H), 3.95 – 3.82 (m, 3H), 3.50 (td, J = 9.6, 6.0 Hz, 1H, CH2O), 2.55 (dd, J = 12.8, 4.7 Hz, 1H), 
2.17 (s, 3H), 2.15 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H), 2.02 (s, 
3H), 1.95 (s, 3H), 1.89 (overlapping s, 3H), 1.85 (overlapping t, J = 12.5 Hz, 1H).
13
C NMR (101 MHz, CDCl3, δ (CDCl3)=77.16 
ppm) δ 171.44, 171.19, 171.05, 170.90, 170.45, 170.37, 170.20, 170.14, 169.93, 169.90, 169.40, 169.20, 101.08 (CH-1 of 
Gal), 98.71 (C-2 of αDNeuAc 2-6), 86.62 (CH-1 of Glc-Br), 75.33, 73.29, 72.71, 72.19, 71.33, 70.94, 69.87, 69.27, 69.21, 68.47, 
67.43, 67.39, 62.88 (CH2O), 62.70 (CH2O), 61.28 (CH2O), 37.69 (CH2-3 of NeuAc), 23.09, 21.09, 21.06, 21.04, 20.93, 20.91, 
20.86 (three overlapping Ac), 20.80, 20.67. 
4,7,8,9-tetra-O-acetyl-N-acetyl-α-neuraminosyl-(2‒6)-2,3,4-tri-O-acetyl-β-D-galactopyranosyl-(1‒4)-2,3,6-tri-O-acetyl-β-
D-glucopyranosyl azide, Na-salt (peracetylated 6SL-azide, 5e) 
 
 
 
 
 
 
50.2 g of crude bromide 4e was converted into crude azide 5e (50.5 g). 
1
H NMR (400 MHz, CDCl3, δ (CHCl3)=7.26 ppm) δ 6.01 (d, J = 9.8 Hz, 1H, NH), 5.39 (dd, J = 3.4, 1.1 Hz, 1H), 
5.35 – 5.25 (m, 2H), 5.19 (t, J = 9.4 Hz, 1H), 5.07 (dd, J = 10.3, 7.7 Hz, 1H), 5.04 – 4.94 (m, 2H), 4.86 (dd, J = 
 
9.6, 8.8 Hz, 1H), 4.62 (d, J = 8.8 Hz, 1H, H-1 of Glc-N3), 4.55 (d, J = 7.8 Hz, 1H, H-1 of Gal), 4.50 (dd, 1H, J = 
11.9, 1.9 Hz, CH2-O), 4.31 (dd, J = 12.3, 2.2 Hz, 1H), 4.20 – 3.96 (m, 4H), 3.93 – 3.85 (m, 2H), 3.81 (dd, J = 10.4, 
6.1 Hz, 1H, CH2O), 3.73 (ddd, J = 10.0, 5.7, 2.0 Hz, 1H), 3.51 (dd, J = 10.4, 7.2 Hz, 1H, CH2O), 2.55 (dd, J = 
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12.8, 4.7 Hz, 1H), 2.17 (s, 3H), 2.15 (s, 3H), 2.11 (s, 4H), 2.06 (s, 7H), 2.05 (s, 3H), 2.04 (s, 3H), 2.031 (s, 3H), 
2.027 (s, 3H), 1.94 (s, 3H), 1.89 (s, 3H), 1.86 (t, overlapping, J = 12.5 Hz, 1H). 
13
C NMR (101 MHz, CDCl3, δ (CDCl3)=77.16 ppm) δ 171.44, 171.13, 171.01, 170.97, 170.61, 170.53, 170.16, 170.12 (two Ac), 
169.67, 169.37, 169.34, 100.82 (CH-1 of Gal), 98.81 (C-2 of αDNeuAc 2-6), 87.80 (CH-1 of Glc-N3), 75.83, 75.14, 72.73, 72.39, 
72.07, 71.26, 71.12, 69.34, 69.17, 68.61, 67.43, 67.34, 62.77 (CH2O), 62.67 (CH2O), 62.12 (CH2O), 49.22 (CH-5 of NeuAc), 
37.63 (CH2-3 of NeuAc), 23.08, 21.08 (two Ac), 20.92 (three Ac), 20.86, 20.85, 20.77, 20.74, 20.66. 
N-Acetyl-α-neuraminosyl-(2‒6)-β-D-galactopyranosyl-(1‒4)-β-D-glucopyranosyl azide, Na-salt (6SL-azide, 6e) 
 
 
 
 
 
50.5 g of peracetylated azide 5e was converted into 27.3 g of azide 6e. 
1
H NMR (400 MHz, D2O, δ DHO=4.79) δ 4.77 (d, 1H, overlapping with DHO, H-1 of Glc-N3), 4.44 (d, J = 7.8 Hz, 
1H, H-1 of Gal), 4.08 – 3.77 (m, 7H), 3.77 – 3.48 (m, 11H), 3.36 (m, 1H), 2.72 (dd, J = 12.4, 4.7 Hz, 1H, H-3’’eq), 
2.04 (s, 3H), 1.74 (t, J = 12.2 Hz, 1H, H-3’’ax). 
13
C NMR (101 MHz, D2O) δ 174.89, 173.46, 103.16 (CH-1 of Gal), 100.26 (C-2 of αDNeuAc 2-3), 89.75 (CH-1 of Glc-N3), 
78.98, 76.54, 74.57, 73.71, 72.51, 72.45, 72.34, 71.81, 70.76, 68.51, 68.38 (two overlapping CH-OH), 63.60 (CH2OH), 62.64 
(CH2OH), 60.02 (CH2OH), 51.78 (CH-5 of NeuAc), 40.10 (CH2-3 of NeuAc), 22.07 (Ac of NeuAc). 
N-Acetyl-α-neuraminosyl-(2‒6)-β-D-galactopyranosyl-(1‒6)-β-D-glucopyrano[2,3-d]oxazolidin-2-one, Na-salt (cyclic-
carbamate of 6SL, 1e) 
 
 
 
 
 
 
5.00 g of azide 6e was converted into crude cyclic-carbamate 1e (5.22 g), contaminated with ca. 10% 6SL. 
1
H NMR (400 MHz, D2O, δ DHO=4.79) δ 5.06 (d, J = 9.0 Hz, 1H, H-1 of Glc-CC), 4.44 (d, J = 7.8 Hz, 1H, H-1 of Gal, 4.29 (dd, J = 
11.0, 7.1 Hz, 1H), 4.13 – 3.78 (m, 10H), 3.49-3.78 (m, 8H), 2.72 (dd, J = 12.4, 4.8 Hz, 1H, H-3’’eq), 2.04 (s, 3H), 1.74 (t, J = 12.2 
Hz, 1H, H-3’’ax). 
 
13
C NMR (101 MHz, D2O) δ 174.96 (Ac of NeuAc), 173.41 (CO2
-
), 159.91 (OCONH), 103.49 (CH-1 of Gal), 100.20 (C-2 of 
αDNeuAc 2-6), 84.68 (CH-1 of Glc-CC), 81.64, 80.88, 79.12, 73.76, 72.58, 72.25, 71.87, 71.67, 70.61, 68.40 (two overlapping 
CH-OH), 68.19, 63.75 (CH2OH), 62.62 (CH2OH), 60.05 (CH2OH), 51.79 (CH-5 of NeuAc), 40.16 (CH2-3 of NeuAc), 21.99 (Ac of 
NeuAc). 
HRMS (ESI(-)) m/z calc for C24H37N2O19 ([M-H]
-
) 657.1996, found 657.2003 
2,3,4-tri-O-acetyl-α-L-fucopyranosyl-(1‒3)-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1‒4)]-β-D-
glucopyranosyl bromide (peracetylated 3FL-bromide, 4c) 
 
 
 
 
 
1
H NMR (400 MHz, CDCl3, δ (CHCl3)=7.26 ppm): δ 6.47 (d, J = 4.1 Hz, 1H, H-1 of Glc-Br), 5.46 (d, J = 4.0 Hz, 1H, H-1 of Fuc), 
5.42 (dd, J = 3.6, 1.1 Hz, 1H), 5.38 (dd, J = 3.4, 1.2 Hz, 1H), 5.18 (dd, J = 10.9, 3.3 Hz, 1H), 5.11 (dd, J = 10.4, 8.1 Hz, 1H), 5.04 
(dd, J = 10.9, 4.0 Hz, 1H), 4.98 (dd, J = 10.4, 3.5 Hz, 1H), 4.91 (q, J = 6.6 Hz, 1H), 4.76 (dd, J = 9.6, 4.1 Hz, 1H), 4.60 (dd, J = 
12.6, 1.9 Hz, 1H), 4.55 (dd, J = 11.4, 6.1 Hz, 1H), 4.50 (d, J = 8.1 Hz, 1H, H-1 of Gal), 4.29 (dd, J = 11.5, 8.1 Hz, 1H), 4.20 (t, J = 
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9.4 Hz, 1H), 4.13 (dd, J = 12.6, 3.6 Hz, 1H), 4.04 (ddd, J = 10.1, 3.6, 1.9 Hz, 1H), 3.96 (dd, J = 10.1, 9.1 Hz, 1H), 3.86 (ddd, J = 
8.3, 6.0, 1.1 Hz, 1H), 2.19 (s, 3H), 2.15 (s, 3H), 2.15 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 1.99 (s, 3H), 1.97 (s, 3H), 
1.96 (s, 3H), 1.25 (d, J = 6.5 Hz, 3H, Me of Fuc). 
 
13
C APT NMR (101 MHz, CDCl3, δ (CDCl3)=77.16 ppm) δ 170.91, 170.70, 170.67, 170.50, 170.21, 170.14 (overlapping two 
Ac), 169.97, 169.11, 100.66 (CH-1 of Gal), 95.61 (CH-1 of Fuc), 87.35 (CH-1 of Glc-Br), 73.69, 73.49, 72.83, 71.89, 71.39, 
71.17, 71.10, 68.95, 68.29, 68.17, 66.67, 64.38, 60.79 (CH2OH), 60.63 (CH2OH), 
20.91 (overlapping three Ac), 20.87, 20.81, 20.78, 20.75, 20.74, 20.65, 15.93 (Me of Fuc). 
2,3,4-tri-O-acetyl-α-L-fucopyranosyl-(1‒3)-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1‒4)]-β-D-
glucopyranosyl azide (peracetylated 3FL-azide, 5c) 
 
 
 
 
 
1
H NMR (400 MHz, CDCl3, δ (CHCl3)=7.26 ppm): δ 5.41 (dd, J = 3.5, 1.0 Hz, 1H), 5.38 (dd, J = 3.4, 1.2 Hz, 1H), 5.32 (d, J = 4.0 
Hz, 1H, H-1 of Fuc), 5.16 (dd, J = 10.9, 3.3 Hz, 1H), 5.12 – 4.89 (m, 5H), 4.65 (dd, J = 12.4, 2.1 Hz, 1H), 4.53 (dd, J = 11.4, 6.1 
Hz, 1H), 4.47 (d, J = 8.1 Hz, 1H, H-1 of Gal), 4.33 (d, J = 8.9 Hz, 1H, H-1 of Glc-N3), 4.30 (dd, J = 11.5, 8.0 Hz, 1H), 4.09 (dd, J = 
12.3, 4.4 Hz, 1H), 3.99 – 3.83 (m, 3H), 3.55 (dp, J = 6.5, 2.9, 2.0 Hz, 1H), 2.19 (s, 3H), 2.15 (s, 3H), 2.14 (s, 3H), 2.08 (s, 3H), 
2.07 (s, 3H), 2.05 (s, 3H), 2.05 (s, 3H), 1.97 (s, 3H), 1.95 (s, 3H), 1.23 (d, J = 6.5 Hz, 3H). 
 
13
C APT NMR (101 MHz, CDCl3, δ (CDCl3)=77.16 ppm): δ 171.27, 170.85, 170.68, 170.51, 170.29, 170.07, 169.90, 169.70, 
and 169.09 (nine Ac), 100.81 (CH-1 of Gal), 95.70 (CH-1 of Fuc), 87.99 (CH-1 of Glc-N3), 75.50, 74.17, 73.85, 72.99, 71.40, 
71.22, 71.02, 69.00, 68.05, 67.95, 66.68, 64.42, 61.32 (CH2O), 60.68 (CH2O), 20.98 (Ac), 20.91 (two Ac), 20.89 (Ac), 20.85 
(Ac), 20.77 (Ac), 20.72 (two Ac), 20.64 (Ac), 15.90 (Me of Fuc). 
α-L-Fucopyranosyl-(1‒3)-[β-D-galactopyranosyl-(1‒4)]-β-D-glucopyranosyl azide (3FL-azide, 6c) 
 
 
 
 
 
 
1
H NMR (400 MHz, D2O, δ DHO=4.79) δ 5.44 (d, J = 4.0 Hz, 1H, H-1 of Fuc), 4.82 (q, J = 6.9 Hz, overlapping with DHO, 1H, H-5 
of Fuc), 4.76 (d, J = 8.8 Hz, overlapping with DHO, 1H, H-1 of Glc-N3), 4.44 (d, J = 7.7 Hz, 1H, H-1 of Gal), 4.05 – 3.62 (m, 
12H), 3.59 (dd, J = 7.8, 4.4 Hz, 1H), 3.52 (t, J = 9.0 Hz, 1H), 3.50 (dt, J = 13.3, 9.4 Hz, 2H), 3.48 (dd, J = 9.9, 7.7 Hz, 1H), 1.19 (d, 
J = 6.8 Hz, 3H). 
 
13
C APT NMR (101 MHz, D2O) δ 101.74 (CH-1 of Gal), 98.39 (CH-1 of Fuc), 90.00 (CH-1 of Glc-N3), 77.26, 76.83, 74.92, 74.19, 
72.39, 72.21, 71.92, 71.10, 69.18, 68.29, 68.00, 66.50 (CH-5 of Fuc), 61.46 (CH2OH), 59.53 (CH2OH), 15.20 (CH3 of Fuc). 
α-L-Fucopyranosyl-(1‒3)-[β-D-galactopyranosyl-(1‒6)]-β-D-glucopyrano[2,3-d]oxazolidin-2-one (cyclic-carbamate of 3FL, 
1c) 
 
 
 
 
 
 
1
H NMR (400 MHz, D2O, δ DHO=4.79) δ 5.14 (d, J = 3.9 Hz, 1H, H-1 of Fuc), 5.06 (d, J = 9.0 Hz, 1H, H-1 of Glc-CC), 4.67 (q, J = 
6.7 Hz, 1H, H-5 of Fuc), 4.44 (d, J = 7.7 Hz, 1H, H-1 of Gal), 4.28 (dd, J = 10.8, 8.0 Hz, 1H), 4.12 (t, J = 8.7 Hz, 1H), 4.09 – 3.95 
(m, 3H), 3.95 – 3.70 (m, 7H), 3.64 (ddd (two dd), J = 19.0, 8.7, 4.1 Hz, 2H), 
3.48 (dd, J = 9.9, 7.6 Hz, 1H, H-2’), 1.22 (d, J = 6.6 Hz, 3H, CH3). 
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13
C APT NMR (101 MHz, D2O) δ 159.96 (OCONH), 101.97 (CH-1 of Gal), 97.19 (CH-1 of Fuc), 84.91 (CH-1 of Glc-CC), 81.76, 
79.89, 75.04, 74.21, 73.43, 72.38, 71.84, 71.31, 69.19, 68.19, 67.78, 66.77 (CH-5 of Fuc), 61.22 (CH2OH), 59.62 (CH2OH), 
15.08 (CH3 of Fuc). 
 
HRMS (ESI(+), done at U. of Zurich): m/z calc. for [C19H31O15NNa]
+
 ([M+Na]
+
) 536.1586, found 536.1587. 
N-Acetyl-α-neuraminosyl-(2‒3)-β-D-galactopyranosyl-(1‒4)-[α-L-fucopyranosyl-(1‒3)]-β-D-glucopyranosyl azide (FSL-
azide, 6f) 
 
 
 
 
 
 
 
3FL-azide 6c (1.00 g), 3SL 2d (1.20 g, Genentech) and trans-sialidase from Trypanosoma cruzi (TcTS, 20.5 mg, c-Lecta, 11301-
2, ca 61 U/g) were stirred in water (5 mL) at r.t. and pH=6.0 for 24 h and monitored by TLC (6:3:1 MeCN-H2O-25% aq.NH3). 
Ca. 40% conversion was observed with only lactose formed as the side product. The reaction mixture was quenched with 
methanol and absorbed on silica gel (5.0 g) after evaporation in vacuo. The resulting solid was chromatographed on silica 
gel (50 g, 0.040-0.063 mm particle size) with 75:15:10 MeCN-H2O-25% aq. NH3 (100 mL) then 70:20:10 MeCN-H2O-25% aq. 
NH3 (300 mL) mixture as eluents. The purest fractions were evaporated and freeze-dried to give 24 mg of product, which 
was used as analytical sample. The remaining fractions containing product together with unreacted 3SL and 3FL-azide were 
evaporated, re-dissolved in 3 mL H2O and passed through Dowex 1x4 resin (HCO3
-
 form) and eluted with water to give 
unreacted 3FL-N3 (452 g). The product was eluted together with 3SL with 60 mM NaHCO3, fractions were combined, 
acidified with Amberlite IR120 (H
+
 form, pH=3), then filtered and the pH was adjusted to 6.0 with 1 M NaOH, followed by 
freeze-drying to give 504 mg of product contaminated with ca. 30% 3SL. 
 
1
H NMR (400 MHz, D2O, δ DHO=4.79) δ 5.43 (d, J = 4.0 Hz, 1H, H-1 of αFuc), 4.76 (d, overlapping with DHO, J = 10.6 Hz, 1H, 
H-1 of GlcN3), 4.50 (d, J = 7.8 Hz, 1H, H-1 of Gal), 4.08 (dd, J = 9.9, 3.2 Hz, 1H), 4.01 (dd, J = 12.5, 2.2 Hz, 1H), 3.97 – 3.45 (m, 
20H), 2.76 (dd, J = 12.5, 4.6 Hz, 1H, H-3eq of NeuAc), 2.03 (s, 3H), 1.80 (t, J = 12.1 Hz, 1H, H-3ax of NeuAc), 1.18 (d, J = 6.6 Hz, 
3H, Me of Fuc). 
13
C NMR (101 MHz, D2O) δ 174.97, 173.84, 101.53 (CH-1 of Gal), 99.61 (C-2 of NeuAc), 98.36 (CH-1 of Fuc), 
90.00 (CH-1 of Glc-N3), 77.17, 76.71, 75.56, 74.90, 74.22, 72.85, 72.18, 71.91, 71.82, 69.34, 69.15, 68.27, 68.06, 
 
67.99, 67.23, 66.46, 62.54 (CH2OH), 61.44 (CH2OH), 59.42 (CH2OH), 51.65 (CH-5 of NeuAc), 39.73 (CH2-3 of NeuAc), 22.00 
(Me of Ac), 15.16 (Me of Fuc). 
N-Acetyl-α-neuraminosyl-(2‒3)-β-D-galactopyranosyl-(1‒6)-[α-L-fucopyranosyl-(1‒7)]-β-D-glucopyrano[2,3-d]oxazolidin-
2-one, Na-salt (cyclic-carbamate of FSL, 1f) 
 
 
 
 
 
 
 
Crude FSL-azide 6f (480 mg, contaminated with ca 30% 3SL) was dissolved in DMF (5 mL) and dehydrated by co-evaporation 
with toluene (2x2 mL, 40°C, P=10 mbar). It was saturated with CO2 generated from dry ice followed by addition of Ph3P (457 
mg, 1.74 mmol, 3 eq.) in DMF (1.5 mL) at +10°C. The cold bath removed and stirring continued for 2 h under CO2 
atmosphere. The obtained solution was added dropwise into stirred acetone-hexane mixture (80 mL, 1:1), filtered, dried in 
vacuo at r.t. to give 496 mg of white hydroscopic solid contaminated with ca. 30% 3SL. 
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1
H NMR (400 MHz, D2O, δ DHO=4.79), selected resonances: δ 5.12 (d, J = 3.8 Hz, 1H, H-1 of αFuc), 5.06 (d, J = 9.0 Hz, 1H, H-
1 of Glc-CC), 2.77 (dd, J = 12.5, 4.6 Hz, 1H, H-3eq of NeuAc), 1.80 (t, J = 12.1 Hz, 1H, H-3ax of NeuAc), 1.21 (d, J = 6.6 Hz, 3H, 
Me of Fuc). 
13
C NMR (101 MHz, D2O) δ 174.99, 173.84, 159.97 (OCONH), 101.72 (CH-1 of Gal), 99.70 (C-2 of NeuAc), 97.19 (CH-1 of 
Fuc), 84.93 (CH-1 of Glc-CC), 81.75, 79.84, 75.56, 75.00, 74.19, 73.32, 72.87, 71.82 (two overlapping CH), 69.63, 69.17, 
68.29, 68.06, 67.78, 67.15, 66.77, 62.55 (CH2O), 61.23 (CH2O), 59.58 (CH2O), 51.66 (CH-5 of NeuAc), 39.70 (CH2-3 of NeuAc), 
22.02, 15.05. 
 
HRMS (ESI (-)) m/z calc. for C30H47N2O23 ([M-H]
-
) 803.2575, found 803.2551 
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Abstract 
Cells that are undergoing programmed cell death are characterized by changes in their surface 
glycosylation. Often it is unclear whether these changes are a cause or consequence of programmed 
cell death. Therefore, we coated cells with oligosaccharides using the cyclic-carbamate method and 
were able to demonstrate that sialyllactose coating induces rapid, caspase-dependent programmed 
cell death. We performed a CRISPR-Cas9 screen using the murine GeCKO v2 gRNA library to identify 
the genetic components of this novel form of programmed cell death. The screen revealed the 
involvement of the three G-protein coupled receptors free fatty acid receptor 4, the olfactory 
receptor 1537, the olfactory receptor 310 and the downstream signaling protein adenylate cyclase 7. 
Sialyllactose-coating led to increased concentrations of the secondary messenger calcium and rapid 
degradation of microtubules and actin. Here we have demonstrated for the first time a fast and novel 
form of cell surface sialylation mediated cell death. The speed of cell death and the possibility to 
inhibit cell death with pertussis toxin as well as the results of our screen indicates that G-protein 
coupled receptor signaling plays a key role in sialyllactose-coating induced cell death. 
Introduction 
There are different types of programmed cell death such as apoptosis, pyroptosis and necroptosis as 
examples of the more well-known types. During programmed forms of cell death the cell initiates a 
defined process leading to its demise. The outcome is defined such as pyroptosis and necroptosis 
that lead to an inflammatory response and apoptosis on the other hand which avoids inflammatory 
responses [1]. 
Glycans are highly enriched on the cell surface and they mediate many cellular processes such as 
leukocyte extravasation by the sialyl-Lewis X epitope [2] and the dampening of immune reactions by 
sialylated glycans [3, 4]. Each cell type has a unique repertoire of glycans and the decoding of the 
information that every cell has on its surface occurs via lectins that also occur at cell surfaces [5, 6]. 
The interest in the roles that glycans play during cell death arose due to studies that were conducted 
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in the 1980s when lectins were constitutively expressed on macrophages and these macrophages 
were able to selectively recognize apoptotic thymocytes [7]. This indicates that dying cells have a 
specific surface glycosylation pattern. Through different mechanisms therefore lectin-glycan 
interactions at the cell surface may regulate or even initiate cell death [8]. Glycosylation of the death 
receptor CD95 and the tumor necrosis factor-related apoptosis-inducing ligand receptors (TRAIL-R1 
and TRAIL-R2) for instance can influence their signaling by enhancing or sterically inhibiting the 
access of the receptors to their ligands Fas ligand and TNF respectively. Fucosylated core-2 O-glycans 
for instance on TRAIL-R1 and TRAIL-R2 enhance TRAIL-induced apoptosis [9]. Sialylation on the other 
hand often protects the cell from cell death receptor-mediated apoptosis. The sialylation of N-linked 
glycans on Fas ligand reduces the sensitivity of B-cell lymphomas to Fas ligand-induced cell death [10, 
11]. TNFR1, a receptor that can also induce cell death in macrophages, has an increased sensitivity 
towards TNF and the Fas ligand when it lacks α2-6-linked sialic acid and as a consequence induces 
more cell death [12]. 
Galectins, a family of soluble lectins that preferentially bind to β-galactoside sugars, frequently play a 
key role in the initiation of cell death. Galectin-1 binding to the surface of T cells is known to initiate 
apoptosis and play an important role in the negative selection of self-antigen recognizing T cells [5, 
13]. The clustering of CD45, CD3 and CD7 with the mucin-like protein sialophorin at the cell surface 
has been shown to be involved during galectin-1 mediated cell death [14]. 
To discover new roles that glycans fulfill during programmed cell death, we coated cells with 
oligosaccharide-cyclic-carbamates as previously described [15]. Interestingly, coating cells with 
sialyllactose-cyclic-carbamates induced rapid programmed cell death. Sialylation in relation to 
galectin and death-receptor mediated cell death has previously only been associated with a 
protective function [12, 16-18]. However, we describe a novel role of sialic acid containing surface 
glycans as drivers of a previously unknown from of programmed cell death. 
Materials and Methods 
Cell culture 
MC-38, RAW264.7, L929, HEK293T and HT-29 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium supplemented with 10% FCS. THP-1 and Jurkat cells were cultured in RPMI-1640 medium 
supplemented with 10% FCS. 
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Oligosaccharide cyclic-carbamates 
Lactose- [Gal(β1-4)Glc], 3SL- [Sia(α2-3)Gal(β1-4)Glc] and 6SL- [Sia(α2-6)Gal(β1-4)Glc] cyclic-
carbamates were provided by Glycom A/S. 
Cell coating with oligosaccharide-cyclic-carbamates 
The cell coating procedure was performed as has been previously described [15]. Briefly, the cells 
were detached from the culture dish with 2 mM EDTA in PBS for 10 min. The cells were washed once 
and resuspended at 400’000 cells/ml in Hank’s balanced saline solution (HBSS). Next, the cells were 
coated with 8 mM of the respective oligosaccharide-cyclic-carbamate for 10 min, unless otherwise 
specified. Before further processing the cells were washed 2 times with HBSS. 
Quantification of cell death 
The cells were stained with 200 ng/ml of propidium iodide for 5 min at 20°C before determining the 
relative amount of propidium iodide positive cells by flow cytometry with a FACScanto II (Becton 
Dickinson). Propidium iodide positive cells were considered to be dead. Jurkat cells were stained with 
20 μg/ml of 7-Aminoactinomycin D. The analysis was performed by flow cytometry with a FACScanto 
II (Becton Dickinson). 7-Aminoactinomycin D positive cells were considered not to be viable. 
6-sialyllactose-cyclic-carbamate coupling to 3-sn-phosphatidylethanolamine and purification 
3-sn-phsopatidylethanolamine (Sigma-Aldrich) was homogenized by sonication for 15 min with a 
bath sonicator in borate buffered saline, pH 10. A 5 fold molar excess of 6SL-cyclic-carbamate was 
added to the 3-sn-phsophatidylethanolamine and the reaction mix was incubated at 20°C for 4 h 
rotating. Afterwards the reaction mix was applied to a DC Kieselgel 60 thin-layer chromatography 
(TLC) membrane and detection of the educts and products was done by staining with p-anisaldehyde. 
The product (6SL-3-sn-phosphatidylethanolamine) was separated from the educts with a mobile 
phase consisting of chloroform:methanol:water (65:25:4). The product (Fig. 3A; arrow) was scraped 
off the TLC plate and extracted with chloroform:methanol (2:1). Next, the chloroform:methanol was 
evaporated and phosphate buffered saline (PBS) was used to make a 6SL-3-sn-
phosphatidylethanolamine homogenate. The phenol-sulfuric acid assay was performed to determine 
the amount of purified 6-sialyllactose-3-sn-phosphatidylethanolamine [19]. 
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6-sialyllactose-3-sn-phosphatidylethanolamine incorporation into Jurkat cell membranes 
1 mM of 6-sialyllacotse-3-sn-phophatidylethanolamine was added to 400’000 Jurkat cells/ml in HBSS 
and the cells were incubated for 4 h rotating at 20°C. The cells were washed two times with HBSS 
before further processing. 
Siglec-3 and sialophorin staining for flow cytometry 
A Siglec-3 probe with a human Fc-domain (R&D Research) was pre-complexed for 10 min with a 
biotinylated anti-IgG-Fc-domain antibody labelled with biotin (Sigma-Aldrich). The cells were stained 
with the pre-complexed Siglec-3 probe for 50 min and then stained with PerCP-Cy5.5 labelled 
streptavidin (Becton Dickinson) for 20 min before analysing the cells by flow cytometry with a 
FACScanto II (Becton Dickinson). 
A PE labelled antibody targeting sialophorin (Affymetrix eBioscience) was used to stain the cells that 
were analysed by flow cytometry with a FACScanto II (Becton Dickinson). 
Cell death inhibitors 
10 μM Q-VD-OPH (Sigma-Aldrich), 100 μM Z-IETD-FMK (Enzo Life Sciences), 20 μM Z-WEHD-FMK 
(Enzo Life Sciences) or 100 μM Necrostatin-1 (Enzo Life Sciences) were added to the cells media for 4 
h. Then, the cells were washed twice with HBSS and coated as described above. 
Production of lentivirus particles for the CRISPR-Cas9 screen with the murine GeCKO v2 library 
Virus production took place in HEK293T cells that were sawn on 2 T-75 plates so that they would be 
70-90% confluent the next day. The following procedure was performed separately for each of the 
two half-libraries A and B. 1’200 μl of Opti-MEM was mixed with 48 μl of Lipofectamine2000 (Life 
Technologies). 1’400 μl of Opti-MEM was mixed with 11.5 μg of the lentivirus packaging plasmid 
psPAX2, 6.4 μg of the lentivirus packaging plasmid pMD2.G and 10.2 μg the murine GeCKO v2 half-
library A or B [20]. 1’200 μl of the Lipofectamine2000 mix and 1’200 μl of the plasmid mix were 
combined and left to incubate at 20°C for 5 min. Then 2000 μl of the Lipofectamine2000-plasmid 
mixture was applied to the cells together with 13 ml of Dulbecco’s Modified Eagle’s Medium with 
10% FCS. After 6 h the media was replaced with fresh Dulbecco’s Modified Eagle’s Medium with 10% 
FCS. The lentiviral particles were harvested 24 h, 48 h and 72 h after the previous media change. The 
media was centrifuged at 500 x g for 5 min and the supernatant which includes the lentivirus 
particles was collected and stored at -80°C before being used for infections. 
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CRISPR-Cas9 screen with murine GeCKO v2 library in L929 and MC-38 cells 
The CRISPR-Cas9 screen was performed with the mouse CRISPR Knockout Pooled Library (GeCKO v2) 
according to a protocol adapted from the originally published research article [20]. Cas9 expressing 
L929 or MC-38 cells were passaged one day before initiating the screen so that the cells would be 20 
– 30% confluent the next day on 10 T-150 plates per half-library A or B and 1 negative control T-150 
plate. That means 1’500’000 cells were seeded per plate and 15’000’000 in total per half-library A or 
B. After 1 day the media was removed and 4 ml of lentivirus containing media for half-library A or B 
were added to each T-150 plate with 8 μg/ml polybrene (Sigma-Aldrich). The cells were incubated for 
2 h and then 14 ml of Dulbecco’s Modified Eagle’s Medium with 10% FCS was added per plate and 
the cells were incubated for a further 24 h. Then, the media was removed and selection was initiated 
with 23 μg/ml of puromycine (InvivoGen) for the L929 cells and 10 μg/ml for the MC-38 cells. The 
cells were incubated for 72 h which was the time it took for the cells on the negative control plate to 
die. All surviving cells were collected and treated with 8 mM of 3SL-cyclic-carbamate for 10 min in 10 
ml HBSS and plated onto 10 T-75 plates per half-library A or B. The cells were kept for a duration of 4 
weeks and clones were picked and cultured in 24-well plate culture dishes. To eliminate false-
positive clones, the cells were re-treated with 8 mM 3SL-cyclic-carbamate when they reached 
confluency. 
Sequencing the gRNA encoding sequence and genomic verification 
All PCRs were done with Taq polymerase (Sigma-Aldrich). 
The gRNA encoding sequence was sequenced with the flanking primers 5’-
GGACTATCATATGCTTACCG-3’ and 5’-TGCTGTCCCTGTAATAAACC-3’. 
Verification PCRs were done with the primers listed in the tables 1 and 2. 
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Table 1: CRISPR-Cas9 screen L929 cells: gRNAs and genotyping primer sequences. 
Gene 
abbreviation 
gRNA Forward primer Reverse primer 
Ang3 GATCACAACTTGCAAGCACA TGAAGAAAAGAAAGCTAACCTCACC GAGGGGAGATAAAAAGCAAACAGAC 
 
Appbp2 
 
TACATGATGAGATGCTCCAC AGTGATTTAGTGTAAGCGTGTCTCT CAAGGACAGAATTCTAAGCCCAAAG 
Aqp7 
 
GGCATCCTTGTTACCGTCCT GGATCGTACCAAGACACATCTCTG GACTTCATAAGACTTCTGTGCACCC 
CbrI 
 
CCCCTTCCACATTCAAGCAG GTGGTGTCTTTCAAGCACAATAGAA AGAAAGTCAATGGCCACAAAAGAAT 
Cisd2 
 
CCAGAAGCGCAAGTACCCCG TTGGGTCTGCTGTGTATATGGTTTA CTACAATAAGCTGCTTTGGTGAGAC 
Cul5 
 
ACGTCGCCATGTTCTCAACT TACTACCTCTTCCCGGTCTGGTC GAACCGCTCTCCTCATACACATC 
Ercc6 
 
GTTATACTTCTGTCGCTTCA CAACATCCCTGAGGCAAATCAATAA TATTACCCATAGCATGTGTACCCTC 
Ffar4 
 
CTCTAGTGCTCGTCGTGCGC n.a. n.a. 
Galnt13 
 
ACTGGAAGCTAAATTTCCGA TCTATAATCAACTTGGAGAGCTAATGT AACACACACAAAGTATCCAAAACTA 
Gata 6 
 
TCTACACAAGCGACCACCTC TCCGGTAAGTATGATAAAATGCCCT AAATATTCTTAGGTGCCAATTCACT 
Mark1 
 
TTCATCTGTCGCTGACGTAA ACTCCCCAATATCAACCATGAGAAA ATTGTCTAAGTGACTGTGAGCTCTT 
Mtm1 
 
TAAGTATAATTCACACTCCT TGTTCTGTTGAGCCATAGGAAGTAA ACAAGGTGGGACGGTAAATAAAATG 
Olfr1537 
 
AAGCATGAAGCCAGTGTTAA n.a. n.a. 
Olfr310 
 
TGTGCACACTTGCAATGACA n.a. n.a. 
Pptc7 
 
GCCTGATTACATGATCCTCC TGACATTGTAAAATGCAGGTAGCAG TAATGTTCCCAATTGTAATCGCCTG 
Rnf133 
 
GACATCGTTGTAGTTATGAT TCAAAATGCTTGTGATCCCAATACC TGGTGACGATCATAAAGGAGACAAA 
Siah2 
 
TTTCAAGTACCAGCATGAAG GAATACCGTCCTTATTCCTGTCCTT CATCATGAATGGACCGAGGTGTG 
Surf4 
 
GTTTGGAATCATCGCACTGC AGCAGCATTGGAATAAAGGTGTTTT TGGCCACTTCTCCAAAAAGAAAAAT 
Table 2: CRISPR-Cas9 screen MC-38 cells: gRNAs and genotyping primer sequences 
Gene 
abbreviation 
gRNA Forward primer Reverse primer 
Adcy7 
 
CATCATTGAGCGCCTCAAAG GTAGATATAAACGCGCAGGAAACAA CAGTGAACTATCTCCCTAGAACCAG 
Anxa8 
 
TCCTACAGGAACCAATGAGC AGCCATACCCAACACTATGTAAGTT GCCCTATGTACACATTTCCATTCTG 
Cnot8 
 
ACCCGTCTGGAATCAACACA n.a. n.a. 
Fam3b 
 
AAGTACTTTGATATGTATGA AGTCACTTAGAGGTAATGTGACCAA ACAGACCCTGTACTCAATAAACACA 
Spn 
 
GAGTCCATGCATCTCACTCG GGAACTGCAGCATCTACATCTATCT CAGTAACATGCCACTTGATTCTTGG 
Zc3hav1 TCATCCATCCTAGGAGATAC CTTGAGTGCATAGGGAAAGACAAAC CAGCAAGAGGAAAGAGGGAGTATAG 
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Microscopy 
For differential interference contrast imaging to record cell death in L929 cells, cultivation was 
performed in μ-Slide 8 well plates for live cell imaging (Ibidi). The cells were cultivated so that they 
would be 70% confluent after 2 days of cultivation, so 15’000 cells were seeded per well. On the day 
of recording the adherent cells were incubated with 8 mM of 3SL-cyclic-carbamate in HBSS just 
before commencing with the recording. Imaging was performed on the widefield microscope LX 
(Leica). 
For imaging the cytoskeleton, L929 cells were grown on coverslips in 24-well plates for 2 days so that 
they reached 50% confluency on the day of staining. To achieve this, 20’000 cells were seeded per 
well. On the day of the experiment, 8 mM 3SL-cyclic-carbamate was added directly to the adherent 
cells for 0 – 15 min. The cells were washed twice in HBSS and then fixed with 3% formalin in water for 
20 min. The cells were permeabilised in PBS with 0.1% saponin and 20 mM glycine. In a first step, 
staining was performed with a β-tubulin targeting primary murine antibody (Sigma-Aldrich), followed 
by staining with an Alexa647 labelled anti-mouse Fc-domain targeting antibody (Abcam) and further 
staining of actin with Alexa488 labelled phalloidin (Abcam) and 4’,6-diamidino-2-phenylindole 
(Biotium) to stain the nucleus. Imaging was conducted on an SP5 confocal microscope (Leica). 
Mitochondrial imaging was performed with living L929 cells. The cells were seeded into μ-Slide 8 well 
plates for live cell imaging (Ibidi) so that they would be 50% confluent in 2 days. Therefore, 10’000 
cells were seeded per well. Before microscopy the cells were incubated in growth media 
supplemented with 25 nM CMXRos (Thermo Fisher Scientific) for 15 min. Then, the cells were 
washed 3 times with growth media before adding PBS supplemented with 5 μg/ml Hoechst® 33342 
(Thermo Fisher Scientific) for 10 min. The cells were washed 3 times with PBS and then Live Cell 
Imaging Solution (Thermo Fisher Scientific) was added to the cells. Imaging was conducted on an SP5 
confocal microscope (Leica). 
Cytoplasmic calcium determination 
To determine the intracellular calcium concentration of MC-38 and L929 cells the FLUOFORTE® 
Calcium assay kit (Enzo Life Sciences) was used according to the provided instructions. The 
measurement was done on an Infinite® 200 Pro plate reader (Tecan Trading AG, Männerdorf, 
Switzerland). 
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Results 
3-Sialyllactose and 6-Sialyllactose cell coating initiates cell death 
Our initial goal was to coat different types of cells with various oligosaccharides using the cyclic-
carbamate approach that we recently described to identify novel functions of cell surface 
oligosaccharides [15]. This was possible with the lactose-, 2-fucosyllatose- (2FL), 3-fucosyllactose- 
(3FL) and 3-fucosyl-3-sialyllactose- (FSL) cyclic-carbamates [15] however we found that coating MC-
38 and L929 cells with 3-sialyllactose- (3SL) or 6-sialyllactose- (6SL) cyclic-carbamate lead to cell 
death after initiating cell coating (Fig. 1). 
 
Figure 1: Cell death by coating MC-38 and L929 cells with 3SL- or 6SL-cyclic-carbamates. MC-38 cells were 
either left uncoated, coated with lactose-, 3SL- or 6SL-cyclic-carbamate for 10 min and then stained with 
propidium iodide to determine the relative amounts of dead cells by flow cytometry. -, uncoated. The 
experiment was performed in triplicates and statistical significance was determined by ANOVA and Bonferroni 
post-testing. The error bars indicate the standard deviation. 
When visualized by differential interference contrast microscopy we noticed that 15 minutes after 
initiating L929 cell coating with 3SL-cyclic-carbamate, the plasma membranes of the cells started to 
bleb (Fig. 2D-G). After 30 minutes some of the cells had undergone secondary necrosis (black 
arrows). Cells that were coated with lactose cyclic-carbamate remained viable during 30 minutes of 
coating (Fig. 2A-C). 
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Figure 2: DIC microscopy to visualize 3SL-cyclic-carbamate coating mediated cell death in L929 cells. Adherently 
growing L929 cells were coated with (A-C) lactose-cyclic-carbamate and images were made after (A) 0 min, (B) 
15 min and (C) 30 min. Alternatively, the L929 cells were coated with (D-F) 3SL-cyclic-carbamate and images 
were made after (D) 0 min, (E) 15 min and (F) 30 min. (G) The marked region in (E) was enlarged to show cells 
with blebs on their membrane. The white arrow marks cells that have gone through secondary necrosis. Scale 
bar: 5 μm. These images are representative for three independent experiments. 
Oligosaccharide-cyclic-carbamates have been derivatized to have a cyclic-carbamate group at their 
reducing end which can bind covalently to primary amines that occur on proteins and lipids such as 
phosphatidylethanolamines [21]. We asked ourselves if cell death primarily occurs due to the 
coupling of oligosaccharide-cyclic-carbamates to specific epitopes on the cell surface or due to 
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general surface glycosylation. To answer this question we coupled 6SL-cyclic-carbamate to 3-sn-
phosphatidylethanolamine and incorporated the custom-made glycolipids into the membrane of 
Jurkat cells as has been done with aminooxy glycans condensed to a polymethyl vinyl ketone scaffold 
via the formation of oximes [22]. Beforehand, we demonstrated by thin-layer chromatography, with 
chloroform:methanol:water (65:25:4) as the mobile phase, that 6SL-cyclic-carbamate is successfully 
attached to 3-sn-phosphatidylethanolamine (Fig. 3A; black arrow). 6SL coupled to 3-sn-
phosphatidylethanolamine was isolated from the educts by scraping the product off the membrane 
and extracting the custom-made glycolipid with chloroform:methanol (2:1) (Fig. 3B). Incorporation of 
6SL-3sn-phosphatidylethanolamine into Jurkat cell membranes was shown by increased staining with 
SIGLEC-3 which was increased by the factor 3.5 (Fig. 3C). 6SL-3-sn-phosphatidylethanolamine 
incorporation into the cell membrane of Jurkat cells did not induce cell death while direct coating 
with 6SL-cyclic-carbamate lead to 80% cell death (Fig. 3D). This implies that the modification of 
certain sites leads to cell death and not the general coating of the cells with sialyllactose. 
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Figure 3: Incorporating 6SL coupled to 3-sn-phospathidylethanolamine into the plasma membrane of Jurkat 
cells does not induce cell death. (A) 6SL-cyclic-carbamate was attached to the amine group on 3-sn-
phosphatidylethanolamine and successful coupling was shown by TLC (black arrow). The presented image is 
representative of three independent experiments. (B) The product from (A) was scraped off the membrane and 
Folch extracted from the Kieselgel residue. Successful purification of the product was shown by TLC. The 
presented image is representative of three independent experiments. (C) The incorporation of 6SL-3-sn-
phosphatidylethanolamine into the plasma membrane of Jurkat cells was shown by staining the cells with a 
Siglec-3 probe. The presented image is representative of three independent experiments. (D) On one hand 6SL-
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3-sn-phsophatidylethanolamine was incorporated into Jurkat cells and on the other hand 6SL-cyclic-carbamate 
was coupled directly to the membrane of Jurkat cells. The extent of cell death was determined by propidium 
iodide staining and flow cytometry. The experiment was performed in triplicate and statistical significance was 
determined by ANOVA and Bonferroni post-testing. The error bars indicate the standard deviation. CC, cyclic-
carbamate; PE, 3-sn-phosphatidylethanolamine; unm., unmodified. 
We next showed that sialyllactose-coating induced cell death occurs in multiple cell lines such as MC-
38, RAW264.7, L929, HEK293T, HT-29 and THP-1 cells (Fig. 4A-F). In all the tested cell lines, except 
RAW264.7, the dose-kill curve was sigmoid with a sharp increase of the extent of cell death (Fig. 4A-
F). In RAW264.7 cells the relationship was linear with a gradual increase of cell death with the 
sialyllactose-cyclic-carbamate dose (Fig. 4B). In all cell lines, except RAW264.7, 3SL-cyclic-carbamate 
was also more potent than 6SL-cyclic-carbamate with the LD50 of 3SL-cyclic-carbamate being lower 
than the LD50 of 6SL-cyclic-carbamate (Fig. 4A-F; Tab. 3). 
Table 3: LD50 3SL-cyclic-carbamate and 6SL-cyclic-carbamate in 6 different cell lines. 
Cell Line LD50(3SL-CC) LD50(6SL-CC) 
MC-38 0.8 mM 3.1 mM 
RAW264.7 5.9 mM 6.0 mM 
L929 2.2 mM 5.5 mM 
HEK293T 1.6 mM 6.7 mM 
HT-29 3.5 mM 7.8 mM 
THP-1 5.9 mM 7.7 mM 
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Figure 4: Comparison of cell death inducing potency of 3SL- and 6SL-cyclic-carbamate in six different cell lines. 
(A) MC-38, (B) RAW264.7, (C) L929, (D) HEK293T, (E) HT-29 and (F) THP-1 cells were coated with increasing 
concentrations of 3SL- or 6SL-cyclic-carbamate for 10 min. Then, the cells were stained with propidium iodide 
and the relative amount of dead cells was determined by flow cytometry. -, uncoated; ●, 3SL-cyclic-carbamate; 
○, 6SL-cyclic-carbamate. The experiment was performed in triplicate and the error bars indicate the standard 
deviation. 
Sialyllactose coating initiated cell death inhibition by caspase antagonists 
The pan-caspase inhibitor Q-VD-OPH [23] lead to a 50% decreased amount of cell death in MC-38 
cells (Fig. 5A), a 30% decrease in RAW264.7 cells (Fig. 5B), a 40% decrease in HEK293T cells (Fig. 5D) 
and a 10 % decrease in THP-1 cells (Fig. 5F). In L929 and HT-29 cells no decrease in cell death was 
evident (Fig. 5C, E). As the pan-caspase inhibitor counteracted cell death, we decided to test more 
specific caspase inhibitors such as the caspase-8 inhibitor Z-IETD-FMK [24, 25] and the caspase-1 
inhibitor Z-WEHD-FMK [26-28]. We also tested the necroptosis inhibitor necrostatin-1 which inhibits 
RIPK1 [29, 30]. Z-IETD-FMK decreased cell death by 40% in MC-38 cells (Fig. 5A), 50% in RAW264.7 
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cells (Fig. 4B), 50% in HEK293T cells (Fig. 5D) but failed to decrease cell death in L929 (Fig. 5C), HT-29 
(Fig. 5E) and THP-1 cells (Fig. 5F). Z-WEHD-FMK lead to a decrease of cell death by 40% in MC-38 cells 
(Fig. 5A), 50% in RAW264.7 cells (Fig. 5B), 20% in L929 cells (Fig. 5C), 50% in HEK293T cells (Fig. 5D) 
and no decrease in HT-29 and THP-1 cells (Fig. 5E, F). Necrostatin-1 only slightly decreased 
sialyllactose coating mediated cell death in THP-1 cells by 10% (Fig. 5F) but did not influence the 
extent of cell death in any of the other cell lines (Fig. 5A-E). 
 
Figure 5: Influence of programmed cell death inhibitors on sialyllactose-cyclic-carbamate mediated cell death. 
(A) MC-38, (B) RAW264.7, (C) L929, (D) HEK293T, (E) HT-29 and (F) THP-1 cells were cultured in the presence of 
Q-VD-OPH, Z-IETD-FMK, Z-WEHD-FMK or necrostatin-1 for 4 h. The cells were then coated with 3SL- or 6SL-
cyclic-carbamate for 10 min and stained with propidium iodide to determine the amount of dead cells by flow 
cytometry. The experiments were performed in triplicate and the error bars indicate the standard deviation. 
The statistical significance was determined by ANOVA and Bonferroni post-testing. 
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CRISPR-Cas9 screen to identify genes involved during sialyllactose-coating induced cell death 
As cell death by 3SL- and 6SL-cyclic-carbamate coating could be inhibited by caspase inhibitors, we 
concluded that sialyllactose coating induced a programmed form of cell death. Interestingly, this 
form of cell death is caspase-8 as well as caspase-1 dependent in MC-38, RAW264.7 and in HEK293T 
cells. In L929 cells, cell death was only dependent on caspase-1. We decided to perform a genetic 
screen on the MC-38 cells and on the L929 cells to find the pathway involved during sialyllactose 
coating induced cell death. Both cell lines were transformed to express Cas9 and then infected with 
lentiviruses containing the murine GeCKO v2 gRNA library which targets 20’611 genes in the murine 
genome [20]. Then the cells were coated with 3SL-cyclic-carbamate to select the clones that are 
resistant towards sialyllactose-coating mediated programmed cell death. 
In the L929 cell line we identified 18 genes that are involved during 3SL-cyclic-carbamate coating 
mediated cell death (Tab. 4). These genes could be chiefly classified as G-protein coupled receptors, 
cytoskeleton interacting proteins, protein degrading proteins, phosphatases, kinases and channel 
proteins (Tab. 4). The three G-protein coupled receptors free fatty acid receptor 4 (Ffar4), olfactory 
receptor 1537 (Olfr1537) and olfactory receptor 310 (Olfr310) were interesting candidates to obtain 
in this screen as G-protein coupled receptors are known for their fast signaling [31]. All three proteins 
have accessible lysines in their extracellular domains (Fig. 6A-C) and Ffar4 has an N-glycosylation site 
at position 21 that is only 11 amino acids away from a lysine residue that is potentially accessible for 
oligosaccharide-cyclic-carbamates (Fig. 6A). Furthermore, cell death could be ameliorated by pre-
incubating the cells for 1.5 h with Pertussis toxin (Fig. 6D) which catalyzes ADP-ribosylation of the G-
proteins α-subunit, which stops G-proteins from interacting with the G-protein coupled receptors 
[32]. In the MC-38 cells we identified six genes that were involved in sialyllactose-mediated cell death 
(Tab. 5). Here, we found proteins involved in cell adhesion and signaling, trafficking and also G-
protein coupled receptor signaling (Tab. 5). The presence of deletory mutations in the identified 
genes were confirmed by genomic PCRs with primers that flank the gRNA targeted sequence (Tab. 1, 
2). Some of the clones have not been sequenced due to redundancies of the flanking sequences that 
make PCRs in these regions difficult such as the genes for Olfr1537 and Olfr310 (Tab. 1, 2). With the 
flanking primers, it was possible to genotype most of the mutations in the isolated clones (Tab. 6, 7). 
Some alleles were not possible to decipher from the chromatograms and are annotated as “unknown 
(not WT)” as wildtype sequences were generally easy to recognize despite more than two alleles 
being present. 
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Figure 6: (A-C) Amino acid sequences of Ffar4, Olfr1537 and Olfr310. The sequences with grey highlighting are 
the extracellular domains of these 7 pass transmembrane proteins. The characterized N-glycosylation sites 
have been indicated in blue and the accessible lysines for oligosaccharide-cyclic-carbamate ligation are 
highlighted in red. (D) Pertussis toxin was used to inhibit G-protein-coupled receptor signaling prior to coating 
cells with 3SL-cyclic-carbamate. 
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Table 4: Candidates from CRISPR-Cas9 screen in L929 cells 
Class Abbreviation Gene ID Full name 
Transcription factors Gata 6 14465 GATA binding protein 6 
GPCR Ffar4 107221 free fatty acid receptor 4 
 Olfr1537 257959 olfactory receptor 1537 
 Olfr310 258222 olfactory receptor 310 
Cytoskeleton Appbp2 66884 Amyloid beta precursor protein binding protein 2 
 Mark1 226778 MAP/microtubule affinity regulating kinase 1 
Protein degradation Cul5 75717 Cullin 5 
 Rnf133 386611 ring finger protein 133 
 Siah2 20439 Seven in absentia 2 
Phosphatase/kinase Mtm1 17772 X-linked myotubular myopathy gene 1 
 Pptc7 320717 PTC7 protein phosphatase homolog 
Channel proteins Aqp7 11832 Aquaporin 7 
Intracellular 
localisation 
Surf4 20932 Surfeit gene 4 
Translocation 
regulation 
Ang3 11730 Angiogenin, ribonuclease A family, member 3 
NADPH metabolism CbrI 12408 Carbonyl reductase I 
Iron binding  Cisd2 67006 CDGSH iron Sulphur domain 2 
DNA repair Ercc6 319955 excision repair cross-complementing rodent repair 
deficiency, complementation group 6 
Glycosylation Galnt13 271786 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminetransferase 13 
    
Table 5: Candidates from CRISPR-Cas9 screen in MC-38 cells 
Class Abbreviation Gene ID Full name 
mRNA stability Cnot 69125 CCR4-NOT transcription complex, subunit 8 
Cells signalling: 
Ribosylation 
Zc3hav1 78781 zinc finger CCCH type, antiviral 1 
Cell adhesion and 
signalling 
Spn 20737 sialophorin 
GPCR signalling Adcy7 11513 adenylate cyclase 7 
Trafficking Anxa8 11752 annexin A8 
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Table 6: Genotyping of mutations from CRISPR-Cas9 screen in L929 cells 
Gene Wildtype allele Clone allele 1 Clone allele 2 Clone allele 3 
Ang3 AAGTTGTGATCTGGAA AAGTTGTGATCTGGAA AAGTTGTGATCTGGAA n.a. 
Appbp2 TCCACTG TCCACTG unknown (not WT) unknown (not WT) 
Aqp7 GGCATCCTTGTTACCGTCCT GGCATCCTTGTTACCGTCCT GGCATCCTTGTTACCGTCCT n.a. 
CbrI CCCCCCCGAAAGTCAAT CCCCCCCGAAAGTCAAT CCCCCCCGAAAGTCAAT CCCCCCCGAAAGTCAA
T 
Cisd2 GGGGTACTTGC GGGGTACTTGC GGGGTACTTGC n.a. 
Cul5 ACGTCGCCATGTTCTCAACT n.a. n.a. n.a. 
Ercc6 AAGCGAC AAGCGAC unknown (not WT) unknown (not WT) 
Ffar4 CTCTAGTGCTCGTCGTGCGC n.a. n.a. n.a. 
Galnt13 CTAAATTTCCCGATGGTATCC CTAAATTTCCCGATGGTATCC WT n.a 
Gata6 CCTTCTACACAAGCGACCACCTCA CCTTCTACACAAGCGACCACCTCA n.a. n.a. 
Mark1 TGACGTAATGG TGACGTAATGG TGACGTAATGG n.a. 
Mtm1 TCTAAGTATAATTCACACTCCTTGGAGAATGAA
TC 
CATTAAGAAAGTAAGTTGAGTTTTTACACG 
TCTAAGTATAATTCACACTCCTTGGAGAATGAA
TC 
CATTAAGAAAGTAAGTTGAGTTTTTACACG 
TCTAAGTATAATTCACACTCCTTGGAGAATGAA
TC 
CATTAAGAAAGTAAGTTGAGTTTTTACACG 
n.a. 
Olfr153
7 
AAGCATGAAGCCAGTGTTAA n.a. n.a. n.a. 
Olfr310 TGTGCACACTTGCAATGACA n.a. n.a. n.a. 
Pptc7 CCTCCAGGAG CCTCCAGGAG unknown (not WT) unknown (not WT) 
Rnf133 GACATCGTTGTAGTTATGAT unknown (not WT) unknown (not WT) unknown (not WT) 
Siah2 CTTCATGCTGGTACTTGAAA unknown (not WT) unknown (not WT) unknown (not WT) 
Surf 4 TCGCACTGC TCGCACTGC WT n.a. 
Sialylated Glycans as Regulators of Cell Activation and Cell Death 
147 
 
Table 7: Genotyping of mutations from CRISPR-Cas9 screen in MC-38 cells 
3-sialyllactose coating leads to extensive cytoskeleton depolymerization 
In L929 cells we discovered that the amyloid beta precursor binding protein 2 (Appbp2) and 
MAP/microtubule affinity regulating kinase 1 (Mark1) were important for sialyllactose-coating 
mediated cell death. Interestingly, both genes are microtubule binding proteins and have previously 
been associated with regulating cell death [33, 34]. Mark1 is known to phosphorylate the protein tau 
[35] which when it is not phosphorylated binds to microtubules and stabilizes them [36]. Once tau is 
phosphorylated, it dissociates from the microtubules which ultimately destabilizes the microtubule 
fibers [37]. The depolymerization of microtubule fibers would also require the protein degrading 
machinery which interestingly also was identified in our screen with the genes for cullin 5 (Cul5), ring 
finger protein 133 (Rnf133) and seven in absentia 2 (Siah2) in the CRISPR-Cas9 screen in L929 cells. 
Therefore we decided to test if 3SL-cyclic-carbamate coating leads to the degradation of the 
cytoskeleton. We used confocal microscopy to visualize actin and microtubules. Actin was stained 
with Alexa488 labelled phalloidin and the microtubules were stained with an antibody that 
recognizes β-tubulin and a secondary antibody labelled with Alexa647. Lactose coating did not 
influence the cytoskeleton which remained intact after initiating lactose-cyclic-carbamate coating 
(Fig. 7A, B, E, F, I, J, M, N). 3SL-cyclic-carbamate coating on the other hand lead to rapid loss of actin 
and microtubule fibers within 15 minutes whereas a clear loss of fibers can already be seen as soon 
as 5 min after initiating 3SL-cyclic-carbamate coating (Fig. 7C, D, G, H, K, L, O, P). As a consequence 
the cytoplasm retracts towards the nucleus (Fig. 7O, P). 
Gene Wildtype allele Clone allele 1 Clone allele 2 Clone 
allele 2 
Adcy7 CATCATTGAGCGCCTCAAAGA CATCATTGAGCGCCTCAAAGA CATCATTGAGCGCCTCAAAGA n.a. 
Anxa8 AGGACCAATGAGCAGGCCATCA AGGACCAATGAGCAGGCCATCA unknown (not WT) unknown 
(not WT) 
Cnot8 ACCCGTCTGGAATCAACACA n.a. n.a. n.a. 
Spn CCCTCGAGTGAGATG CCCTCGAGTGAGATG unknown (not WT) unknown 
(not WT) 
Zc3hav1 
 
GTATCTCCTAGGATGGATGA WT unknown (not WT) unknown 
(not WT) 
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Figure 7: Cytoskeleton depolymerization during 3SL-cyclic-carbamate coating of L929 cells. L929 cells were 
coated with (A-H) lactose-cyclic-carbamate or (I-P) 3SL-cyclic-carbamate for (A, E, I, M) 0 min, (B, F, J, N) 5 min, 
(C, G, K, O) 10 min, (D, H, L, P) 15 min. These cells were fixed in formalin and stained with (A-D, I-L) actin 
staining phalloidin or (E-H, M-P) an antibody that stains β-tubulin. The cells were visualized by confocal 
microscopy. Scale bar: 5 μm. The experiment was performed three times and these are representative images. 
Loss of mitochondrial membrane potential and integrity 
Cell death is often associated with a loss of mitochondrial membrane potential [38, 39]. We analyzed 
the membrane potential with the mitochondrial stain CMXRos which has decreased intensity when 
the membrane potential is lost [40]. We recorded living L929 cells stained with CMXRos. Lactose-
cyclic-carbamate coating lead to no loss in CMXRos staining during live cell imaging (Fig. 8) but 3SL-
cyclic-carbamate staining lead to a loss of mitochondrial membrane integrity as soon as 2 min after 
initiating 3SL-cyclic-carbamate coating (Fig. 8). The imaging also reveals a loss of mitochondrial 
membrane integrity (white arrow) as can be seen by the bleb that grows and then bursts between 10 
and 12 min after initiating 3SL-cyclic-carbamate coating (Fig. 8). That means mitochondrial 
components such as cytochrome c are being leaked into the cytoplasm which often drive 
programmed forms of cell death [41]. 
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Figure 8: Loss of mitochondrial membrane potential and integrity due to 3SL-cyclic-carbamate coating. L929 
cells were loaded with the membrane potential indicating dye CMXRos and coated with lactose- or 3SL-cyclic-
carbamate. Single cells were observed for 14 min by live-confocal microscopy. Pictures were made every 2 min. 
The white arrow indicates a swelling bleb that bursts. Scale bar: 5 μm. The experiment was repeated 3 times 
and these are representative images. 
Increased levels of cytoplasmic calcium during 3SL-coating mediated cell death 
Programmed cell death is characterized by a surplus of the second messenger calcium in the 
cytoplasm [42]. Interestingly, our CRISPR-Cas9 screen in L929 cells revealed the involvement of the 3 
G-protein coupled receptors Ffar4, olfactory receptor 1537 (Olfr1537) and olfactory receptor 310 
(Olfr301) (Tab. 4). G-protein coupled receptor signaling is of especial interest for this study as they 
are known to initiate fast signaling events which would be necessary to drive the cell death 
procedure described here [31]. Calcium is actually also a second messenger that can be released into 
the cytoplasm after G-protein coupled receptor activation [43]. 
Another candidate that the CRISPR-Cas9 screen in L929 cells revealed is the surfeit gene 4 (Surf4). 
The encoded protein is localized to the membrane of the ER and is known to be relevant for the 
correct localization of the protein STIM-1 in the ER membrane. STIM-1 plays a key role regulating 
store-operated Ca2+ entry [44]. 
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We therefore decided to assess the intracellular calcium concentration during 3SL-cyclic-carbamate 
mediated cell death in MC-38 and L929 cells with the intracellular FluoForte AM dye which fluoresces 
green when it associates with calcium ions [45, 46]. In both MC-38 and L929 cells, increased 
intracellular concentrations of calcium were observed (Fig. 9). In MC-38 cells, green fluorescence 
remained 2 times higher than the baseline throughout the whole period of 300 s that was recorded 
(Fig. 9A). In the L929 cells, a 3.5 fold increase was observed just after measuring the green 
fluorescence after having initiated the 3SL-cyclic-carbamate coating procedure but it rapidly declined 
back to baseline levels within 100 s of the recording (Fig. 9B). 
 
Figure 9: Tracking intracellular calcium levels during 3SL-cyclic-carbamate coating. MC-38 and L929 cells were 
loaded with the intracellular calcium sensor FLUOFORTE® AM and then coated with lactose-, 3SL-cyclic-
carbamate or left uncoated. Fluorescence derived from the FLUOFORTE® AM dye was recorded on a plate 
reader for 300 s. ◓, 3SL-cyclic-carbamate; ●, uncoated; ○, lactose-cyclic-carbamate.  Each data point represents 
the mean of three independent experiments and the error bars indicate the standard deviation. 
Sialophorin and its role during sialyllactose-coating mediated cell death 
Sialophorin (Spn) is a highly glycosylated mucin-like protein that occurs on the cell surface of many 
immune cells [47]. In the CRISPR-Cas9 screen with the MC-38 cells, Spn was one of the identified 
candidates. We were able to show that MC-38 cells express sialophorin by staining them with a PE 
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labelled antibody for sialophorin and then performing flow cytometry. Sialophorin staining was 3.5 
times more intense in wildtype cells than in the isotype control (Fig. 10A). The isolated MC-38 clone 
that contained the sialophorin targeting gRNA had no increased staining with the sialophorin 
targeting antibody compared to the isotype control which demonstrates that the clone has a 
complete sialophorin knockout (Fig. 10B). Next, we performed a bioinformatics analysis of the 
extracellular domain of sialophorin and identified the lysines-23, -34, -81, -160 and -207 as possible 
acceptors for 3SL- or 6SL-cyclic-carbamate (Fig. 10C). In total the extracellular domain of sialophorin 
has 25 O-GalNAc- and 1 N-GlcNAc-glycosylation site that have been characterized (Fig. 10C). 
 
Figure 10: Sialophorin null mutant. (A) Wildtype MC-38 cells and (B) sialophorin gRNA containing MC-38 cells 
were stained with a sialophorin staining antibody and analyzed by flow cytometry. Red, unstained; blue, 
isotype control; orange, α-Spn-PE. The experiment was performed three times independently and these are 
representative images. (C) Amino acid sequence of sialophorin's extracellular domain. Green, O-glycosylation 
sites; blue, N-glycosylation sites; red, lysines for potential oligosaccharide-cyclic-carbamate coupling. 
Discussion 
Characteristic for sialyllactose-cyclic-carbamate mediated cell death is the speed at which it takes 
place. That means cell death must be rapidly initiated. Interestingly, the CRISPR-Cas9 screen we 
performed with L929 cells revealed the 3 G-protein coupled receptors Ffar4, Olfr1537 and Olfr301. In 
the MC-38 cell CRISPR-Cas9 screen we revealed the adenylate cyclase 7 as a candidate, a protein 
which is downstream of G-protein coupled receptors and is responsible for metabolizing ATP into 
cAMP [48]. These are interesting candidates as G-protein coupled receptors are known to initiate fast 
signaling responses that take place in seconds [31]. We also demonstrated in silico that all three G-
protein coupled receptors have accessible lysines in their extracellular domains that can be coupled 
to sialyllactose-cyclic-carbamate and that the general G-protein coupled receptor signaling inhibitor 
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Pertussis toxin is able to decrease the amount of cell death. Ffar4 actually has an N-linked 
glycosylation site at position 21 that is only 11 amino acids away from a lysine that is accessible for 
sialyllactose-cyclic-carbamate coupling (Fig. 6). Previous reports have actually strongly indicated that 
G-protein coupled receptor signaling could play a key role in programmed cell death signaling. The 
overexpression of the Gαs protein in the SH-SY5Y cell line leads to increased sensitivity of the cells to 
apoptotic stimuli [49]. Also in cardiomyocytes the activation of Gαs by the β1- and β2-adrenergic 
receptors was able to drive the cells towards a pre-apoptotic state [50]. 
One possibility is that sialylation on some surface proteins such as G-protein coupled receptors, such 
as Ffar4, may serve as a molecular switch to initiate cell death in circumstances that require the rapid 
induction of cell death such as virus infection or the acquisition of cancer cell properties. 
Sialyltransferases have been shown to be present at the cell surface and are also still functional 
although the biological relevance of them is still disputed [51]. The cell surface sialyltransferase CMP-
NeuAc:GM3 is capable of sialylating the ganglioside GM3 at the plasma membrane [52, 53]. St6gal1 
has also been reported to be secreted and able to catalyze sialylation outside the cell [54]. 
Additionally, dendritic cells have been claimed to have active cell surface sialyltransferases [55]. 
Another surface protein revealed in our CRISPR-Cas9 screen in MC-38 cells was sialophorin. This 
protein is well known to be involved during cell death in thymocytes by forming aggregate with other 
surface protein like CD3, CD7 and CD45 which is galectin-1 dependent [14]. Sialophorin directly 
interacts with galectin-1 during the formation of this complex and its absence leads to 50 % less 
galectin-1 binding to the cell surface and reduced cell death in thymocytes exposed to galectin-1 
[56]. In thymocytes, the actual signaling of cell death occurs due to the clustering of CD45, which has 
an intracellular phosphatase that then becomes active leading to caspase-3 activation [57]. Maybe 
sialophorin can interact with other proteins such as G-protein coupled receptors and also lead to 
their clustering on the cell surface and enhance their activity.  
We demonstrated that sialyllactose coating initiated cell death was caspase dependent (Fig. 5). 
Caspase activity has been shown to initiate apoptosis via caspase-8 [58] or caspase-9 [59] and 
pyroptosis via caspase-1 [60]. Caspase-8 and caspase-9 both lead to the activation of caspase-3 which 
initiates classical apoptosis [59]. Recently however, caspase-3 has been shown to be capable of 
initiating a pyroptosis-like phenotype by cleaving the protein gasdermin-E which once activated 
starts creating membrane pores [61]. This shows that it is not possible to rigidly categorize cell death 
into different types. Sialyllactose-coating induced cell death is dependent on caspase-8 such as MC-
38, RAW264.7 and HEK293T cells but still there is rapid formation of pores which makes it possible to 
stain the cells with propidium iodide. Furthermore, sialyllactose-coating initiated cell death in MC-38 
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and HEK293T depends on both caspase-8 and caspase-1 activity. In fact, caspase-8 has previously 
been shown to be involved during pro-IL-1β processing to mature IL-1β and this was NLRP3-
inflammasome dependent [62]. In the absence of caspase-1, caspase-8 actually induces apoptosis 
instead [62]. It still remains to be shown how the caspase interplay unfolds precisely during 
sialyllactose-coating mediated cell death. 
Here, we have discovered a novel form of cell death that is dependent on cell surface sialic-acid. It is 
extremely rapid and requires the activity of G protein receptor coupled signaling and may present a 
fast way to remove cells and induce inflammation. The precise epitopes that are modified by 
sialyllactose-cyclic-carbamate ligation and what occurs to induce programmed cell death, still remain 
to be identified. However the discovery of cell death mediated by surface sialylation represents a 
mile-stone in cell death and glycobiology research. A fitting name for this process may be glycoptosis 
or sialoptosis in contemplation of the many forms of programmed cell death that have already been 
discovered. 
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Conclusions and Implications for further Research 
The influence of human milk oligosaccharides on immune regulation 
For the first time we demonstrated that the HMOs FSL and LST-c are capable of inducing a metabolic 
shift in antigen presenting cells. The human monocytic cell line THP-1 and murine mesenteric lymph 
node derived dendritic cells react by increasing their lactate secretion when they have been 
stimulated with FSL or LST-c. Many tumors produce increased amounts of lactate which makes 
antigen presenting cells such as macrophages secrete more immune dampening cytokines like IL-10 
and TGF-β [1]. The immune dampening influence of lactate production by antigen presenting cells 
may reflect a physiological role of increased lactate production in comparison to the 
pathophysiological role that is fulfilled by lactate produced by cancer cells. 
Gut development in the infant requires a sensitive balance between immune activation and 
tolerance. The intestine is required for the infant to access the necessary nutrients from its 
environment and therefore it forms an interface with the outside world which is highly enriched with 
diverse bacteria. Some of these bacteria are actually beneficial to the infant’s health such as 
Lactobacillus spp. or Bifidobacteria spp. and should be tolerated however other bacterial species are 
pathogens such as Salmonella spp. or Campylobacter spp. and must be eliminated. The human 
intestine has to learn when to defend and when to attack in this early stage of human life [2]. The 
glycans in human milk have often been regarded as components in human milk that support the 
immune systems maturation but also promote the growth of benefactors while inhibiting 
colonization with pathogens in the human gut [3]. Bacteria in the colon for instance can ferment the 
HMOs to short-chain fatty acids which make an acidic milieu that is beneficial for the growth of 
genera such as Bifidobacteria, Lactobacillus or Bacteroides that are associated with the healthy 
infants gut. Short-chain fatty acids are also able to bind to receptors on regulatory T-cells and 
support their activation [4], contributing to tolerance in the intestine. The importance of FSL and LST-
c mediated lactate production by antigen presenting cells in vivo still remains to be elucidated. One 
possibility to determine the roles of FSL and LST-c on immunity would be to use rats or mice as they 
only produce simple trisaccharide milk oligosaccharides such as 3SL and not larger oligosaccharides 
such as LST-c and FSL [5-7]. It would be possible to then supplement suckling rats or mice with FSL or 
LST-c to determine alterations in gut immunity and its development. With this type of model system 
it would be possible to track major changes in gut immunity during challenges such as in the dextran 
sodium sulphate intestinal bowels disease model [8] or during the development of food allergies like 
in the peanut allergy model [9]. 
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FSL and LST-c both share certain structural characteristics. As HMOs, they both possess lactose at 
their reducing end. Furthermore, they both also share an α2-3 linked sialic acid [10, 11]. Possible 
receptor candidates are galectins [12] and Siglecs [13]. The prior bind to β1-4 linked galactose which 
occurs in the reducing end lactose, but also in the poly-lactosamine chains, and the latter can bind to 
sialic acid. LST-d was also able to decrease the acidity of the media but to a lesser extent then LST-c. 
While LST-d has a terminally linked α2-6 linked sialic acid, LST-c possesses an α2-3 linked sialic acid. 
As LST-c induced the stronger effect, the receptor on the cell surface must have a stronger affinity to 
α2-3 linked sialic acid. Therefore possible Siglec receptors are the Siglecs-1, -4, -5 and -8 which have 
higher affinities for α2-3 linked sialic acid [14]. To determine which Siglec or galectin is involved, the 
CRISPR-Cas9 technology could be used which enables the placement of site-specific deletory 
mutations [15]. 
In the experiments that we conducted, our interest was limited to direct stimulatory roles that HMOs 
have on antigen presenting cells. However, what is the influence of HMOs on interactions that 
antigen-presenting cells have with other cells? T-cell activation and the ensuing initiation of specific 
adaptive immune reactions, requires stimulation by dendritic cells for instance. The binding of α1-2 
mannosylated glycans from Mycobacterium tuberculosis or N-linked glycans on the glycoprotein 
gp120 from the human immunodeficiency virus to DC-SIGN on dendritic cells are known to initiate 
the production of IL-10 for example which leads to tolerating type T-cell responses [16, 17]. As DC-
SIGN also can bind to fucosylated glycans it may be possible for fucosylated HMOs to bind to DC-SIGN 
and initiate similar effects [18]. DC-SIGN normally interacts with ICAM-3 [19] and ICAM-2 [20] on T-
cells during activation. That means fucosylated glycans could interfere with or modulate this 
interaction to alter dendritic cell initiated T-cell responses. Similar mechanisms could also apply for 
other lectins that interact with receptors on T-cells such as the macrophage Gal/GalNAc-specific C-
type lectin that recognizes LeX and LeY containing GalNAc structures and may therefore bind to 
corresponding HMOs [21]. 
Antigen-presenting cells such as dendritic cell and macrophages also influence the skewing of T cell 
responses towards Th1, Th2, Th17 or Treg type immune responses. Campylobacter jejuni for instance 
is a pathogen that possesses lipid bound oligosaccharides (LOS) at its cell surface that have terminal 
sialic acid residues. Depending on the terminal linkage of the sialic acid on the LOS the profile of 
cytokines that are produced differs. α2-3-linked sialic acid on LOS will interact with SIGLEC-1 on 
dendritic cells which will induce a Th2 response by producing IL-4 and TGF-β. On the other hand, 
terminally linked α2-8-linked sialic acid on the LOS binds to SIGLEC-7 which leads to Th1 polarization 
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by initiating the secretion of IFN-α or -β  and IL-12 [22]. Sialylated HMOs may regulate specific 
immune reactions in a similar way by binding to the same receptors. 
Signaling by C-type lectin receptors also influences the production of cytokines by dendritic cells. The 
receptors DCIR and MICL have intracellular ITIM-domains which recruit SH2-domain containing 
phosphatases after ligand binding [23, 24]. This ultimately leads to the inhibition of Toll-like receptor 
mediated IL-12 and TNF production [25, 26]. Sialylated HMOs can bind to selectins for instance which 
are a class of C-type lectins that play a role during leukocyte extravasation from the blood into the 
surrounding tissue [27, 28]. It is likely that HMOs interact with other C-type lectins and initiate 
signaling or they may block the access of endogenous ligands to their receptor and modulate the 
secretion of cytokines. Determining the binding specificities of various human milk oligosaccharides 
to lectins on the surface of dendritic cells would open up the possibility to determine how HMO 
binding induces signaling or interferes with and therefore modulates signaling by C-type lectin 
receptors. This may occur in context of T cell priming but also during the direct recognition of 
pathogen-associated patterns. 
In the mammary gland, lactose is synthesized by the lactose synthase complex [29]. In fact, the β1-4 
galactosyltransferase that extends glucose with galactose is the same enzyme that is able to extend 
GlcNAc with β1-4-linked galactose during the synthesis of glycoproteins and -lipids in the Golgi 
apparatus [29]. Lactose can be extended to HMOs in the Golgi apparatus of the mammary gland and 
the resulting epitopes are similar to the ones identified on glycoproteins and –lipids produced by 
other cell types [30]. One possibility is that these HMOs may therefore be responsible for obtaining 
tolerance towards common oligosaccharide structures. For this it would be necessary to present 
certain oligosaccharides on MHC-proteins. The zwitterionic polysaccharide A from Bacteroides fragilis 
can be presented on MHC- class II for instance which leads to CD4+  T cell responses [31]. The capsular 
polysaccharide of Streptococcus pneumoniae is also presented on MHC-class II [32]. The presentation 
of antigens by dendritic cells does not only induce inflammatory immune reactions but is also 
important to mount regulatory immune responses. Many dendritic cells actually present self-
antigens and initiate tolerance reactions via regulatory T cells. Especially dendritic cells that produce 
retinoic acid by the retinoic acid synthesizing enzyme promote the differentiation of Foxp3+ 
regulatory T cells [33-36]. In the gut, retinoic acid producing CD103+ dendritic cells are especially 
common which promotes the development of tolerance towards antigens [33]. One possibility is that 
HMOs are ingested by CD103+ dendritic cells and presented to naïve T cells that mediate tolerance to 
common glycan structures. 
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Discovering novel regulatory roles of multivalent oligosaccharides 
With the cyclic-carbamate technology we were able to modify proteins, entire mammalian and 
bacterial cells with oligosaccharides. We demonstrated that cells could be coated with 
oligosaccharides to study the binding of glycans on cells to lectins such as E-selectin. Our study was 
performed solely in vitro but the application of this technology can potentially be expanded to 
investigating the role of cell-surface glycans in vivo. What could the consequence be of presenting E-
selectin ligands on cancer cells? E-selectin is expressed by epithelial cells and is responsible for the 
extravasation of leukocytes that present the E-selectin ligand sialyl-Lewis X [37]. During tumor cell 
extravasation, monocytes associate with tumor cells and aid their extravasation from the blood 
vessels by their binding to E-selectin [38]. The technology we developed enables us to study the 
consequence of directly modifying cancer cell surfaces such as the colon tumor cell line MC-38 with 
E-selectin ligands like FSL. Many cancer cells have increased amounts of E-selectin-ligands on their 
surface [39, 40]. The presentation of additional E-selectin ligands on the cell surface may therefore 
increase the extent of metastasis. 
Increased presentation of sialic acid containing glycans on the cell surface may also increase the 
tolerance of the immune system towards the cancer cell. Siglecs are receptors that bind to sialic acid 
which activates the intracellular ITIM-domain, leading to the recruitment of SH2-domain containing 
phosphatases which counteract immune activation [41, 42]. One possibility is that cell surface 
sialylation may enable cancer cells to dampen immune responses by NK-cells or antigen presenting 
cells that express Siglec receptors. The coating of cancer cells with Siglec-ligands would enable us to 
answer this question. We were able to couple 6SL to 3-sn-phosphatidylethanolamine and incorporate 
it into the membrane of Jurkat cells that could bind to Siglec-3 as a consequence. Siglec-3 is 
expressed by the myeloid lineage but its function is not understood. Oligosaccharide-cyclic-
carbamate mediated ligation to the cell surface is a suitable method to study the role of Siglec-3 in 
the myeloid lineage. Another approach involving the presentation of Sia residues as aminooxy 
glycans condensed to a polymethyl vinyl ketone scaffold by oxime formation, was able to 
demonstrate the role of Siglec-7 as a negative regulator of NK-cell mediated cancer cell death for 
example [43]. 
The cyclic-carbamate technology presented here also enables us to coat bacterial cells with 
oligosaccharide cyclic-carbamates and study the regulatory roles of glycans on the cell surface. 
Pathogens such as Neisseria gonorrhoea [44] or Pseudomonas aeruginosa [45] may present sialic acid 
at their cell surface. Cell surface sialylation is known to recruit the complement factor H which 
interferes with the complement reaction by cleaving complement factor 3b [44]. Siglecs on immune 
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cells such as phagocytes may also recognize bacterial sialic acid. The cyclic-carbamate technology 
enables us to examine the influence of bacterial surface sialic acid on their interaction with 
phagocytes and the cytokine environment that they produce. The interaction of bacterial cell surface 
Sia with Siglecs may enable the bacteria to evade immune surveillance and clearance. 
I was also able to modify proteins with the cyclic-carbamate technology. Staphylococcus aureus 
protein A and bovine serum albumin were demonstrated to be suitable acceptors for oligosaccharide 
cyclic-carbamates in this work. This method opens up the possibility to study the roles of specific 
oligosaccharide structures that occur on highly glycosylated proteins like mucins. To do this a peptide 
backbone is required that is rich in lysines that would enable the dense presentation of 
oligosaccharides by the cyclic-carbamate technology. Furthermore if the N- and C-terminal amino 
acids were cysteines, this would enable the formation of intramolecular disulfide bonds using 
glutathione derivatives to synthesize mucin-like gel matrixes [46, 47] (Fig. 1). 
 
Figure 1: (A) Schematic representation of how mucins form a gel like-barrier by interactions of hydrophobic 
protein domains, electrostatic interactions, hydrogen bonds and covalent bonds between cysteine-rich 
domains of different mucin monomers. (B) Possible amino acid sequence of a peptide to form artificial mucin 
gels. Every second position is a lysine that could be modified with oligosaccharide cyclic-carbamates while the 
outer flanks are cysteines that can form intermolecular disulfide bonds (modified from [48]). 
With this technology the role of the mucin MUC2 could be studied by using the custom-made mucin 
gel to reconstitute parts of the intestine by caecal injection. The role of the glycans on MUC2 as 
immune dampeners that stimulate the production of IL-10 but decrease the production of IL-12 by 
antigen presenting cells in the gut has been previously demonstrated [49]. The technology presented 
here enables the homogenous presentation of glycans and the identification of specific glycan 
epitopes that could mediate this change in vivo. It is also possible to modify polylysine stretches with 
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oligosaccharide-cyclic-carbamates. This opens up the possibility to coat cell culture plates with 
polylysine and then modify the amine groups with oligosaccharide-cyclic-carbamates. This would 
enable the creation of high-density oligosaccharide environments in which immune cells could be 
cultured and the influence of high-density glycans on their activation could be tested. The influence 
of high-level sialylation may increase the activation of Siglecs and thereby counteract the activation 
of antigen-presenting cells or even induce regulatory immune responses during the activation of T-
cells by dendritic cells for instance. 
The glycans on therapeutic proteins such as erythropoietin (EPO) have a key role on the efficacy of 
the biopharmaceutical. The extent of sialylation increases the serum half-life of EPO for example and 
therefore highly-sialylated forms of EPO are used as therapeutics [50]. Second generation EPO 
therapeutics actually have additional N-glycosylation sites to increase the amount of sialylation 
which leads to more terminal Sia being presented by the protein [51]. The production of protein 
therapeutics is expensive as they must be synthesized in mammalian cells that can perform 
glycosylation and sialylation reactions [52]. Furthermore, the production of cell produced 
biotherapeutics requires extremely stringent production standards to avoid batch variations or even 
the production of immunogenic biopharmaceuticals [53]. The production of chemically synthesized 
pharmaceuticals is less expensive and more robust. Non-glycosylated therapeutic proteins such as 
calcitonin can be synthesized chemically but glycoproteins such as EPO are not synthesized by 
chemical synthesis yet [54]. A possible chemical strategy to produce glycoproteins such as EPO would 
be to replace the asparagines at the N-glycosylation sites with lysine residues that can be modified 
with specific oligosaccharide cyclic-carbamates. Chemical production may lead to a decrease in the 
production costs for biopharmaceuticals which would alleviate the pressure on health-systems that 
are confronted with increasing expenses worldwide [55]. 
Sialyllactose-coating mediated cell death (Sialoptosis) 
Coating mammalian cells with 3SL- or 6SL-cyclic-carbamates lead to rapid, caspase-dependent cell 
death. The precise mechanism and pathway still remain unknown. However, the initial stimulus must 
be derived from a receptor at the plasma membrane as this is the site of oligosaccharide-cyclic-
carbamate ligation. The primary reaction partners of the cyclic-carbamate group are primary amines 
and thiol groups, whereas secondary amines are less efficient reaction partners [56]. These groups 
occur on proteins as well as lipids at the cell surface. The incorporation of sialyllactose-modified 
phosphatidylethanolamine into the plasma membrane did not lead to an increase in cell death and 
therefore we concluded that specific oligosaccharide-cyclic-carbamate ligation sites at the cell 
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surface are responsible for the observed cell death. One possibility to determine which sites at the 
cell surface are modified would be to cleave off surface peptides by digestion with trypsin and then 
to perform mass spectrometry, to discover which peptides are modified by oligosaccharide-cyclic-
carbamate ligation. This technology can be used in combination with the CRISPR-Cas9-screening 
technology to identify the sites of modification. The initiation of cell death is very rapid and therefore 
the modified residue must be easily accessible. Interestingly, sialophorin, a candidate resulting from 
our CRISPR-Cas9 screen, is a membrane inserted mucin that protrudes from the plasma membrane 
and is therefore easily accessible. Other membrane-bound mucins such as MUC1 or MUC4 also 
protrude from the plasma membrane (Fig. 2) and would be easily accessible for oligosaccharide-
cyclic-carbamate ligation. 
 
Figure 2: Many membrane incorporated mucins such as MUC1, MUC4, MUC16 and MUC17 depicted here 
protrude out of the plasma membrane and its surrounding glycocalyx (modified from [57]). 
Sialophorin is known to be an important component that can mediate galectin-1 induced cell death 
by crosslinking cell surface signaling proteins such as CD45 which initiates apoptosis. Probably, other 
cell surface mucins besides sialophorin are also able to mediate crosslinking of cell surface receptors 
and regulate cell death in this manner. 
Siglecs that bind to sialic-acid containing glycans at the cell surface are also able to induce cell death. 
Siglec-8 for instance is situated on the plasma membrane of eosinophils and its ligation is known to 
induce cell death. Siglec-8 stimulation in the presence of IL-5 leads to apoptosis while the presence of 
IL-5 leads to necrotic cell death. In the presence of IL-5, SIGLEC-8 ligation upregulated ERK1/2 
phosphorylation, which ultimately lead to cell death [58]. In neutrophils the ligation and crosslinking 
of SIGLEC-9 leads to cell death [59]. Galectins are another class of glycan binding proteins that are 
secreted by cells and bind to glycans containing β1-4-linked galactose at the cell surface. In some 
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cases, galectin mediated crosslinking of cell surface proteins induces cell death [60]. Due to the bi- or 
multivalent carbohydrate binding sites that galectins have, they are suitable crosslinkers of 
glycoprotein containing proteins at the cell surface. Sialylation alters the binding properties of the 
galectins to the respective glycans. Galectin-2 binding for instance is reduced in the presence of sialic 
acid. Galectin-1 binding to α2-3-sialylated glycans is not ameliorated but α2-6-sialylation leads to 
reduced binding. Galectin-3 on the other hand can tolerate both α2-3 and α2-6-linked sialic acid [61]. 
The binding of the galectins-4 and -9 is also impacted by terminal sialic acid [62, 63], while the 
binding of galectin-8 is enhanced by sialylation [64, 65]. 
Cell death initiated by sialyllactose coating is probably mediated by several pathways which makes it 
difficult to perform genetic screens as the cell can circumvent the blockage of one cell-death 
pathway by taking an alternate route. Caspase-3 can for instance initiate classical apoptosis but is 
also able to initiate pyroptosis by activating gasdermin E [66]. Many of the candidates isolated in my 
research don’t completely eliminate cell death due to the likely presence of redundancies. To avoid 
such compensating mechanisms the generation of mutants in one or several cell death pathways 
may be necessary. Then, the CRISPR-Cas9 screen can be performed to find more upstream 
candidates. Caspase-3 is at the center of the apoptotic pathway while caspase-1 and -11 are central 
pyroptotic initiators and the mixed lineage kinase domain-like protein (MLKL) is the bottleneck of 
necroptosis. To stop the cell from initiating alternative cell-death pathways during the CRISPR-Cas9 
screen, single, double or even triple mutants of the central cell death initiating proteins can be 
applied. 
Finally, what could the meaning of sialylation-mediated cell death be? I stipulate that the sudden 
sialylation of specific epitopes on the cell surface may serve as signals for the cell to commit suicide. 
This may be in response to cells becoming malignant but also during infection with intracellular 
bacteria or with viruses. The presence of extracellular sialyltransferases has been shown but their 
biological activity on proteins at the membrane remains disputed. In fact, extracellular sialylation by 
ecto-sialyltransferases has been proposed to occur after exposure to radiation but also 
lipopolysaccharide stimulation [67] which would support the notion that cell surface sialylation 
mediated cell death may trigger cell death in response to malignancy or infection. My screen 
revealed that G-protein coupled receptors and cell-surface bound mucins may play a role during 
sialic-acid coating mediated cell death but before determining the biological meaning of this 
phenomenon, a specific pathway and initiator at the cell surface must be identified. 
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